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Abstract
The EVI-1 proto-oncogene, which is frequently activated in murine retrovirally 
induced leukaemias and human acute myeloid leukaemias by non-random 
chromosomal translocations involving 3q26— where the EVI-1 gene is 
located— encodes a transcriptional repressor. Repression is mediated by a 200 base 
pair proline-rich region designated Rp and also by a weaker second domain designated 
IR, which are both located between the two DNA binding domains (ZF1 and ZF2). 
Deletion mutagenesis studies, the results of which are reproduced in this thesis, reveal 
that the Rp, ZF1 and ZF2 domains are all required for optimal transformation of Rati 
fibroblasts. Moreover, it was demonstrated that several of these non-transforming 
evi-1 mutants, lacking either ZF1, Rp or both ZF1 and ZF2 (DNA binding defective 
mutants), could revert the transformed phenotype of evi-1-transformed Rati 
fibroblasts. Recent work has shown that evi-1 can bind the murine c-terminal binding 
protein 2 (mCtBP2) co-repressor and that evi-1 binds mCtBP2 through two conserved 
amino acid motifs residing in the Rp domain of the protein. The work described in 
this thesis has also shown that the integrity of these binding sites is crucial for evi-1 - 
mediated repression and transformation in mammalian cells. Together these results 
suggested that AZF1 and ARp mutants with partially and fully intact DNA binding 
domains, respectively could inhibit transformation through a DNA binding 
competition for evi-1 binding sites. On the other hand, the DNA binding defective 
AZF12 mutants may sequester CtBP proteins or other factors necessary for FLevi-1 
regulation and in turn inhibit the biological activity of the wild type protein.
In addition, until now no studies have addressed the significance of evi-1 functional 
domains for the biological activity of evi-1 in haematopoietic cells. Using retroviral 
infection of primary bone marrow cells it was shown that FLevi-1, the alternative 
evi-1 splice form A324, and ARp and AZF1 deletion mutants all blocked the 
production of erythroid and myeloid progenitors in an identical manner in methyl 
cellulose colony assays. The AZF2 and AZF12 mutants produced an intermediate 
phenotype. These results suggested that either distinct regions of the evi-1 protein are 
required for the transformation of fibroblasts and inhibition of haematopoietic cell 
colony formation or that the evi-1 proteins act in a dominant negative fashion over 
endogenous proteins required for haematopoiesis.
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Chapter 1: Introduction
1.1 Eukaryotic gene transcription: An Intertwined Network of 
Chromatin Remodelling Machines and Transcription Factors
A cell must regulate the transcription of nearly all its genes and therefore it stands to 
reason that a high proportion— an estimated 10%— of a cell’s genes are exclusively set 
aside for proteins involved in transcriptional regulation. The appropriate genes must be 
transcribed and this requires an open chromatin conformation together with the required 
transcription factors. However, after transcription initiation many other modes of 
regulation can be imposed. These include transcript elongation, stability and 
polyadenylation and each of these can be regulated in a cell-specific manner. Translation 
itself and post-translational protein modifications provide an additional layer of 
complexity whereby protein production can also be modulated.
Advances within the field of gene regulation are fast unfolding and studies continue to 
reveal a multitude of regulatory mechanisms controlling differential gene expression in 
particular cell types. The following sections will focus on transcription and aspects of its 
regulation including new concepts that illuminate the importance of histone-DNA liaisons 
within this process.
1
1.1.1 Unravelling Chromatin Precedes the Initiation of Transcription
Over 2m of DNA is extensively folded into a human cell in such a way that it squeezes 
into a nucleus of around 20/mi diameter. The primary level of compaction of eukaryotic 
DNA is the formation of linear arrays of nucleosome core particles. A  nucleosome 
consists of around 140 base pairs of DNA wrapped 1.8 times around a complex of eight 
histones two each of H2A, H2B, H3 and H4. This initial arrangement, referred to as the 
“beads-on-a-string” structure, is then further folded into a solenoid arrangement of at least 
30nm in diameter. Looped fibres of around 100-200nm predominate the bulk chromatin 
structure of the interphase nucleus— a cell cycle period in which the genome must be 
accessible for transcription, replication, repair and recombination processes. It is this 
packaging of the eukaryotic genome into chromatin that permits dynamic unfolding of 
specific loci so that DNA sequences are accessible to enzymes that “read” the cells 
genetic material. (Reviewed in Kornberg and Lorch, 1999, Koshland and Strunnikov, 
1996, Lodish et al., 1995).
Coactivator multiprotein complexes with histone acetylase transferase (HAT) activity can 
stimulate transcription at several levels including the stimulation of the pre-initiation 
complex and remodelling of chromatin (Reviewed in Kornberg and Lorch, 1999, Davie 
and Spencer, 1999, Kuo and Allis, 1998 and Davie and Chadee, 1998). One way of 
making chromatin accessible appears to be regulated by acetylation of free amino acid 
groups of lysine at the N-terminal end of positively charged histone molecules by
2
coactivator molecules: this results in a decreased net positive charge, a lower affinity for 
the DNA phosphate backbone and stimulation of transcription. Conversely, a histone 
deacetylase (HDAC) corepressor complex can deacetylate histones and transcription 
factors to prevent the formation of the pre-initiation complex (Reviewed in Hui and Bird, 
2000, Kornberg and Lorch, 1999, Kuo and Allis, 1998, Davie and Chadee, 1998, and 
Davie and Spencer, 1999): the net result is a repression of transcription. Current 
mechanisms concerning chromatin remodelling are discussed in section 1.1.3.2.4, below. 
Regardless of the exact mechanism, it is widely accepted that a relaxation or activation of 
chromatin is imperative for the onset— and maintenance— of gene transcription.
1.1.2 Initiation o f Transcription—Assembly o f  the General Transcription 
Factors
The regulation of transcription initiation is a major point of control for gene expression in 
multicellular organisms ranging from invertebrates to mammals (Reviewed in Halle and 
Meisterernst, 1996). The initiation of transcription by RNA polymerase II (RNA pol II) 
requires stable assembly of the polymerase at the promoter as a large pre-initiation 
complex. The components of the complex have been elucidated over many years and 
include basal or general transcription factors (GTFs): TFILA, TFIIB, TFIID, TFIIF, TFIIE 
and TFIIH. Of these TFIID and TFIIH are also comprised of many subunits and both 
contain independent activities. TFIID consists of the TATA-Binding Protein (TBP) plus 
TBP-associated factors (TAFs) and specifically binds DNA, and TFIIH includes both
3
kinase and helicase activity. It is now recognised that these GTFs gain access to the 
promoter in a highly regulated and defined order.
In most eukaryotic core promoters a TATA box element is located approximately 25 base 
pairs (bp) upstream of the transcription initiation start site which is recognised by TATA- 
binding protein (TBP). By binding the TATA box, TBP initiates GTF assembly. The 
TAFs then bind to TBP, creating TFIID. GTF assembly continues with the recruitment of 
TFILA, TFIIB and the remaining GTFs. TFIIB facilitates the association of the pre­
assembled RNA pol II. Subsequently a large RNA pol II complex forms— consisting of 
the multi-subunit polymerase II in a large conglomerate with “mediator” (which consists 
of “suppressor” of RNA polymerase B (SRB) proteins and coactivator proteins— distinct 
from the basal transcription factors) in addition to some of the basal transcription factors. 
Initiation of transcription (formation of the first phosphodiester bond in the RNA) leads to 
a transition of the polymerase, still complexed with a subset of basal transcription factors 
into an early elongation state. A subsequent transition, sometimes called promoter 
clearance results in the stable elongation complex of polymerase, DNA, RNA and 
associated elongation factors. A great deal of phosphorylation is observed in the C- 
terminal domain (CTD) of RNA Pol II in the elongation complex. Once elongation has 
been terminated, RNA pol II detaches from DNA and, before it can re-enter initiation, the 
CTD must be dephosphorylated Although the presence of a core promoter sequence and 
the assembly of basal transcription apparatus is sufficient for transcription initiation of a 
specific gene— albeit minimal levels— upstream factors are required to modify 
transcriptional rates.
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1.1.3 Regulation o f Transcription
1.1.3.1 Regulatory Elements 
Enhancers
Enhancers are positive regulatory elements that serve to increase the basal level of 
transcription, which is initiated through the core promoter elements. Their functions, 
unlike those of the core promoter, are independent of their orientation and distance from 
the gene they regulate (Blackwood and Kadonaga, 1998). Indeed enhancer elements can 
activate transcription at considerable distances. They often contain elements recognised 
by ubiquitous transcription factors and elements recognised by tissue-specific 
transcription factors, thereby providing a basis for tissue-specific gene expression. 
Enhancer motifs have been identified that are required for transcriptional induction by 
various agents. Among these are the glucocorticoid response element (GRE), which 
binds the glucocorticoid receptor (GR), the serum responsive element of the c-fos gene 
and the heat shock response elements of the heat shock genes (reviewed in 
Atichson,1988).
Silencers (Silencer Elements)
Silencers, as the name suggests, are regulatory sequences that inhibit transcriptional 
activity of specific genes. A silencer is a short, specific sequence of nucleotides that tend 
to be located 5 ’ upstream of the promoter region of a gene. These sequences recruit
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transcription factor proteins to the promoter, which in turn perform specific functions to 
ultimately down regulate gene expression. It has become evident that many different 
types of silencers are involved in the regulation of many aspects of gene regulation— such 
as cytoplasmic retention of transcription factors, activity of transcriptional activators, 
chromatin structure, intron splicing and GTF assembly (Clark and Docherty, 1993)— to 
ultimately down regulate gene expression. One classical silencer is the AT-rich element 
found in human thyrotrophin (hTSHfi) gene promoter, which consists of multiple binding 
sites for the ubiquitous POU homeoprotein, OCT-1 (Kim et al., 1996).
1.1.3.2 Transcription Factors
Transcription factors are modular proteins that recognise short conserved nucleotide 
sequences involved in regulating the transcription of various genes. The region of DNA- 
protein binding is typically characterised by around 20 amino acid/nucleotide contacts, 
which ensures strong and specific binding. In human and other eukaryotic transcription 
factors, several distinct functions can often be identified and located in different parts of 
the protein: (1) DNA binding domains, (2) dimerisation domains, (3) activation domains 
and (4) repressor domains. Transcription factors, with often quite different specificities, 
are characterised into several “families” by common structural motifs. Indeed, 
identification of these domains has provided some insight into how these factors can bind 
DNA, contact a variety cellular target proteins and how such complex interactions might 
influence gene expression and ultimately cell-specific proliferation/differentiation.
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Some of the major structural domains implicated in eukaryotic gene regulation are 
described below.
1.1.3.2.1Conserved Families o f DNA-Binding/Protein Interaction Domains 
Leucine Zippers or bZIP Factors
The leucine zipper is a helical stretch of amino acids rich in leucine residues, (typically 
one every 7 amino acids) which was first identified as a dimerisation domain in the 
CCAAT/enhancer binding protein (C/EBP) (Landshultz et al., 1988). Each monomer unit 
consists of an amphipathic a-helix of hydrophobic amino acids facing one way and polar 
groups facing the other way. Two a-helices of individual monomers join over a short 
distance to form a coiled coil structure (O'Shea et al., 1991) with predominant interactions 
occurring between hydrophobic amino acids of the individual monomers. The region 
beyond these interactions separates, so that the overall dimer is Y-shaped, allowing the 
dimer to grip the double helix like a clothes peg through basic DNA binding motifs, 
hence the term bZIP factors. Leucine zippers are also able to occasionally form 
heterodimers as well as homodimers, which provide essential combinatorial control 
mechanisms for gene regulation. The oncoproteins FOS and JUN (Glover and Harrison,
1995) and the yeast regulatory protein, GCN4 (O'Shea, 1991) belong to the large family 
of bzip transcriptional modulators.
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Helix Loop Helix (HLH) Motif
The (HLH) motif consists of two a-helices, one short and one long, connected by a 
flexible loop— that enables the two helices to lie in planes that are parallel to each other. 
The HLH motif mediates both DNA binding and protein dimer formation (Murre et al.,
1989) and it permits occasional heterodimer formation (Henthorn et al., 1990). 
Heterodimers can form between a full length HLH protein and a truncated HLH protein 
(which lacks the entire region of the a-helix necessary to bind DNA tightly). Therefore, 
these heterodimers are thought to inactivate specific gene regulatory proteins. Members 
of the HLH family include MAX, E47 and MYOD (reviewed in Kohn et al., 1997).
Helix Turn Helix (HTH) Motif
The homeobox-containing homeotic genes were originally identified in Drosophila with 
the proteins they encode being critical for regulating development (De Robertis et al.,
1990). Homeobox-containing proteins have been found in all species from yeast to 
humans and homeodomains are remarkably conserved across species (reviewed in 
Patikoglou and Burley, 1997), although the remainder of the protein structure may be 
divergent. The HTH motif is common to homeodomains. This motif is characterised by 
two short a-helices separated by a short amino acid sequence, which creates a |3-turn, so 
that the two helices are orientated on different planes. The more C-terminal helix acts as 
the specific recognition helix as it fits into the major groove of DNA. HTH proteins 
include the Drosophila homeodomain proteins Antennapedia (Antp) and Engrailed(Eng), 
the yeast protein MATa2 and the mammalian protein C-MYB (reviewed in Patikoglou 
and Burley, 1997).
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Zinc Fingers
Zinc finger protein modules are highly abundant across all species from yeast to 
mammalian genomes. The zinc finger motif is co-ordinated with a zinc ion by four 
conserved amino acids to form a loop or “finger”, a structure often arranged in sequential 
arrays. Zinc fingers can be divided into different sub-groups by the nature and spacing of 
their zinc chelating residues. The two most common forms are the classical CCHH, 
TFIIIA (Miller et al., 1985) or C2H2 zinc fingers (characterised by the binding of a zinc 
ion by two conserved cysteine residues and two conserved histidine residues) and the 
GATA-like CCCC (Omichinski et al., 1993) or C2C2 fingers (consisting of four 
conserved cysteine residues). However, common to both forms is an a-helix and a (3- 
sheet folded around a zinc ion and it is the a-helix that makes contacts with the major 
groove of DNA (Parraga et al., 1988 and Omichinski et al., 1993). Recent studies have 
also uncovered the role of zinc finger motifs in mediating protein-protein interactions 
(Tsang et al., 1997 and Merika and Orkin, 1995). Examples of zinc finger proteins 
include the eukaryotic GTF, TFILA (Miller et al., 1995), Ying Yang 1 (YY1) (Shi et al., 
1996) and the Drosophila protein, u-shaped (Haenlin et al, 1997).
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1.1.3.2.2Trans-Activation Domains
Many of the promoter-specific regulatory proteins are sequence-specific DNA binding 
proteins capable of functioning as transcriptional activators (Hope and Struhl, 1986 and 
Keegan et al., 1986). Activation domains are large, often map to multiple regions within 
a protein and have been loosely classified as to whether they are rich in glutamine, proline 
or acidic amino acids (Seipel et al., 1992). The serum response elements of the steroid 
hormone receptor superfamily represent another class of activation domain (Treisman, 
1992). Indeed, proteins belonging to these different classes modulate transcriptional 
activation in very different ways: (1) “Proximal” activation domains, typified by the 
glutamine-rich domains of SP1, OCT1 and OCT2, only stimulate transcription from a 
position close to the TATA box, usually in response to a remote enhancer (Seipel et al., 
1992) (2) Acidic domains, exemplified by the yeast DNA binding protein GAL4 and
herpes simplex virus VP 16, stimulate transcription from both remote and proximal 
promoter positions (Seipel et al., 1992). (3) Proline-rich activation domains found in 
AP-2 and CTF/NF-1 demonstrate considerable proximal but little remote promoter 
activity (Seipel et al., 1992).
Most activators are regarded as “promiscuous” and are thus able make direct physical 
interactions with sequence-specific transcription factors or with the GTFs. For example 
the HSV protein VP16 binds sequence-specific OCT-1 and the GTFs TBP, TFIID, 
TAFII31, TFIIB, TFILA and TFIIH (reviewed in Flint and Shenk, 1997). Activators may 
enhance the formation of the pre-initiation complex by a “direct” mechanism (which
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involves interaction with free GTFs and/or a holoenzyme complex that recruits these 
components to the core promoter) or by an “indirect” mechanism (involving interactions 
with, and modifications of, a pre-existing TFIID-core promoter complex that in turn 
mediates the recruitment of the other components). Co-activator proteins are cofactors 
that are required to recruit the transcriptional machinery— and ultimately RNA pol II— to 
transcribe target genes. Recent studies have also shown that a number of coactivators 
regulate the remodelling of chromatin (reviewed in Xu et al., 1999 and Torchia et al., 
1998). It appears that coactivators can recruit histone acetyltransferases (HATs), which 
catalyse a process that destabilises histone-DNA contacts by histone acetylation, thereby 
allowing the binding of other transcription factors.
1.1.3.2.3Repressor Domains
DNA binding transcriptional repressors act by a variety of mechanisms including direct 
interactions with activators or GTFs, competition with activators or GTFs for access to 
the DNA or the recruitment of corepressors with intrinsic repression activity. Each 
repressor generally contains a small repression domain. Similar to activation domains, 
repressor regions are characterised according to the primary amino acid content. 
However, these inhibitory domains are often small and discreet, compared to activation 
domains, and found in defined regions of proteins (reviewed in Hanna-Rose and Hansen,
1996). Some repressor domains are alanine-rich like the N-terminal repression motif in 
Drosophila gene kriippel (Licht, 1994). Several others are proline-rich such as the 
repressor domains belonging to the oncoprotein, Ecotropic Viral Integration Site-1 (EVI-
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1) (Bartholomew et al., 1997) and suppressor protein, Wilms Tumour 1 (WT1) (Saha et 
al., 1993). In addition, high charge represents a common feature of repressor regions: an 
example of this is a potent repressor region named £rw/?/?e/-associated box (KRAB) 
(Witzgall, 1994). Much larger, charged and hydrophobic residue repressor regions are 
present in the well-characterised thyroid hormone receptor (TR) and the retinoic acid 
receptor a  (RARa) (Baniahmad et al., 1992). Several unique repressor motifs have also 
been described (Wang et al, 1995 and Gashler et al., 1990). Potential mechanisms for the 
negative regulation of transcription by repressors are discussed below.
Four major mechanisms of transcriptional repressor function are hypothesised:
(1) Repressors may directly compete with activators for binding to a common target 
DNA or (2) may bind simultaneously with activators but may “quench” their functions, 
possibly by masking the activation domain. (3) Repressors may bind DNA and interact 
with the general transcription machinery inhibiting a transcriptionally competent state.
(4) Repressors may also recruit corepressors. Interactions of repressors with such targets 
have been described and suggest a direct involvement in transcriptional repression.
Competitive binding
A repressor may bind directly to DNA and mask a transcriptional activation domain. For 
instance, the vitamin D3 response element (VDRE) of the bone protein, osteocalcin 
mediates regulation by vitamin A and vitamin D3 receptors and surprisingly, the 
oncogene jun-fos. As such, jun-fos is able to suppress basal levels of the osteocalcin
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gene and down-regulate hormonal induction by vitamins A and D3 in vitro (Schiile et al.,
1990).
Repressor interactions with activator or coactivator proteins
Repressors that can interact with activator or coactivator proteins are predicted to be able 
to inhibit only certain promoters because they interfere with the activity of one or more 
activators that specifically bind that promoter. A recent study using in vitro assays has 
shown that the haematopoietic transcription factor, GATA-1 can negatively regulate 
myeloid differentiation by directly interacting with the PU .l transactivator— arguably the 
most crucial factor known for the development of myeloid progenitors in vivo (Nerlov et 
al., 2000).
Repressor interactions with basal transcription factors
Repressors that react with basal transcription factors are predicted to be able to repress a 
minimal RNA pol II promoter which contains only a TATA box or initiator element 
(Fondell et al., 1993). Several models have been put forward to describe how this might 
work. For instance, the repressor may interfere with the proper assembly of any one of 
the general transcription factors to the pre-initiation complex; or the repressor could 
interact with the general transcription machinery preventing an isomerisation or 
disassembly step— resulting in a kind of “frozen” assembly. Another possibility would be 
that a “saboteur” factor could be loaded onto the general assembly by the repressor. This 
could perhaps act through either of these aforementioned mechanisms. The repressor 
domain of the Drosophila Even Skipped (eve) homoeodomain protein can interact
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directly with TBP in vivo and in vitro (Um et al., 1995). More recently, the repressor 
activity of EVE was demonstrated to be evolutionarily conserved when EVE was found to 
be a potent repressor of several promoter-types in mammalian cells. Moreover these 
studies confirmed that EVE specifically inhibits the pre-initiation complex by preventing 
the assembly of TFIID (McKay et al., 1999).
Repressor interactions with corepressor proteins
Corepressors are proteins that bridge the interaction of the repressor with its ultimate 
target. Several sequence-specific repressor proteins have been identified, which are 
essential for Drosophila development (Rivera-Pomar and Jackie, 1996). These repressors 
fall into two categories: (1) Short-range repressors that work over distances of less than 
100 base pairs to inhibit the core promoter or quench upstream activators and (2) Long 
range repressors that work over distances of 1Kb or more to repress transcription. 
Although the exact mechanisms are unknown, it appears that two evolutionary conserved 
corepressor proteins, Groucho (Fisher and Caudy, 1998) and dCtBP {Drosophila C- 
terminal binding protein) (Nibu et al., 1998)) are essential for the long and short range 
modes of repression, respectively. CtBP factors are conserved across species and 
mammalian homologues have been identified and characterised (Schaeper et al., 1995 
(human) Turner and Crossley et al., 1998 (mouse)).
In the last 5 years, a number of mammalian nuclear hormone receptor interacting proteins 
have also been isolated including nuclear receptor corepressor (NcoR) (Horlein et. al., 
1995 and Kurokawa et al, 1995B) and its homologue silencing mediator of retinoid and
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thyroid hormone receptor (SMRT) (Chen and Evans, 1995). These corepressors interact 
with several unliganded receptors including the retinoic acid receptor (RAR) and thyroid 
hormone receptor (TR). These proteins contain transferable repressor regions and it is 
believed that they function in a multicomponent corepressor complex containing histone 
deacetylase (HDAC) activity and the re-establishment of a repressive chromatin state 
(Hienzel et al., 1997).
1.3.2.4Histones - Repressor and Activator functions
Histone modification facilitates nucleosome assembly and remodelling through 
acetylation or deacetylation of histone “tails” at the N-terminus or by perturbation of 
DNA-histone contacts. Several key factors have now been identified with intrinsic 
chromatin remodelling activity, which has been linked to both gene regulation and the 
initiation of transcription, amongst other processes: 1) Chromatin assembly factors 
(reviewed in Kornberg and Lorch, 1999). Chromatin assembly is fundamental for 
duplication and maintenance of the genome. The core chromatin assembly machinery 
required for ATP-dependent assembly of periodic nucleosomal arrays comprise a protein 
complex called ATP-utilising chromatin assembly and remodelling factor (or ACF) with 
a core histone chaperone such as chromatin assembly factor 1 (CAF-1) or nucleosome 
assembly protein 1 (NAP1) (Ito et al., 1997A and Ito et al, 1997B). 2) Histone acetylases 
and deacetylases. When the core histones are acetylated a neutralisation of charge on 
lysine residues causes a reduction in the affinity of histone-DNA interactions leading to 
increased access of transcription factors to the repressed chromatin template. Indeed,
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there is a positive correlation between the extent of core histone acetylation and gene 
activity (reviewed in Kouzarides, 1999). Histone aceytltransferases (HATs) include the 
HAT1 protein, GCN5 protein, the TAFII250 subunit of TFIID, CBP/p300, P/CAF, and 
the SRC-1 family of coactivators (reviewed in Torchia et al., 1998, Kuo and Allis, 1998). 
Conversely, acetyl groups are removed from histones by specific histone deacetylase 
(HDAC) enzymes. Histone deacetlylation is associated with transcriptional repression 
and HDACs include HDAC1, HDAC2 and RpAp48 (reviewed in Torchia et al., 1998, 
Kuo and Allis, 1998 and Ng and Bird, 2000). 3) DNA methylation (reviewed in Ng and 
Bird , 1999). Methylation of cytosines in a DNA recognition element can block the 
binding of sequence-specific trans-acting proteins (Hsieh, 1999). Other studies suggest 
that methylation of cytosine residues at CpG sites may provide direct binding sites for 
certain DNA binding activators or repressors. Indeed, the MeCP2 chromosomal protein 
binds specifically to methylated DNA, via its methyl CpG binding domain, and represses 
transcription by displacing histone HI (Nan et al., 1997). Interestingly, recent studies 
have shown that MeCP2 can also bind to components of the mSin3A/HDAC complex. 
Moreover the repressive activities of MeCP2 repressor domain can be alleviated upon 
addition of Trichostatin A-specific HDAC inhibitor (Nan et al., 1998). 4) Chromatin 
remodelling machines. These molecular machines include multiprotein complexes in 
yeast (SWI/SNF and RSC), in Drosophila (NURF, BRM, CHRAC and ACF complexes) 
and in mammals (BRG1- or hbrm- associated complexes) (reviewed in Kornberg and 
Lorch, 1999). Each of these complexes contain a ribonucleoside triphosphate (NTP) 
binding subunit which is thought to act as a processive ATP-binding DNA-translocating 
motor that disrupts histone-DNA interactions.
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Emerging studies provide evidence for an interlaced interplay amongst these mechanisms 
and transcription factors to facilitate cellular processes in the context of chromatin 
(Kadonaga, 1998 and Bestor, 1998). At present, histone acetylation and methylation 
represent the best-understood mechanisms of chromatin remodelling. However, many 
fundamental questions concerning this new exciting field remain unanswered such as 
what mechanisms direct these remodelling complexes to chromatin, what controls their 
range of action and what underlies their diversity. In addition, considering all DNA 
templated processes (transcription, replication, recombination, repair and segregation) 
deal with DNA packaged into chromatin, future studies elucidating conceptual links 
between these nuclear processes are eagerly awaited.
1.2 Normal Haematopoiesis
1,2.1 The Origins o f Haematopoiesis
It has been known for many years that the establishment of the haematopoietic system 
occurs at specific sites in the embryo through a succession of developmental programs, 
which result in the production of precursor colony-forming cells (CFC) that in turn 
differentiate into all mature blood cell types entering the circulation (reviewed in Metcalf, 
1999).
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Today, the ontogenic source of definitive (adult) haematopoietic stem cells in the 
developing foetus is a controversial issue—with developmental biologists debating over 
an intra- or extraembryonic origin for blood stem cells. Evidence from some studies 
indicates that an intra-embryonic site called the aorta-gonad mesonephros (AGM) is the 
sole site of origin of definitive haematopoiesis (Medvinsky et al., 1993, Medvinsky and 
Dzierzak, 1996). On the other hand, more recent work suggested that haematopoietic 
events in the mouse embryo are initiated in the yolk sac and the AGM (Dzierak et al., 
1998). The most recent studies in this field propose a new paradigm for blood cell 
production in the developing foetus where the yolk sac is the exclusive site of primitive 
(embryonic) haematopoiesis. However, definitive haematopoiesis occurs in both the 
yolk-sac and the AGM (Palis et al., 1999) (Figure 1). It is proposed that the yolk sac 
provides two important functions within the developing mouse embryo. Firstly, between 
embryonic day 7.0 (E7.0) and E9.0 in the extraembryonic mesoderm, where blood islands 
are formed (Haar and Ackerman, 1971 cited in Palis et al., 1999). This primitive, 
transient wave of cells are incredibly short lived and sustain the survival and growth of 
the embryo until liver rudiment colonisation at E12 (Copp, 1995). Secondly, definitive 
haematopoietic progenitors are synthesised in the yolk sac between E8.5 and E10, 
possibly derived from newborn repopulating cells found in this tissue (Yoder et al., 1997), 
which in turn rapidly enter circulation. It is postulated that progenitors subsequently seed 
the liver at E9.5 to initiate intraembryonic haematopoiesis. As development progresses 
colony forming unit-spleen (CFU-S), multipotential progenitors and long term 
repopulating stem cells, derived independently in the AGM region at E9 to late E10 
(Medvinsky and Dzierak, 1996), seed the liver at E l l  and ultimately replace the yolk sac-
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derived circulating cells. These AGM-derived cells are found thereafter in the 
bloodstream of the embryo proper. Later this haematopoietic activity shifts to the spleen, 
and thereafter to the bone marrow.
Future studies must clearly define the relationship and the exact origins of the primitive 
and definitive haematopoietic progeny.
1.2.2 Haematopoiesis in the Adult
After birth definitive haematopoiesis occurs in the bone marrow (also the spleen in mice). 
The principle functional obligation of the bone marrow is to supply circulating blood with 
mature blood cells during steady-state conditions and during periods of increased 
demands. In the normal adult the daily production and export of cells within the marrow 
amount to approximately 2.5 billion red cells, 2.5 billion platelets and 1 billion 
graulocytes per kilogram of body weight (Erslev and Lichtman, 1990). Blood cells are 
produced within a specialised environment known as the haematopoietic 
microenvironment, consisting of different cell types (fibroblasts, macrophages, 
endothelial cells and adipocytes) and their products (cytokines and extracellular matrix 
(ECM)) (reviewed in Whetton and Spooncer, 1998). All mature blood cells ultimately 
arise from haematopoietic stem cells, which are pluripotent cells capable of self-renewal, 
maintenance, and differentiation into all haematopoietic lineages (Keller et al., 1985). 
These stem cells give rise to progenitors that lack the capacity for self-renewal. These 
progenitors in turn give rise to more mature precursor cells, which are committed to a
19
specific haematopoietic lineage and are morphologically recognisable (Metcalf, 1984 
cited in Metcalf, 1998). Cultured in vitro, some progenitor cells are bipotential or 
multipotential (e.g. erythroid/megakaryocte (BFU-Meg), granulocyte/macrophage (CFU- 
GM) or granulocyte/erythroid/megakarocyte/macrophage cells (CFU-GEMM). However, 
most of these committed progenitors form colonies composed of a single lineage (e.g. 
erythroid (BFU-E), granulocyte (CFU-G), macrophage (CFU-M), eosinophil (CFU-Eos), 
basophil (CFU-Baso), or megakaryocyte (CFU-Meg) cells. It is these precursors that give 
rise to the mature, terminally differentiated blood cells found in the circulation. The 
generally accepted hierarchical scheme of haematopoiesis is shown in Figure 2.
However, this rigid fate map is likely to be a deceptively simplified scenario. Indeed, 
although it is reasonable to assume that multilineage progenitors are partially descendant 
from either bipotential or unipotential progenitors, the relative frequencies and varying 
proliferative potential of these different progenitor cells suggests that not all single 
lineage progenitors are necessarily the descendants of bipotential or multipotential 
progenitor cells. Furthermore, recent studies have provided evidence for the existence of 
a distinct class of transit cells within this scheme called pre-progenitor cells (PPC) 
(Metcalf, 1998 and reviewed in Metcalf, 1999). These cells are believed to be the 
progeny of stem cells and the ancestors of lineage committed progenitor cells. However 
these studies suggested that not all of the lineage committed progenitor cells are the 
progeny of pre-progenitor cells since some are formed directly by pluripotent stem cells. 
Other studies utilising new methods that facilitate the isolation of multipotential cells 
have provided an opportunity to interrogate the mechanisms of hierarchical 
differentiation. These studies have lead to the notion that selective gene activation is a
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multistep process that may ultimately depend on chromatin changes (Felsenfeld et al., 
1996 and Flickinger, 1999). Another consideration is the mode of cytokine action: it is 
not clear whether these growth factors instruct lineage selection or merely provide a 
permissive environment for stochastic programs of differentiation. In summary, a degree 
of hierarchical structure within haematopoiesis is a certainty but intermediary cell states 
must be fully scrutinised to gain a more realistic model of this process.
One common pathway of haematopoietic lineage restriction involves the formation of 
stable transcription complexes that instigate exclusive programs of gene expression. 
Indeed, it is believed that these processes governing cell differentiation rely on the 
combinatorial action of both lineage-specific and ubiquitous transcription factors.
Exactly how the expression of transcription factors is initiated remains unclear. 
Possibilities include orchestration of factors by stochastic expression of key lineage- 
affiliated regulators or a finely tuned response to instmcted expression. Whatever the 
mechanism, the past decade has proved a fruitful time for the identification and 
characterisation of these key regulators of haematopoietic development, some of which 
will be discussed in section 1.2.2.1 that follows.
1.2.2.1 Nuclear Regulators in Haematopoiesis
Our interests concerning haematopoietic development will focus on the erythroid and 
myeloid lineages in later chapters of this thesis. Therefore the regulation of 
lymphopoiesis and megakaryopoiesis will not be discussed here. However, these
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biological processes were reviewed recently in Henderson and Calame, 1998 (B-cell 
development), Kuo and Leiden, 1999 (T-cell development) and Baatout, 1998 
(megakaryopoiesis). The principle factors involved in erythroid and myeloid regulation 
are addressed below.
1.2.2. L I  Transcriptional Control o f Erythropoiesis
Studies examining cis-elements and globin gene control in erythroid cells defined distant 
regulatory sequences known as the locus control regions (or LCRs), which act over large 
distances within the globin loci. Interestingly, three motifs are common to the LCRs and 
promoters of all erythroid-specific genes examined-to-date including NF-E2 and GATA 
(Orkin, 1995 and Baron, 1997).
The NF-E2 gene product is a bZIP transcription factor, which also contains a dimerisation 
domain. NF-E2 is an obligate heterodimer of a haematopoietic-specific p45 subunit and a 
ubiquitous p l8  subunit that belongs to the MAF family of proteins (Blank et al., 1997 and 
Francastel et al., 1997). Several earlier studies provided evidence for NF-E2 as the major 
enhancer function of |3- globin gene expression (Talbot et al., 1990, Jarman et al., 1991, 
Shivadasani and Orkin, 1996). Absence of p45 nf-e2 in mice results in mild, albeit 
consistent, red blood cell abnormalities, including hypochromia, anisovytosis and 
reticulocytosis (Shivadasani and Orkin, 1995). NF-E2 is also expressed in 
megakaryocytes and mast cells (Andrews et al., 1993). Others have implicated 
phosphorylation in the regulation of NF-E2 transcriptional activity during erythroid 
differentiation (Nagai et al., 1998). Recently, the p45 subunit of NF-E2 has been
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recognised to mediate protein-protein interactions: p45 can interact with key regulators of 
chromatin modification and transcriptional activation namely, the CREB Binding Protein 
(CBP) and TAFnl30 (Cheng et al., 1997 and Amrolia et al., 1997 respectively).
GATA-1, the founding member of the GATA factor family, is one of the most extensively 
studied erythroid transcription factors. It is a member of a highly conserved family of 
transcription factors, which bind the conserved motif GATA, present in all erythroid- 
specific promoter regions investigated so far. Therefore, it is considered that GATA-1 is 
involved in regulating most, if not all, erythroid specific genes. Gene targeting 
experiments reveal that a loss of GATA-1 results in a developmental arrest at the 
proerythroblast stage and apoptosis (Penvy et al., 1995, Weiss et al., 1994 and Weiss and 
Orkin. 1995), which results in embryonic lethality by E11.5 (Fujiwara et al., 1996).
Others have demonstrated that the GATA-1 protein consists of an N-terminal activation 
domain (Martin and Orkin, 1990) and two zinc fingers: the C-terminal finger binds DNA 
and the N-finger stabilises DNA binding at GATA sites (Trainor et al., 1996). In addition 
to binding DNA the N-finger can also interact with several co-factors, including the 
recently identified Friend of GATA-l(FOG-l) (Tsang et al., 1997), which can both co­
operatively activate (Tsang et al., 1997) and also inhibit (Fox et al., 1999) GATA-1- 
mediated activation. GATA-1 is regulated by the transcriptional co-activator CBP 
(Blobel et al., 1998). Since CBP can associate with molecules which possess histone 
acetylase activity and complexes containing RNA pol II this interaction (1) suggests 
GATA-1 regulation through recruitment of a histone acteyltransferase complex and (2) 
provides a link between GATA-1 and components of the basal promoter machinery. It
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must be noted that GATA-1 expression is not restricted to erythroid cells, indeed its 
detection in megakaryocytes, mast cells, multipotent progenitors and early monocytic 
cells suggests that it plays a role in the differentiation of multiple blood lineages 
(reviewed in Orkin, 1998).
The SCL/TAL1 gene, a member of the bHLH family, can bind E box DNA sequences by 
forming heterodimers with bHLH proteins encoded by the E2A, HEB or E2-2 genes 
(Voronova and Lee, 1994 and Hsu et al., 1991). Gene targeting experiments in mice 
reveal that this gene is essential for yolk-sac erythropoiesis and SCL null embryonic stem 
(ES) cells fail to contribute to any haematopoietic lineages in chimaeric mice (Orkin and 
Zon, 1997)—indicating the role of SCL is cell autonomous. SCL, similar to GATA-1, is 
normally expressed in erythroid cells, mast cells, megakaryocytes and progenitor/ “stem 
cells” (Green et al., 1991 and Visvader et al., 1991). Constitutive expression of wild-type 
and dominant negative forms of SCL in erythroleukemia cell lines provide indirect 
support for a role of SCL in erythropoiesis (Apian et al., 1992). Several studies have also 
suggested a role for SCL in vascular differentiation. Forced expression of SCL in 
zebrafish embryos resulted in an expansion of haematopoietic and vascular precursors 
(Gering et al., 1998). Moreover in the zebrafish mutant cloche, expression of SCL cDNA 
partially rescues defects in haematopoietic and vascular lineages, implying that SCL lies 
downstream of cloche in the developmental cascade (Liao et al., 1998).
Other critical genes involved in erythropoiesis include erythroid kriippel-like factor 
(EKLF) and the LIM domain protein, LM 02. Null mutations in either of these genes,
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GATA-1 or SCL result in a similar mutant phenotype— a complete lack of erythropoiesis 
in the yolk sac—which implicated some regulatory interplay or common role for these 
genes in haematopoietic development. (Fujiwara, 1996 Warren et al., 1994, Shivadasani 
et al., 1995 and Robb et al., 1995). Several studies have identified various associations 
between these proteins. Indeed, a large multiprotein complex was discovered by in vitro 
analyses of a protein DNA complex containing GATA-1, LM 02, SCL/TAL1, E2A (a 
basic HLH protein) and LBD1 (another LIM-domain protein) that binds a DNA sequence 
consisting of E box and GATA sites separated by approximately 9bp (Wadman et al.,
1997). Furthermore, since GATA-1, NF-E2 and EKLF all directly interact with and can 
be regulated by CBP (reviewed in Blobel et al., 2000) it is tempting to speculate that all 
three proteins co-operate to form a high molecular weight complex linked through CBP at 
the locus control region (LCR) of the p-globin gene cluster. Indeed it would appear from 
the increasing number of factors known to directly bind GATA-1 that the presence of 
GATA-1 binding sites may be central in recruiting factors to multiprotein complexes 
which activate distinct target genes during erythropoiesis.
2.2.1.2Transcriptional Control of Myelopoiesis
PU.l, the product of the PU.l/SPI-1 proto-oncogene, is a member of the ETS 
transcription family (Klemsz et al., 1990). All ETS factors are characterised by a 
conserved DNA binding domain of 80 amino acids (Karim et al., 1990). PU .l is 
preferentially expressed in myeloid and B cells and plays a pivotal role in their 
development (Chen et al., 1995A). Indeed, PU .l knockout mice lack neutrophils, 
monocytes and B cells (Scott et al., 1994) and others have shown PU .l expression to
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instruct multipotent progenitors to differentiate along the myeloid lineage (Nerlov and 
Graf, 1998). The structure of PU .l is that of a winged HTH DNA binding domain 
(Kodandapani et al., 1996) at the C-terminus and an activation domain at the N-terminus 
that is believed to interact with other regulatory proteins (Klemsz et al., 1996). PU.l 
regulates the expression of almost all characterised myeloid genes, including growth 
factor receptors. In particular, it directs macrophage specific expression of the M-CSF 
receptor (Zhang et al., 1994 and Olson et al., 1995), which is critical for monocytic cell 
survival and proliferation. Interestingly, a recent study has shown that PU.l can directly 
interact with GATA-1 and as such GATA-1 negatively regulates myeloid differentiation 
(Nerlov et al., 2000). On the other hand, overexpression of PU .l can block erythroid 
differentiation (Rektman, 1999) by interacting with and repressing GATA-1-mediated 
transactivation. Thus, it is postulated that the opposing effects of these factors may 
determine lineage-specific differentiation. These studies indicate that PU. 1 is both a 
“master” regulator of myeloid differentiation and a regulator of erythroid development.
AML-1 is a member of the core binding factor (CBF) or polyoma enhancer binding 
protein 2 (PEBP2) family of transcription factors. CBF factors consist of heterodimers 
between DNA binding a  subunits and a p subunit that is unable to bind DNA but 
enhances the binding of the a  subunit (Wang et al., 1993). Several a  subunits have been 
detected including CBFA1, CBFA2 and CBFA3 (Miyoshi, 1995). The CBFa contains 
the runt domain which shares homology with the Drosophila pair-rule segmentation gene, 
runt. The runt homology domain allows binding of AML1 to its target sequence 
TGYGGTY and binding to CBFp which increases DNA binding affinity (Ogawa, 1993).
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AML1 knockout studies demonstrated the importance of this gene in development. The 
AML1 knockout mice have a severe disruption in definitive haematopoiesis with defects 
in all haematopoietic lineages (Okuda et al., 1996). Recent studies have demonstrated 
that AML1 can act as a repressor and an activator or transcription in a cell-specific 
manner. For example AML1 interacts directly with the bzip domain of C/EBP to 
synergistically activate the M-CSF receptor promoter (Zhang et al., 1994). More 
recently, AML1 was found to co-operate with LEF-1 to repress transcription of the T-cell 
receptor a  enhancer (Levanon et al., 1998). It is speculated that AML1 is a “master” 
regulator that facilitates the assembly of protein complexes for transcriptional regulation 
during the differentiation of primitive cells into definitive haematopoietic elements.
C-MYB, the cellular homologue of the v-myb oncoprotein, is a sequence-specific 
transcriptional activator (Biedenkapp et al., 1988). C-MYB is highly expressed in 
immature haematopoietic cells and is down-regulated during terminal differentiation of 
these cells (Westin et al., 1982 and Gonda and Metcalf, 1984). Moreover, chemically or 
cytokine-induced differentiation of myeloid or erythroid leukaemia cells results in a 
down-regulation of C-MYB (Westin et al., 1982, Gonda and Metcalf, 1984 and Kuehl et 
al., 1988). Furthermore, forced expression of C-MYB inhibits erythroid differentiation 
(Clarke et al., 1988), whereas antisense oligonucleotide inhibition is accompanied by 
growth arrest and reduced haematopoietic colony formation (Gewirtz and Calabretta,
1988). These results suggest that down-regulation of C-MYB is necessary for terminal 
differentiation. Consistent with this, c-myb knockout mice are severely anameic and die
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in utero at the foetal liver stage (Mucenski et al, 1991). Interestingly, primitive 
erythropoiesis in the yolk sac and megakaryopoiesis in the liver are unaffected in these 
embryos. Therefore, it is believed that either C-MYB is required for the proliferation of 
multipotential progenitors or that it is required independently for the proliferation of 
multiple haematopoietic lineages.
Several studies have provided evidence that the retinoic acid receptor (RAR) may be key 
for myeloid differentiation. For example vitamin A deficiency is associated with 
defective haematopoiesis and retinoids stimulate granulopoiesis (Wolbach et al., 1925, 
Hodges et al., 1977 cited in Tenen et al., 1997). Furthermore retinoic acid (ATRA) can 
induce myeloid differentiation in HL60 cells and in primary leukaemic cells (Collins et 
al., 1990). The RARa protein is divided into six conserved domains. The C-terminal 
domain contains to C2C2 zinc finger motifs. Through this domain RARa binds to retinoic 
acid response elements (RAREs). RAREs consist of a direct repeat (A/G)G(G/T)TCA 
separated by 2 or 5 nucleotides. RARa binds as a heterodimer to this site along with the 
retinoic acid receptor X (RXR) which stimulates transcription in response to ATRA 
(Umesono et al., 1991). The importance of RARa in myeloid differentiation was 
recognised when Collins et al. (Collins et al.,1990 and Damn et al., 1993) developed an 
HL60 cell which could not differentiate by ATRA treatment. RARa was mutated in this 
cell line but differentiation of these cells by ATRA was restored upon infection with a 
retrovirus expressing the wildtype receptor. Moreover, RXRa overexpression in the 
resistant cells restored myeloid differentiation, which suggested that the mutant receptor 
acted as a dominant negative by heterodimerising with wildtype RXR forming an inactive
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complex. The overexpressed RXR is believed to recruit other RAR isoforms in the cell to 
overcome the block and activate the differentiation program. Similarly it is believed that 
these isoforms which may compensate for RARa in RARa knockout mice show no major 
defects in haematopoiesis.
A number of others transcription factors have been implication in the regulation of 
normal myeloid development including the myeloid zinc finger protein MZF-1, the 
Wilms Tumour Suppressor Gene (WT-1), ETS factors (including SPI-B , FLI-1, ELF-1, 
ETS-2), various HOX  genes, Mixed Lineage Leukaemia protein (MLL), C-MYC, p53, C- 
JUN  and NF-kB  (reviewed in Tenen et al., 1997). However the proposed intricacies of 
their function within myelopoiesis will not be discussed here.
Interestingly, the most frequent targets of chromosomal translocations in the acute 
leukaemias are genes that encode these haematopoietic transcription factors, which merits 
the importance of these “master” regulators in the control of blood cell development. 
Considerable progress within this field can be attributed to a combination of genetic 
analyses in mice deficient in haematopoiesis-specific nuclear regulators, the molecular 
cloning of translocation breakpoints and mechanistic analyses of these factors in 
appropriate in vitro model systems (Shivadansi and Orkin, 1996, Rabbitts, 1994, Rowley, 
1998, Rowley, 1999 and Sanchez-Garcia, 1997). Subsequent studies uncovered (1) how 
some of these proteins interact with each other to regulate transcription (2) how 
interactions with DNA can modulate chromatin configuration and (3) the role of some of 
these factors in leukaemogenesis.
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1.3 Nuclear Oncogenes in Leukaemogenesis
Normal haematopoiesis is a developmental continuum characterised by an intrinsic 
flexibility that ensures both the maintenance of circulating blood cells and a prompt 
adaptation to abnormal circumstances (for example, blood loss and infection) that alter 
tissue homeostasis. This process requires highly orchestrated processes for its 
maintenance, suggesting that even the slightest imbalance could have immediate, 
dramatic consequences. Leukaemia is envisioned as an extreme manifestation of an 
uncoupling of proliferation and differentiation within the haematopoietic pool, which 
perturbs the relationship between resting, cycling and terminally differentiated cells.
Over the last quarter of a century, many experimental data have collectively implicated 
loci involved in the regulation of cell proliferation as being the genomic defects of cancer 
cells. On the basis of their biochemical activity, where known, and the type of genetic 
alteration that affects the transformed cell, “cancer genes” have been divided into two 
broad groups: proto-oncogenes and tumour suppressor genes. The proto-oncogenes code 
for proteins that are components of the cellular signalling pathways such as transcription 
factors, growth factors and cell cycle components. Proto-oncogene alterations (such as 
point mutants, gene amplification or translocations) lead to a subsequent gain-of-function 
that accelerates cell division. These changes are dominant and normally affect only a 
single allele of the gene. Tumour suppressor genes, on the other hand, are subject to loss 
of function recessive alterations most commonly through deletions or point mutations that 
truncate the protein or alter an essential functional domain. It is widely accepted that 
tumourigenesis involves a multi-step process involving several intrinsic and extrinsic
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genetic changes all acting synergistically to maintain the transformed phenotype of the 
“diseased” cells.
1.3.1 Activation o f Proto-oncogenes
1.3.1.1 Chromosomal Translocations and Insertions
As early as 1900 scientists proposed that chromosomal abnormalities were directly related 
to the development of neoplasia. However, it was not until after the discovery of 
chromosomal banding techniques in the late 1960s that consistent recurring gains and 
losses of chromosomes in leukaemias, lymphomas and some solid tumours were 
identified (Rowley et al., 1975 cited in Rowley, 1998) (See Table 1). Moreover, the 
discovery of non-random, somatically acquired chromosomal translocations and 
inversions led to a remarkable surge of knowledge regarding the genetic changes in 
leukaemic cells. Over 150 different tumour-specific breakpoints have now been 
recognised with a remarkable 65% and 100% of acute leukaemias and chronic myeloid 
leukaemias harbouring chromosomal rearrangements. The most frequent targets of these 
chromosomal translocations or inversions turned out to be genes that encode transcription 
factors involved in normal haematopoiesis.
Many of these transcription factors are converted into activated oncoproteins in certain 
neoplasias after translocation by two principle mechanisms (Figure 4). (1) Recombinase 
error results in the activation of normally silent proto-oncogenes. (2) More commonly,
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breaks occurring within introns between coding regions of two transcription factors genes 
in separate chromosomes, create a fusion gene encoding a chimaeric protein with unique 
properties.
1.3.1.1.1 Translocation-Generated Oncogenes in Myeloid Leukaemias
The translocations involved in the inappropriate activation of transcription factors in 
myeloid leukaemias show remarkable specificity for haematopoietic cells blocked in 
defined stages of differentiation (reviewed in Shivadansi and Orkin, 1996, Rabbitts, 1994, 
Rowley, 1998, Rowley, 1999 and Sanchez-Garcia, 1997). These observations implied 
that the resultant oncoproteins interfere with specific transcriptional networks that 
normally function concurrently with growth factors and their receptors to regulate 
haematopoiesis. Indeed, this property has been reinforced by gene targeting experiments 
whereby null mutations are introduced into mutant mice— specific examples of which are 
discussed below.
Acute Myeloid Leukaemia (AML)
AML is a clonal, malignant disease of the haematopoietic tissue. It is characterised by the 
proliferation of leukaemic blast cells primarily in the marrow and impaired production of 
normal blood cells. The leukaemic cell infiltration is accompanied nearly invariably by 
anaemia and thrombocytopenia. AML is classified on the basis of the morphological 
appearance of the bone marrow into seven subtypes, FAB M1-M7 which differ depending 
on the predominant cell type involved.
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Acute M yeloid Leukaemia-1 (AML-1) fusions
Translocations that disrupt the AML1 gene are amongst the most common aberrations 
found in human leukaemias. The t(8;21) found in 15% of myeloid leukaemias gives rise 
to the AML1-ETO transcriptional repressor (Erickson et al., 1992 Feinstein et al., 1995, 
Miyoshi et a l, 1991 and Nisson et al., 1992). The t(3;21) results in the production of 
several fusion proteins namely AML1/EAP, AML1/MDS-1 and AML-EVI-1 (Mitani et 
al., 1994 and Nucifora and Rowley, 1995). inv(16) fuses the AML1 DNA binding partner, 
CBF|3 to a smooth muscle myosin heavy chain gene, MHY11 giving CBF(3-MYH11 in 
15% of acute myeloid leukaemias (Liu et al., 1993). Studies carried out with these 
fusions, (Klampfer et al., 1996, Mitani et al., 1994 and Liu et al., 199, respectively), 
suggest that they may act as dominant negatives to mediate oncogenic changes, either by 
producing a transcriptionally inactive dimer or by forming a complex that actively 
interferes with other components of the transcriptional apparatus.
Acute Promyelocytic Leukaemia (APL)
Acute promyelocytic leukaemia (APL) accounts for approximately 15% of all AMLs and 
comprises the M3 subtype (Chen et al., 1996 cited in Strout et al., 1997). The APL 
disease is characterised by the accumulation of leukaemic promyelocytes in the bone 
marrow, and unique to other AML forms, is frequently sensitive to all-trans retinoic acid 
(ATRA).
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Retinoic A cid  Receptor CL (RARCL) fusions
APL is currently associated with four different gene rearrangements fusing RARa to the 
promyelocytic leukaemia gene (PML), promyleocytic leukaemia zinc finger (PLZF), 
nucleophosmin (NPM), or nuclear matrix associated (NuMA) genes, which lead to the 
formation of reciprocal fusion proteins (N-RARa and RARa-N). RARa-PML is created 
by t(15:17) (Goddard et a l, 1991), RARa-PLZF by t(ll;17)(q23;q21) (Licht et al., 1995), 
RARa-NMA by t(5;17)(q32:q21) (Brunei et al., 1995) and RARa-NuMA 
t(ll;17)(ql3;q21) (Wells et al., 1996). The multimerisation of N-RARa fusion proteins 
are believed to interfere with normal ATRA-mediating signalling and sequestering 
cofactors. In particular, the involvement of PML- and PLZF- RARa fusions in APL 
pathogenesis have gained much notoriety in the past few years as a important paradigm 
for differentiation therapy (Redner et al., 1999 and Melnick and Licht, 1999 and 
references therin). Both PML-RARa and PLZF-RARa inhibit the activity of wildtype 
RARa in a dominant negative fashion (Chen et al., 1996B and Licht et al., 1996, 
respectively). Most commonly, APL is associated with the expression of PML-RARa 
and is sensitive to pharmacological levels of ATRA treatment which release repressive 
nuclear corepressor complexes and induce myeloid differentiation (reviewed in Fenaux et 
al., 1996). However, APL patients which harbour the PLZF-RARa fusion are insensitive 
to ATRA treatment and have an overall poor prognosis (Chen et al., 1996B). This is the 
result of a ligand insensitive association of a corepressor with the PLZF protein (David et 
al., 1997, Lin et al.,1998 and Grignani et al., 1998).
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Chronic Myeloid Leukaemia (CML)
Chronic myelocytic leukaemia is a clonal disorder of the pluripotent haematopoietic stem 
cells which usually has a biphasic course. The initial phase is characterised by clonal 
expansion of a CML clone with terminal differentiation, which is followed by an acute 
blastic crisis phase which results in cell proliferation, maturation arrest and karyotypic 
clonal evolution.
The BCR-ABL Fusion
The reciprocal translocation t(9;21)(q34;qll), a hallmark of the chronic phase of CML 
(De Klein et al., 1982), generates the BCR-ABL fusion on the Philadelphia chromosome, 
which is now detected in almost 100% of patients with clinically typical CML (reviewed 
in Osarogiagbon et al., 1999). The product of the BCR-ABL chimera is an abnormal 
tyrosine kinase, p210bcrabl, which gives haematopoietic cells the characteristics of 
excessive proliferation (Daley et al., 1990), resistance to physiologic apoptotic signals 
(McGahon et al., 1994) and resistance to chemotherapy (Chomel et al., 2000). 
Interestingly, the BCR-ABL fusion has also been identified in AMLs (Najfeld et al., 
1998) suggesting that it arises in primitive cells with multilineage potential.
In summary, most of these oncogenes activated/created by chromosomal abnormalities 
are likely to play a role in tumour-specific cell differentiation and/or proliferation controls 
due to their homology or identity to genes involved in other experimental systems that 
affect development or differentiation. Subversions in these orderly processes result in
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blockades allowing the accumulation of immature proliferating cells or tumour cells. 
Moreover, it is hypothesised that the formation of aberrant multi-protein complexes, 
which occur after chromosomal translocations is paramount to tumour development.
Some other examples of proto-oncogene activation include gene amplification and 
retroviral insertions:-
1.3.1.2 Gene Amplification
Many cancer cells contain multiple copies of structurally normal oncogenes. These 
amplifications are generally associated with more advanced tumours (reviewed in 
Schwab, 1998).
1.3.1.3 Retroviral Insertions
Common sites of integration for animal tumour viruses are near or within proto­
oncogenes causing their activation: cellular genes are brought under control of the viral 
LTR or are fused to viral sequences with the consequent production of novel proteins 
(Hayward et al., 1981). This knowledge has led to the use of insertional mutagenesis as a 
means of identifying novel proto-oncogenes that are consistent targets of proviral 
insertion (Nusse and Varmus, 1982).
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One specific nuclear oncogene identified in this way was Ecotropic viral integration site-1 
or EVI-1 (Morishita et al., 1988). Subsequent work has shown that EVI-1 encodes a zinc 
finger protein, is essential for foetal and adult development and that unscheduled EVI-1 
expression is associated with myeloid leukaemias and myelodysplastic syndromes in mice 
and humans. The remainder of this chapter discusses the properties of the EVI-1 
transcription factor in detail.
1.4. The Evi-1 Transcription Factor
1.4.1 Identification o f Evi-1
EVI-1 was discovered using AKXD recombinant inbred (RI) mouse strains derived from 
crosses of AKR/J and DBA/2J. The high levels of leukaemia susceptibility in AKXD 
strains are the result of inheritance of endogenous ecotropic MuLV proviruses, namely 
Emv-11 and Emv-14 (Mucenski et al., 1986, Gilbert et al., 1993). Tumourigenesis 
involves the expression of these endogenous ecotropic proviruses, recombination between 
somatic viruses, and re-integration near cellular oncogenes. The DNA from all tumours 
of the strain AKXD 23 was found to contain proviruses that were inserted into the same 
chromosomal domain designated ecotropic viral integration site 1 {evi-1) (Mucenski et 
al., 1988). In a separate study evi-1 activation by retroviral insertions was found in IL-3- 
dependent myeloid leukaemia cell lines (Mucenski et al., 1988). In light of this 
knowledge further studies detected evi-1 rearrangements in myeloid cell lines and
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leukaemias in NSF/N or NSF/N hybrid mice injected as neonates with wild mouse 
ecotropic or MCF-MuLV and Cas-Br-E MuLV (Mucenski et al., 1988, Bergeron et al., 
1992). Evi-1 insertions are predominantly myeloid-specific. However, some have been 
found is a small number of B and pre-B cell tumours (Mucenski et al., 1988). The 
subsequent elucidation of the intron-exon structure of the 5 ’ end of the gene revealed that 
proviral insertions were oriented in the same transcriptional direction (5’-*3’), and were 
tightly clustered, occurring within a 0.6Kb stretch of DNA. The intron-exon structure of 
EVI-1 is not characterised. However, the genomic organisation of the first three exons is 
known and translation is initiated in exon three (Matsugi et al., 1990). In humans, MDS1 
was recently identified as a previously unreported exon of EVI-1 with the addition of this 
exon creating the MDS1/EVI-1 isoform. MDS1 has been mapped 170-400Kb upstream of 
EVI-1 (Nucifora et al., 1994). (MDS-1 is discussed later in sections 1.4.3.1 and 1.4.6.1).
A second common integration site associated with evi-1 has also been identified in 
Friend-virus induced murine leukaemias. Nearly a quarter of all myeloblastic leukaemias 
induced by this virus were found to exhibit proviral insertions in this particular site which 
was then named fim-3 (Borderaux et al., 1987). Characterisation of another common 
integration site, cb-1, demonstrated that it was identical to fim-3 (Bartholomew et al.,
1989). It was subsequently shown that these proviral insertions also activate evi-1 
expression. Genomic organisation of the cb-l/fim-3/evi-l region shows that fim-3 is 
located 90Kb upstream of the first exon of evi-1 (Bartholomew and Ihle, 1991). It is 
believed that these insertions act from a distance to activate evi-1 transcription by an 
enhancer-insertion mechanism. Ectopic expression of evi-1 in murine myeloid
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leukaemias is therefore a consequence of retroviral insertion at either the fim3 or evi-1 
loci.
1.4.2 Development and Evi-1
To determine the molecular mechanisms of EVI-1 action in leukaemogenesis it is 
imperative that we understand the normal function and regulation of the EVI-1 gene.
1.4.2.1 Evi-1 and mdsl/evi-1 expression in adult murine tissues 
EVI-1
The zinc finger regions of EVI-1 share homology with egl-43, a zinc protein in C.elegans 
which is involved in migratory activity and development (Garriga et al., 1993). Primary 
northern blot analyses of murine tissues have revealed high evi-1 levels in the kidney, 
uterus, lung and heart (Morishita et al., 1990 and Perkins et al., 1991B, Wimmer et al.,
1998). Therefore, the restricted spatiotemporal pattern of evi-1 expression in adult tissues 
suggests that evi-1 is involved in organogenesis.
During examination of cell lines, EVI-1 has not been detected in myeloid, T-cell and B- 
cell leukaemic cell lines and cell lines derived from a range of organs, including lung, 
placenta, ovary, spleen and heart in these studies (Morishita et al., 1990). EVI-1 is
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expressed in primary foetal kidney cells but not in many established kidney cell lines 
(Bartholomew and Clark, 1994).
MDS1/EVI-1
The evolutionarily conserved MDS1 gene shares homology with the PR domain of the 
retinoblastoma binding zinc finger protein, RIZ (Buyse et al., 1995 and Fears, 1996), to a 
lesser extent the PR domain of the transcriptional repressor PRDI-BFI/Blimp 1 (Huang et 
al., 1994) and egl-43 (Nucifora et al., 1997). The fusion transcript between evi-1 and 
mds-1, described in section 1.4.1 earlier, has also been detected in normal murine tissues, 
including haematopoietic progenitor cells, pancreas, kidney and lung (Sigurdsson et al., 
1995 and Wimmer et al., 1998). Wimmer et al., 1998 demonstrated that endogenous 
levels of evi-1 and mds-l/evi-1 when up-regulated in mouse embryonic stem cells 
induced them to differentiate into myeloid haematopoietic cells in vitro. Indeed, 
mdsl/evi-1 expression overlaps remarkably with evi-1 expression patterns in murine 
tissues, with no major shift in their relative abundance (Wimmer et al., 1998). 
Furthermore, considering MDS1/EVI-1 expression is down-regulated in leukaemic 
samples relative to overexpressed EVI-1 levels and the transcriptionally antagonistic 
nature of these proteins (Solderholm, 1997), finely tuned levels of these isoforms may be 
of great importance for either normal or leukaemic development.
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1.4.2.2 Evi-1 Expression in Murine Embryonic Development
Whole mount in situ hybridisation studies of murine embryos revealed that on days 9.5,
12.5 and 14.5 post-coitum high level evi-1 expression was evident in the urinary system, 
the Mullerian ducts, the limb buds, endothelial cells and valve leaflets of the heart, the 
tracheal bronchial epithelium of the lungs and epithelial cells of the developing nasal 
cavity (Perkins et al., 1991). Interestingly, this restricted pattern of gene expression 
overlaps with that of other transcriptional regulatory genes (including some HOX  and 
RAR genes) (Perkins et al., 1991). Thus, it has been postulated that zinc finger proteins 
such as EVI-1 may function in murine development by controlling other important 
regulatory genes such as above. Indeed in Drosophila, zinc finger proteins are heavily 
implicated in cell fate and decisions concerning body plan (Chavrier et al., 1990).
Evi-1 knockout experiments were subsequently performed to address its’ biological 
function in murine development (Hoyt et al., 1997). Homozygous evi-1 knockout mice 
lack the full length evi-1 transcript and die in utero at 10.5 days post-coitum (d.p.c.). In 
comparison to normal littermates at 10.5 d.p.c. multiple malformations are apparent: The 
most obvious being an reduced foetal size, a malformed forebrain, large pericardial sacs 
and large-scale haemorrhaging. Furthermore, disruption of paraxial mesechyme ventral 
to the neural tube was evident along with defective myotome at somite-regions. It is 
noteworthy that tissues which normally express high levels of evi-1, including kidney and 
ovary, are relatively unaffected in evi-1 homozygous mutants. However, the knockout 
mice used in these experiments are not null mutants as they continue to express the
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continue to express the alternatively spliced evi-1 transcripts. Therefore, these evi-1 - 
expressing tissues may be somehow salvaged from more detrimental knockout effects by 
the compensatory effects of evi-1 isoforms.
1.4.3 EVI-1 is an Oncogene Involved in Human Disease
1.4.3.1 Myelogenous Leukaemias
Ectopic expression of EVI-1 has been correlated with the progression of human 
malignancies namely, acute myelogenous leukaemia (AML), myelodysplastic syndrome 
(MDS) and chronic myelocytic leukaemia in blastic crisis (CML-BC).
Accumulated evidence demonstrates that EVI-1 is transcriptionally activated in these 
leukaemias by translocations and inversions involving chromosome 3q26—where EVI-1 
is located—which include t(2;3)(pl5;q26), inv(3)(q21q26), t(3;3)(q21;q26), 
t(3;7)(q27;q22), t(3;12)(q26;pl3), t(3;13)(q26;pl3-14), t(3;17)(q26;q22) and 
t(3;21)(q26;q22) (reviewed in Nucifora, 1997).
In general, 3q21q26 aberrations and EVI-1 activation in myeloid leukaemias are 
correlated with abnormalities in megakaryopoiesis which is characterised by high platelet 
counts (Bitter et al., 1985, Bernstein et al., 1986) and lack of response to conventional 
chemotherapy (Testoni et al., 1999). However, it is likely an array of additional genetic
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lesions contributes to leukaemogenesis associated with unscheduled EVI-1 expression. 
For example, myelogenous leukaemias have been described with simultaneous 3q21q26 
abnormalities and monosomy 7 (Igarashi, 1998).
Acute Myeloid Leukaemia (AML)
In AML cases with inv(3)(q21q26) and t(3;3)(q21q26), EVI-1 is located near the q26 
breakpoint, while the ubiquitously expressed Ribophorin I  gene is located 50kb upstream 
near the q21 breakpoints. As a consequence of these rearrangements, Ribophorin I  is 
positioned transcriptionally towards either the 3 ’ end of the EVI-1 gene in the case of inv 
(3) or towards the 5 ’ end of the EVI-1 gene in t(3;3). This indicates that Ribophorin I  
provides enhancer elements for EVI-1 transactivation (Suzukawa et al., 1994).
Chronic Myeloid Leukaemia (CML)
The reciprocal translocation t(9;21)(q34;qll) is a hallmark of the chronic phase of CML 
(CML-BC) (De Klein et al., 1982) resulting in the generation of the p210bcr~abl fusion gene 
on the Philadelphia (Ph) chromosome (Ben-Neriah, 1986). Subsequently, a series of 
additional aberrations accumulate resulting in blastic crisis. t(3;21)(q26;q22) is one of 
these additional alterations in CML-BC (Rubin et al., 1987). This particular translocation 
is also seen to a lesser extent in MDS and secondary leukaemias (so called therapy-related 
MDS or Acute Lymphoblastic Leukaemias) (Bitter et al., 1985)— discussed below. This
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raises the possibility that the molecular event underlying this reciprocal translocation has 
a critical role in the progression from a preleukaemic state to a leukaemic state.
EVI-1 Fusion Genes
The t(3;21)(q26;q22) can produce the chimaeric protein, AML1-EVI-1 that results from 
AML1 and EVI-1 crossing the t(3;21) breakpoint resulting in a fusion of the N-terminal 
runt homology domain of AML1 to the EVI-1 gene (Mitani et. al., 1994). Interestingly, 
between the t(3;21) breakpoint and EVI-1 there are two other genes EAP, which encodes 
the ribosomal protein L22 and MDS1, which encodes a small polypeptide of unknown 
function (Nucifora et al, 1994). All three chromosome 3 genes are in the same 
transcriptional orientation, directed away from the breakpoint site, and in the same 
orientation as AML1. These recombinant chromosomes exhibit eight different chimaeric 
RNA transcripts including AML1/MDS1/EVI-1 and EAP/MDS1/EVI-1 (Fears et al., 
1995, Zent et al., 1997). In addition, TEL1(ETV6)— recently discovered as a potent 
sequence specific transcriptional repressor (Lopez et al, 1999)— is one of the most 
frequently rearranged transcription factors in human leukaemias and has been 
documented as a fusion protein with MDS1/EVI-1 as a result of t(3;12)(q26;pl3) (Peeters 
et al., 1997). Generally, it is hypothesised that these fusion proteins act dominantly over 
the endogenous proteins necessary for normal haematopoiesis.
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Myelogenous leukaemia expressing EVI-1 without 3q26 abnormalities
The myelodysplastic syndromes (MDSs) are a subset of haematological malignancies 
with altered proliferation and differentiation of the erythroid and myeloid lineages of 
which approximately 30% of cases will progress into full blown AML. MDSs are 
characterised into 3 categories; refractory anaemia (RA) is followed by increasing 
advanced disease states refractory anaemia with ringed sideroblasts (RARS), RA with 
excess of blasts (RARE) and RA with excess of blasts in transformation (RAEBT).
Some studies have reported the incidence of EVI-1’s expression in MDS patients as 
generally low with ectopic EVI-1 expression detected without chromosome 3q26 
abnormalities in primarily RAEB and RAEBT (Russell et al., 1994 and Fichelson et al., 
1992, Dreyfus et al., 1995). As with CML-BC it appears that EVI-ls appearance is 
associated with leukaemia progression.
Chromosomal abnormalities involving 3q26 have been established in less than 5% of 
human leukaemias. However, recent findings strongly argue that overexpression of EVI-1 
in MDSs and AMLs without 3q26 abnormalities is much more common and suggests a 
major role in tumourigenesis for these neoplasias (Ogawa et al., 1996). Expression of 
EVI-1 without 3q26 aberrations has now been documented in 70% of CML-BCs, 20.3% 
of AMLs and 27.3% of MDS-derived leukaemia (Ogawa et al., 1996). Others have also 
detected abnormal EVI-1 expression in acute promyelocytic leukemia (APL) without 
3q26 structural abnormalities (Russel et al., 1994).
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However, these results must be interpreted with caution: a number of possibilities exist 
which may explain the prevailing EVI-1 expression associated with these malignancies;
(1) it may simply be a consequence of a small deletion: this is exemplified by the SCL 
oncogene, which was originally cloned from the breakpoint of t(l;14)(p32;qll) found in 
1-3% of human T cell acute lymphoblastic leukaemia (T-ALL) (Begley et al., 1989). A 
functionally equivalent abnormality, not observed cytogenetically, is a small site-specific 
interstitial 90kb deletion event on chromosome 1 that brings SCL under control of SIL 
(SCL interrupting locus)— a ubiquitously expressed T cell gene. The recorded frequency 
of the SIL-SCL deletion event in T-ALL is 6-26% (reviewed in Begley and Green, 1999 
and references therein). ; (2) activation of EVI-1 -regulating proteins or (3) the cells may 
be arrested at a stage of development where EVI-1 is normally expressed in 
haematopoietic development.
1.4.3.2 EVI-1 Expression in Non-Haematological Malignancies
Using RT-PCR techniques and RNAase protection assays, high level EVI-1 expression 
has been detected in ovarian cancers, endometrial carcinomas and melanomas (Brooks et 
al., 1996). Therefore, it is possible that EVI-1 is also important in the progression of 
some solid tumours. Similar to many haematological disorders some ovarian carcinoma 
cell lines displayed 3q26 abnormalities, suggesting this is important in both 
haematological and non-haematological disorders where EVI-1 is aberrantly expressed. 
As yet, the role of EVI-1 in non-haematological tissues is unknown.
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1.4.4 Structure o f EVI-1
Characterisation of a 5.1Kb EVI-1 cDNA revealed an open reading frame of 3126 
nucleotides encoding a predicted 145KD C2H2 zinc finger protein (Morishita et al., 1988) 
(Figure 3). The N-terminal domain of EVI-1 comprises seven repeats of the zinc finger 
motif (ZF1) and there are three additional zinc finger motifs toward the C-terminus (ZF2). 
There is a proline-rich repressor domain (Bartholomew et al., 1997) and an acidic domain 
at the C-terminus of unknown function. EVI-1 is localised in the nucleus, exhibiting a 
dotted pattern of localisation in leukemia cells that contain the provirally active allele 
(Matsugi et al., 1990). The gene is conserved between humans and mice with human and 
mouse open reading frames 91% homologous at the DNA level and 94% homologous at 
the amino acid level (Morishita et al., 1990).
1.4.4.1 Alternative EVI-1 Splice Forms (Figure 3)
A shorter isoform of EVI-1, with a predicted molecular weight of 88Kd, is produced via 
alternative splicing in both human (Morishita et al., 1990) and mouse (Bordereaux et al., 
1990). This form lacks zinc fingers six and seven and the IR domain and was designated 
A324 (since it lacked 324 amino acids altogether). In addition, an extra nine amino acids 
are detected within the repressor domain of both the human (Morishita et al., 1990) and 
mouse (Bartholomew, unpublished) A324. Furthermore, A324 isoform lacks the 
biological activity of the Full length EVI-1 protein (FLEvi-1) (Kilbey and Bartholomew,
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1998). Another EVI-1 variant designated, A105 lacks 105 C-terminal amino acids 
(Bartholomew, personal communication) and represents 50% of EVI-1 protein in murine 
cells examined. This isoform retains the biological activity of the FLEvi-1 protein, 
indicating the truncated region is dispensable for EVI-1 function. The MDS1/EVI-1 
splice form has a distinct transcription initiation site than the other EVI-1 isoforms and 
has an additional 188 novel amino acid residues derived form an upstream exon—  
designated MDS 1 (which contains a conserved PR domain)— at the 5 ’ end of the 
previously reported EVI-1 protein (Fears et al., 1996). The functional significance of 
these isoforms are under investigation. (M DSl/EVI-lis discussed in sections 1.4.2.1 and 
1.4.6.5).
1.4.5 Biochemical Properties o f  EVI-1
The discovery of ten zinc finger motifs in EVI-1 strongly suggested that it encoded a 
sequence-specific DNA binding protein that plays a role in transcriptional regulation. 
Consensus binding sites have been determined for both ZF1 and ZF2: ZF1 binds to 
TGACAAGATAA, which shows an overlap for the erythroid-specific GATA family of 
transcription factors that bind the consensus sequence motif (A/T)GATA(A/G) (Perkins 
and Kim, 1991 and Delwel et al., 1993) and ZF2 binds to GAAGATGAG (Funabiki et 
al., 1994). In vitro studies have revealed that EVI-1 can bind to the ZF2 site. However, 
only a truncated EVI-1 protein can bind to the ZF1 site (Bartholomew, 1997) which 
suggests that some region in EVI-1 suppresses binding of ZF1 domain to its recognition
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sequence in vitro, raising the possibility that in vivo binding of ZF1 to its site may be 
regulated.
1.4.6 Biological Effects o f  EVI-1
1.4.6.1 EVI-1 functions as a Transcriptional Repressor
The EVI-1 protein acts as a repressor of gene transcription in several cell types 
(Bartholomew et al., 1997 and Funabaki et al., 1994) and the repressor activity resides in 
the proline-rich region between amino acids 514 to 724 (Bartholomew et al., 1997)
(Figure 3). An additional repressor domain is located between ZF1 and the defined 
repressor domain shown in Figure 3. However, this region (IR) gives only partial 
repression (Bartholomew, 1997).
EVI-1 can suppress binding of the erythroid-specific transcription factor, GATA-1 to its 
recognition site (Kreider, 1993) in choloroamphenicol tranferase (CAT) reporter assays. 
Although no physiological GATA sites have been recognised by EVI-1, it is postulated that 
interactions with other transcription factors or co-ordinator proteins, may be required to 
increase the binding affinity. Alternatively, EVI-1 (like many of the erythroid-related 
transcription factors) may directly bind to GATA-1 through the GATA-1 consensus site in 
ZF1 to inhibit its activity.
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TGFp, one of the best-characterised cytokines, inhibits proliferation in a number of cell 
types (Massague et al., 1990). Indeed, the TGFp receptor and its downstream 
components, are often targets for mutations in some cancers (Eppert et al., 1996 and 
Riggins et al., 1996). More recently, EVI-1 (Kurokawa, 1998A), was found to repress the 
growth-inhibitory effect TGFp in epithelial cells by a direct interaction of the ZF1 domain 
with the intracellular mediator, Smad3. The Rp region is also essential for this 
repression, although the mechanism is unknown. Therefore the abrogation of this 
inhibitory factor could be one molecular mechanism whereby EVI-1 induces 
leukaemogenesis.
Recent studies have demonstrated that EVI-1 directly interacts with the short-range 
transcriptional corepressor murine C-terminal Binding Protein 2 or mCtBP2 (Turner and 
Crossley 1998). The recognition motif, P-DLS-K found in mammalian, viral and 
Drosophila proteins, mediates interactions with CtBP corepressors (Turner and Crossley 
et. al., 1998). Two similar motifs, PFDLTTK and PLDLSNG are located between amino 
acids 553-559 and 584-590 within Rp of EVI-1 (Figure 3). However, it is not known 
whether these sites are involved in mCtBP2 binding, or if this binding is required for 
repression or biological activity of the EVI-1 protein.
Little is known concerning the target genes of EVI-1 (discussed below in section 1.4.7). 
However, several potential EVI-1 responsive genes have been identified including
50
150 B9-11 (named after the clone number) and Inositol triphosphate type 2 receptor gene2 
(ltrp2), which are both down-regulated in leukaemic cells expressing EVI-1 (Matsugi et 
a l, 19951 and Kim et al., 19982).
1.4.6.2 EVI-1 Transforms Rati Fibroblasts
Rati cells modified to express either evi-1 or the AML1/EVI-1 fusion protein form 
transformed foci in soft agar assays. Interestingly, enhanced transformation is observed 
on transfection of p210 bcr/abl Rati fibroblasts with AML1/EVI-1 expressing constructs 
(Kurokawa et a l, 1995). Furthermore, introducing evi-1 deletion mutants into these 
assays demonstrates that the DNA binding domains, ZF12 and ZF23 and the repressor 
domain, Rp1 are all essential for this transforming activity (Bartholomew et al., 19971, 
Kilbey and Bartholomew, 19982 Kurokawa et al., 19953).
The hallmark of cancer is uncontrolled cellular growth, leading to high numbers of 
invasive abnormal cells. In addition to altering the growth properties of several 
mammalian cell-types, as described above, overexpressing evi-1 also abrogates 
components of the cell cycle engine. In evi-1 transformed Rati fibroblasts the activity of 
the cyclin dependent kinases (CDKs) Cdk2 and Cyclin E is up-regulated, the G1 phase of 
the cell cycle is shortened and total cellular levels of the CDK-inhibitor p27 are down- 
regulated (Kilbey et al., 1999). Furthermore, evi-1 expression promotes an increase in 
survival potential and saturation density. Together, all of these changes are consistent 
with a reduced requirement for adhesion and mitogenic signals in these cells— features
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common to transformed cells. Within a leukaemic setting it is envisaged increased Cdk2 
activity would increase the sensitivity of haematopoietic cells to growth factors and thus 
impart a selective advantage on haematopoietic cells.
1.4.6.3 Evi-1 Overexpression Abrogates Haematopoietic Cell Growth
Studies have shown that ectopic evi-1 expression can block the growth of EPO responsive 
cells namely normal murine bone marrow progenitor cells and 32Epol cells (Kreider et al., 
1993). Similarly, introduction of evi-1 or AML1/EVI-1 retroviral vectors into 32Dcl3 cells, 
appears to block the ability of cells to differentiate in response to Granulocyte Colony 
Stimulating Factor (G-CSF) (Morishita et al., 1992 and Tanaka et al., 1995, respectively). 
Similar studies by Khanna-Gupta et al. led to the realisation that it is level of evi-1, rather 
than aberrant evi-1 expression alone which is the important determinant of this differentiation 
block (Khanna-Gupta et al., 1996). Finally, the 3q21q26 syndrome has been closely 
associated with a thrombocytopenic phenotype (Bitter et al., 1985, Bernstein et al., 1986) and 
lack of response to conventional chemotherapy (Testoni et al., 1999). In vitro, 
overexpression of evi-1 in embryonic stem cells produces abnormally high numbers of 
megakaryocyte colonies— demonstrating that high levels of evi-1 are linked to abnormal 
megakaryopoiesis (Sitailo et al., 1999).
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1.4.6.4 EVI-1 as an Activator
Studies have revealed that as well as its repressor activity, EVI-1 can also act as a 
transcriptional activator. EVI-1 binds to the consensus sequence GACCAGATAAGATANi. 
28CTCATCTTC in HEC1B and NIH3T3 cells using artificial constructs with ZF1 and ZF2 
sequences located upstream of the minimal thymidine kinase (tk) promoter (Morishita et al.,
1995). EVI-1, AML/EVI-1 and AML1/MDS1/EVI-1 also stimulate transcriptional activation 
of the c-fos promoter and raises AP-1 activity with ZF2-dependence (Tanaka et al., 1994, 
Kurokawa et al., 1995).
1.4.6.5 Biological Activity of EVI-1 Fusions—Potential Implications for 
Leukaemogenesis
Thus far AML1/EVI-1 TEL1/EVI-1 2, MDS1/EVI-1 3 and AML1/MDS1/EVI-1 4 
fusion genes have been cloned (Nucifora, 1994 *, Raynaud, 1996 2, Sood et al., 1999 3’4). 
AML1/EVI-1 was subsequently found to dominantly suppress AML1 transactivation, 
leading to a block in myeloid differentiation (Tanaka, 1995). In addition, AML1/EVI-1 
was shown to have a higher affinity for the AML1 binding partner, CBFp compared to 
wild-type AMLl(Tanaka et al., 1998)—which may account for the dominant effects of 
AML1/EVI-1. Indeed, AML1/EVI-1 and AML1/MDS1/EVI-1 enhance AP-1 activity, 
repress TGFp signalling and transform R ati fibroblasts (Kurokawa et al., 1995.
Kurokawa et al., 1998B), as evi-1 does (Tanaka, 1995, Kurokawa, 1998A and Kurokawa, 
1995 respectively). On the other hand, mdsl/evi-1 enhances TGF-P signalling and
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strengthens its growth-inhibitory effect. Furthermore, whereas EVI-1 represses activation 
by the GATA-1 erythroid factor, MDS 1/EVI-1 enhances GATA-1-mediated 
transactivation (Solderholm et al., 1997). In addition, whereas mdsl/evi-1 has no effect 
on granulocytic differentiation induced by G-CSF in the haematopoietic precursor cell 
line 32Dcl3, the AML1/MDS1/EVI-1 fusion— similar to evi-1 alone (Khanna-Gupta,
1996)—blocks differentiation resulting in cell death. The different response of myeloid 
cells constitutively expressing normal or fusion evi-1 proteins to G-CSF and TGF-p may 
depend on the transactivation properties of these proteins resulting in divergent 
expression of downstream target genes regulated by these proteins. Interestingly, a 
recent study has demonstrated that expression of AML1/MDS1/EVI-1 in mouse bone 
marrow cells induces an acute myelogenous leukaemia in these animals (Cuenco et al., 
2000). Whatever the exact mechanisms, it is clear that the regulation of tumour growth 
by chimaeric proteins will depend on the fusion partner with AML1.
Together these findings suggest that EVI-1 fusion proteins during leukaemogenesis may 
repress physiologically important genes or abnormally regulate genes normally repressed 
(or activated) by AML1 in an EVI-1-specific manner. Furthermore, direct interactions of 
the mSin3A corepressor with AML1 appears to be necessary for AML1-mediated 
repression (Lutterbach et al., 2000), suggesting that HDACs, the downstream effectors of 
Sin3A, are potential therapeutic targets of AMLs— in a similar manner to APL 
malignancies (Reviewed in Melnick and Licht, 1999).
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1.4.7 Potential Targets o f EVI-1
Unfortunately, our knowledge of the downstream target genes regulated by EVI-1, and 
indeed many oncoproteins, remains poor. Therefore, in order to bridge the gaps within 
contemporary models of leukaemia progression, and more specifically to ascertain a 
molecular role for EVI-1 in myeloid leukaemias, it is important to determine EVI-ls genetic 
targets within cells. Potential EVI-1 targets include the lineage-specific regulators of 
haematopoiesis, negative regulators of cell growth and components of the apoptotic pathway.
1.4.7.1 Subversion of Haematopoietic Lineage-Restricted Transcription Factors by 
EVI-1
During leukaemogenesis, EVI-1 (and other transcriptional repressors) may inhibit the 
regulation of key haematopoietic modulators. As discussed at length in section 1.3, studies 
concerning the molecular genetics of leukaemia reveal the importance of regulatory factors in 
normal haematopoiesis. Since the accumulative evidence implicates ectopic evi-1 
overexpression in the disruption in erythroid (Krieder et al., 1993), myeloid (Morishita et al., 
1992, Tanaka et al., 1995 and Khanna-Gupta et al., 1996) and megakaryocyte (Bitter et al., 
1985, Bernstein et al., 1986, Testoni et al., 1999 and Sitailo et al., 1999) lineages it seems 
logical to postulate a role for EVI-1 in disrupting key regulator factors involved in the normal 
development of these lineages. Candidate erythroid/ megakaryocyte targets for direct or 
indirect EVI-1 dysregulation during leukaemogenesis include GATA-1, GATA-2, NF-E2 and
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c-Mpl receptor, which are key regulators of erythropoiesis and megakaryopoiesis. Candidate 
Evi-1 targets within the myeloid lineages include the myeloid-specific regulators (section 
1.2.2.1.2) such as PU .l, H OX genes, RARs and C-MYB.
1.4.7.2 Repression of Negative Regulators of Cell Proliferation
Another interesting possibility is that EVI-1 may down-regulate negative regulators of 
cell proliferation such as the cyclin-dependent kinase inhibitors (CDKI’s), many of which 
are candidate tumour suppressor genes. As discussed in section 1.4.6.2, recent studies 
have shown that constitutive expression of evi-1 in Rati cells down-regulates total levels 
of the p27 CDKI (Kilbey et al., 1999). Other possibilities include EVI-1 -mediated 
repression of the pl6INK4B, pl2INK4A and p21 CDKI’s (Hirama and Koeffler, 1995). 
Indeed, deletions and/or mutations of these CDKI’s have been reported in a variety of 
human cancers/ leukaemias (Hirama and Koeffler, 1995).
1.4.8 Project Aims
The evi-1 proto-oncogene is frequently observed in patients with certain myeloid 
leukaemias. In human myeloid leukaemias and murine retrovirally induced leukaemias 
ectopic expression of evi-1 is a result of non-random chromosomal translocations or 
retroviral insertions of 3q26, respectively, where the gene is located (Bartholomew et al., 
1989 and Morishita et al., 1992). More recent work has demonstrated that evi-1 is a
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repressor of transcription (Bartholomew et al., 1997). Repression is mediated through a 
200 base pair proline-rich repressor region— designated Rp— which is essential for the 
transformation of R ati fibroblasts by evi-1 (Bartholomew et al., 1997). However, the 
precise mechanisms of evi-1-mediated repression are unknown. Furthermore, no studies 
have addressed the relevance of the Rp domain— and other evi-1 functional domains—for 
the biological activity of evi-1 in haematopoietic cells. Therefore, the principle objectives 
of this project were to (1) utilise specific evi-1 deletions mutants as genetic tools to 
investigate the biological activity of evi-1 in cell lines and primary bone marrow cells,
(2) to address potential mechanisms of evi-1-mediated transcriptional repression.
1.4.8.1 Investigating the functional significance of Evi-1 domains for the biological 
activity of Evi-1 in mammalian cells.
These studies utilised the full length evi-1 (FLevi-1) and evi-1 mutant retroviral 
constructs to examine the biological activity of evi-1 in an established Rati model 
system. It was postulated that several of these deletion mutants, which lack important 
evi-1 biological domains, could function in a dominant negative fashion and inhibit the 
activity of the wild-type FLevi-1 protein. Therefore, Rati cell lines were modified to 
constitutively coexpress FLevi-1 and a selection of evi-1 deletion mutants to test whether 
the transformed phenotype of these cell lines were reverted using the Rati system. Using 
the same retroviruses, the effects of overexpressing evi-1 in bone marrow cells were 
analysed. An experimental system was established whereby the production of
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haematopoietic colony growth of bone marrow cells infected with retrovirus was 
examined in methyl cellulose colony assays. As before, mutant constructs were used in 
these assays to establish the importance of evi-1 functional domains for the biological 
activity of evi-1— but this time in a primary bone marrow experimental system.
1.4.8.2 Mechanisms of Evi-l-Mediated Biological Activity
As a transcriptional repressor, it is likely that the biological activity of evi-1 is mediated 
by interactions with transactivator proteins, general transcriptional machinery or cofactors 
such as co-repressors. Therefore, such interactions were looked for and the consequences 
of protein-protein interactions on the biological activity of evi-1, investigated. Mutants 
lacking these respective protein-binding domains were examined in in vitro reporter 
assays— established previously in our laboratory— which assay evi-1 repressor and 
transforming activities.
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Chapter 1 Figures
Figure 1: Model of Haematopoietic Origins in the Mouse
AGM, aorta gonad mesenephros; RBC, red blood cells; LTRSC NB, long term new born- 
repopulating stem cells; LTRSC ADULT, long term adult-repopulating stem cells. (See 
section 1.2.2).
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Figure 2: Cell Lineages of the Haematopoietic System: Hierarchical
Model
LTRSC, long term repopulating stem cell; CFU-GEMM, colony forming unit 
granuolcyte/eythroid/monocyte/macrophage; CFU-GM, colony forming unit- 
granulocyte/macrophage; CFU-Eos, colony forming unit-Eosinophil; CFU-G, colony 
forming unit-granulocyte; CFU-M, colony forming unit macrophage; CFU-Baso, colony 
forming unit-Basophil; CFU-Meg, colony forming unit-megakaryocyte; BFU-Meg, burst- 
forming unit/megakaryocyte; BFU-E, burst-forming unit-erythroid; CFU-E, colony 
forming unit erythroid.
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Figure 3: Protein Structure of Full Evi-1 and Evi-1 Alternative Splice
Forms.
Grey boxes, zinc fingers (ZF1 and ZF2); Blue box, the Repressor Domain (Rp); 
Black/White striped box, the Acidic Domain (Ac); Black box, the Intervening Region 
(IR) Red Box, MDS1; Black X, mCtBP binding site; Light Grey Box; extra 9 amino acids 
in A324 isoform; P, proline residues within repressor domain.
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Figure 4: Two distinct mechanisms by which chromosomal
translocations aberrantly activate genes encoding transcription factor
A) Recombinase error results in the activation of normally silent proto-oncogenes.
B) Breaks occurring within introns between coding regions of two transcription 
factors genes in separate chromosomes, create a fusion gene encoding a chimaeric 
protein.
(For A + B, R=regulatory region and TF=transcription factor).
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Table 1: Table of Fusion Genes Created by Chromosomal
Translocations in Leukaemias and Solid Tumours
AML, acute myeloid leukaemia; APL acute promyelocytic leukaemia; ALL, acute 
lymphoblastic leukaemia; ANLL, acute non-lymphoblastic leukaemia; MDS, 
myelodysplastic syndrome; CML chronic myeloid leukaemia.
Tumour-Type Cytogenetic
Abnormality
Genes Involved Protein
HAEMATOPOIETIC TUMOURS
CML, (MDS, 
APL)
t(3;21)(q26;q22) AML1/EVI-1 Drosophila runt homologue/ 
Multiple zinc fingers
MDS t(3;21)(q26;q22) AML1/EAP Drosophila runt homologue/ 
Ribosomal protein L22
MDS t(3;21)(q26;q22) AML1/MDS1 Drosophila runt homologue/ 
40% Homologue to RIZ
ANLL t(6;9)(p23;q34) DEK/CAN Nuclear Protein/Nucleoporin
AML t(8;21)(q22;q22) AML1/ETO Drosophila runt homologue/ 
Zinc Finger
APL t(ll;17)(q23;ql2
)
PLZF/RARa Zinc finger/Retinoic acid receptor 
a
APL t(5;17)(q32:q21) NMA/RARa Nucleophosmin/ Retinoic acid 
receptor a
APL t(l 1; 17)(ql3;q21 
)
NuMA/RARa nuclear matrix associated genes/ 
Retinoic acid receptor a
APL t(15;17)(q22;ql2
)
PML/ RARa Zinc finger/Retinoic acid receptor 
a
AML, ANLL inv(16)(pl3;q22) MYH11/CBFP Smooth muscle myosin heavy 
chain/ Heterodimerises with AML1
ALL t(l;19)(q23;pl3) PBX1/E2A Homeodomain/
(3 HLH transcription factor
B ALL, CML t(9;22)(pl2;q22) BCR/ABL Serine Kinase/Tyrosine Kinase
AML t(9; 12)(q34;p 13) TEL/ABL ETS-related transcription factor/ 
Tyrosine Kinase
AML, Pre-B 
ALL
t(12;21)(pl2;q22
)
AML1/TEL Drosophila runt homologue/ 
ETS-related transcription factor
ALL t(10;14)(q24;qll
)
H O X ll/T C R a Homeobox/T-cell receptor 
promoter
SOLID TUMOURS
Primitive
neurectodermal
tumours
(Ewing_s
Sarcoma)
t(ll;22)(q24;ql2
)
FLI1/EWS ETS-related Transcription 
factor/Nuclear Protein
t(21;22)(q22;ql2
)
ERG/EWS ETS-related Transcription 
factor/Nuclear Protein
t(7;22)(p22;ql2) ETV1/EWS ETS-related Transcription 
factor/Nuclear Protein
Melanoma t(12;22)(ql3;ql2
)
ATF1/EWS BZip transcription factor/Nuclear 
Protein
*(Adapted from Strout e al., 1997 and Sanchez-Garcia, 1997)
Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Cell Culture
2.1.1.1 Cells and Reagents
Cells
Supplier: Anne Wyke, Beatson Institute for Cancer Research, Switchback Road,
Glasgow G611BD.
Rati
Supplier: Dr. A. Kilbey, Glasgow Caledonian University, Biochemistry Department,
Cowcaddens Road, Glasgow G4 OBA.
Rati Mxneo Stables (2/7)
Rati FL Evi-1 Stables (3/7)
Supplier: Dr. D Baltimore, Rockefeller University, Box 161,1230 York Avenue,
New York, NY 10021.
Bosc23
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Supplier:
Supplier:
Supplier:
Supplier:
Supplier:
Reagents
Supplier:
American Type Culture Collection, Rockville, Maryland 20852, USA. 
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C. Bartholomew, Glasgow Caledonian University, Biochemistry 
Department, Cowcaddens Road, Glasgow G4 OBA.
Da-3
American Type Culture Collection, Rockville, Maryland 20852, USA. 
NIH3T3
Dr. Vincent O’Brien, Beatson Institute for Cancer Research, Switchback 
Road, Glasgow G611BD.
Cos-7
Harlan UK Ltd, Shaws Farm, Blackthorn, Bicerster Oxon, 0X 6 OTP. 
CBA/Ca female mice (Primary Murine Bone Marrow Cells flushed from 
femurs).
Beatson Institute Central Services 
Sterile distilled water 
Sterile PBS (dulbecco “A ”)
66
Sterile PBS/1 mM Edta
Supplier: Gibco Europe Life Technologies Limited, Paisley, UK.
7.5% (w/v) sodium bicarbonate 
lOOmM sodium pyruvate 
200mM L-Glutamine 
0.25% Trypsin ImM Edta.4Na 
Mycophenolic Acid Crystalline 
Geneticin G418 Sulphate 
HT Supplement 50X 
HAT Supplement 50X
Supplier: Stem Cell Technologies INC. Metachem Diagnostics Ltd. 29 Forest Road,
Piddington, NN7 2DA,UK.
Pokeweed Mitogen Stimulated Murine Spleen Conditioned Medium 
(PWM-SCCM): prepared by incubating mouse spleen cells for one week 
at 37°C in R PM I1640 and pokeweed mitogen, supplemented with bovine 
insulin to replace all serum components. It is not concentrated or purified.
Complete M ethocel: 1% Methylcellulose in Iscoves's MDM, 15% Feotal Bovine 
Serum, 1% Bovine Serum Albumin, lO^g/ml Pancreatic Insulin, 200/^g/ml 
Human Transferrin, 10"4 M 2-Mecaptoethanol, 2mM L-Glutamine, 50ng/mL rm 
SCF, lOng/mL rm IL-3, lOng/mL rh IL-6 and 3units/ mL rh Erythropoietin
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Zapoglobin
Supplier: Sigma Chemical Co., Poole, UK.
R PM I1640 (with NaHC03, without Glutamine)
IX  DMEM (4500mg L-Glucose, HOmg Sodium Pyruvate and Glutamine) 
10X DMEM (with 4500 mg/L glucose at IX. Without L-glutamine, folic 
acid and sodium bicarbonate)
a-MEM (with Ribonucleotides and Deoxyribonucleotides)
Feotal Calf Serum (European Origin)
New Born Calf Serum (Mycoplasma Screened, Virus Screened)
Horse Serum (European Origin)
Xanthine Sodium Salt 
Adenine
Hepes Buffered Saline
CaCl2
Polybrene
Chloroquine
Penicillin/Streptomycin Solution 100X
Supplier: Fisions Scientific Equipment, Loughborough, England.
DMSO
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Supplier: Dow Corning GMBH, 65201, Wiesbaden, USA.
Vacuum Grease
Supplier: Difco Laboratories, Detroit MI 48232-7058, USA.
Agar Noble
2.1.1.2 Cell Culture Kits
Supplier: Stratech Scientific Limited, 61-63 Dudley Street, Luton, Bedfordshire,
LU2 ONP.
Invisorb® Spin DNA Micro Kit III
2.1.1.3 Cell Culture Plasticware
Supplier: A/S Nunc TCS Limited, Botolph Claydon, UK.
Nunc Delta Tissue Culture Flasks (T25, T75, T150)
Nunc Cryotubes
Supplier: Beckon Dickinson Labware, Plymouth, UK.
Falcon tissue culture dishes 30mm, 60mm, 90mm and 150mm.
Supplier: Costar Corporation, Cambridge MA, USA.
6 well, 24 well and 96 well tissue culture plates 
Cell scrapers
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Supplier: Bibby Sterilin, Tilling Drive, Stone, Staffordshire ST15 OSA.
Sterilin petri dishes 30mm, 60mm, 90mm.
Supplier: Technical Photosystems, Cumbernauld, UK.
KodaColor Gold 400 Slide Film
2.1.1.4 Cell Culture Solutions, Media and Semi-solid Media 
Cell Culture Solutions 
2XHBS pH7.05 -lOOmls
1.6g NaCl, 0.074g KC1, 0.027g NaHPO4.2H20, 0.2g Dextrose and lg  HEPES.
Add 90mls distilled water pH to 7.05 with 1M NaOH make up to 100ml with distilled 
water. Filter sterilise with 0.2/jm Filter.
2M CaCl2- lOOmls 
54g CaCl2
Make up to lOOmls with distilled water. Filter sterilise with 0.2 jum filter.
Xanthine (40X) Add 0.2g Xanthine to 20ml 0.1N NaOH. Filter sterilise with 0.2/mi 
filter. Aliquot, cover in foil and store at 4°C.
Adenine 12.5mg/ml
Add 0.05g Adenine to 4mls distilled water. Filter sterilise with 0.2/mi filter. Store at 
4°C. Use within one week.
70
Mycophenolic Acid (250X)
Add 250mg to 40mls 0.1N NaOH. Filter sterilise with 0.2/mi sterilising cup. Aliquot, 
cover in foil and store at -20°C.
Chloroquine made up at lOOmM
Add 1.29g Chloroquine to 25mls distilled water. Filter sterilise with 0.2/un filter. 
Aliquot, cover in foil and store at -20°C.
IL-3 at 0.1/^g/ml
5g in 10 ml Filter Sterile. Filter sterilse with 0.2jum filter. Aliquot and store at -20°C. 
G418 (400mg/ml)
Add 5g to 12.5ml PBS. Filter sterilise with 0.2/rni filter. Aliquot and store at -20°C.
Cell Culture Media and Semi-Solid Media
Bosc23 HAT-supplemented growth medium
IX  Dulbecco’s Modified Eagles Medium (1 X DMEM), 10% FCS, 2mM L-Glutamine, 
IX  HAT Supplement, 25Qag/ml Xanthine (IX), 25/rg/ml Adenine and 50^g/ml 
Mycophenolic Acid (IX).
Bosc23 HT-supplemented growth medium
IX DMEM, 10% FCS, 2mM L-Glutamine, IX  HT supplement and 25/rg/ml Adenine.
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Bosc23/Bone marrow co-cultivation medium
a-Mem, 25% horse serum, 2mM L-Glutamine, IX  HT supplement, 25/jg/ml adenine and 
250 [ig/ml xanthine.
R ati fibroblast culture medium
IX  DMEM, 5% NBCS and 2mM L-Glutamine.
R ati Transformation Assay Semi-solid Media 
Base Agar— lOOmls
IX  DMEM (made from 10X DMEM concentrate), 10% FCS, 0.375% Sodium 
Bicarbonate Solution (stock @ 7.5%), O.lmM Sodium Pyruvate, 2mM L-Glutamine, 3% 
Agar, 1 x Penicillin /Streptomycin - Made up to lOOmls with distilled sterile water.
Top Agar =1:1 Base Agar:Cells (in lx  DMEM/20%FCS).
Cos7 and NIH3T3 culture medium 
lx  DMEM, 10% FCS and 2mM L-Glutamine.
Da-3 culture medium
R P M I1640,10% FCS, 4mM L-Glutamine and O.lng/ml IL-3.
Trypsin solution for routine passing
0.25% Gibco trypsin in sterile PBS/lmM EDTA
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2.1.2 Cell Culture Machinery
Supplier: Beatson Institute Workshop, Beatson Institute for Cancer Research,
Switchback Road, Glasgow, G115AY.
Cloning Rings
Supplier: ORME Technologies, Whitbrook Way, Middleton, Manchester M24 2RH.
Heraus
37°C 10% CO2 incubator 
37°C 5% CO2 incubator 
33 °C incubator
Supplier: The Baker Company, Philip Harris Scientific, Lichfield, Staffordshire
W 5140EE, UK.
Class II Type A Tissue Culture Hood
Supplier: Olympus Optical Company Ltd, Great Western Industrial Park, Dean
Way, Middlesex UB2 48D.
Microscope plus associated camera
Supplier: Leica Camera, Knowhill, Milton Keynes MK58LB.
Inverted Microscope
Supplier: Scharfe System GMBH, Emil-Adolff Strape 14, D-72760 Reutlingen
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Scharfe System Casy I - Coulter Counter
2.1.3 Antisera and associated materials
Supplier: Amersham International, Little Chalfont, UK.
anti-mouse/horse radish peroxidase conjugate 
anti-rabbit/horse radish peroxidase conjugate 
GAL4 monoclonal
Supplier: Dr. C. Bartholomew, Glasgow Caledonian University, Biochemistry
Department, Cowcaddens Road, Glasgow, G4 OBA.
Evi-1 anti-serum, mouse polyclonal (1806)
2.1.4 Protein Electrophoresis and Immunoblotting
2.1.4.1 Protein Electrophoresis and Immunoblotting Reagents 
Supplier: Amersham, Little Chalfont, UK.
High Molecular Weight Rainbow Markers (14.4kDa to 220kDa) 
Hybond ™ N* nylon membrane 
Enhanced Chemoluminescence Reagent Solution 
Supplier: Pierce, PO BOX 117, Rockford, Illinois, 61105, USA.
Coomassie Blue Protein Assay Reagent
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Supplier: Sigma Chemical Co., Poole UK.
Micro BCA/ Q1SO4 Protein Assay Kit (Bicinchoninic Acid Solution 
including Copper II Sulphate and Protein Standards)
TEMED (N,N,N’,N’- Tetramethylethylenediamine) 0.1% (w/v) Ponceau S 
Solution in 5% acetic acid)
Bovine Serum Albumin (BSA), Fraction V
Supplier: Severn Biotech Ltd, Kidderminster, UK.
Design-a-gel 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide solution
Supplier: Technical Photosystems, Cumbernauld, UK.
Fuji RX X-Ray film
Supplier: Whatmann, Maidstone, UK.
3mm filter paper
2.1.5 Protein Extraction and Processing
Supplier: Sigma Chemical Co., Poole UK.
All Protease Inhibitors 
Protein A  sepharose beads
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Supplier: Dow Chemical Company Ltd., Sully, Penarth
Vale of Glamorgan, South-Wales, CF64 5YB.
Saran Wrap
Supplier: Swann Morton Limited, Owlerton Green, Sheffield S62BJ.
Disposable Scalpels
Supplier: Asda, Saughs Road, Robroyston, Glasgow City Centre,
Strathclyde, G331P.
Marvel
2.1.5.1 Immunoblotting Solutions and Buffers
Group A protease inhibitors—  Stock Solutions all stored at -20°C.
50mM PMSF (100X) Add 0.87g to 100ml isopropanol
50mM Benzamidine (100X) Add 0.78g to 100ml distilled water
1M p-glycerophosphate (100X) Add 21.6g to 100ml distilled water
ImM Sodium Orthovanadate (20X) Prepare lOOmM Stock: Add 1.83g to 100ml distilled
water. Dilute to ImM with distilled water, pH to 8.0 and boil in a water bath until yellow
colour disappears.
Group B protease inhibitors
lmg/ml Leupeptin (lOOOx) in distilled water
Pepstatin A (1000X) in methanol.
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Whole Cell Extract Lysis Buffer
20mM Hepes, 5mM EDTA, lOmM EGTA, ImM DTT, 0.4M KCL, 0.4% Triton X-100, 
10% Glycerol and 5mM NaF. Add protein inhibitors 5/jg/ml Aprotinin, O.Olmg/ml 
Okadaic acid, 5/^g/ml Pepstatin A, 5/ig/ml leupeptin, lOOmM PMSF and 50mM 
Benzamidine
SDS-PAGE Electrophoresis Gel Recipe
SDS Resolving Gel SDS-PAGE Stacking Gel (for 7.5% Gel)
Acrylamide/Bis (30:8) 10ml 3.2ml
1M Tris pH8.8 15ml ---
10% SDS 0.4ml 0.2ml
dH 20 15ml 14ml
1M Tris pH6.8   2.5ml
10% Ammonium persulphate 375/d 200//1
temed 20/^1 20/d
Protein Electrophoresis Tank Buffer (10X Concentrate)
1M Tris 
1M Glycine 
2% (w/v) SDS
Semi-dry transfer buffer for immunoblotting 
48mM Tris
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39mM Glycine 
0.037% (w/v) SDS 
20% methanol
Immunoblot Wash Buffer TBST (10X concentrate)
Tris 24.2g/21
NaCl 175.3g/21
Tween-20 10ml/21
pH to 8.0 with concentrated HCL
PAGE/SDS 2x Sample Buffer
Tris/HCL pH6.8 1.3ml
Glycerol 2ml
20% SDS 2.5ml
(3-Mercaptoethanol 800ml
dH20 4.2ml
add a pinch of bromophenol blue powder.
Immunoblot Stripping Buffer 
0.2M Glycine pH2.5 
1% (w/v) SDS
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2.1.5.2 Protein Electrophoresis and Immunoblotting Equipment
Supplier: Beatson Institute Workshop
Semi-dry Blotting Apparatus
Supplier: Genetic Research instrumentation Dunmow, UK.
Atta protein electrophoresis apparatus
2.1.6 Plasmid Preparation Solutions and associated materials
2.1.6.1 Bacterial Media and antibiotics 
Supplier: Difco Laboratories, Detroit MI 48232-7058, USA.
Bactotryptone 
Bacto Yeast Extract
Supplier: Gibco Europe Life Technologies Limited, Paisley, UK.
Luria-Broth Base 
Luria-Broth Agar
Supplier: Sigma Chemical Co., Poole, UK.
Ampicillin
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2.1.6.2 DNA Analysis— Materials
Supplier: Boehringer Mannheim UK., Lewes, East Sussex, England.
Calf Intestinal phosphatase (lU/^1)
Supplier:
Supplier:
Supplier:
Supplier:
Supplier:
Supplier:
BDH
Bromophenol Blue 
Agarose Gel Loading Buffer
Biowhittaker UK Limited, Biowhittaker House, Berkshire, RG41 2PL.
All Restriction Enzymes + 10X Restriction Buffers 
T4 DNA polymerase
Sartorius AG, 37070 Goettingen, Germany 
Collodium bags (Dialysis Tubes)
Vernon-Carus Limited, Penwortham Mills, Preston, Lancs, England. 
Cotton Mesh
Bioline, 16 The Edge Business Centre, London NW2 6EW, UK.
Biotaq DNA Polymerase
Promega, Delta House, Chilworth Research Centre, Southampton S016 
7NS.
DNTPs
T4 DNA Ligase (10U/ju\) + 10X Buffer
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Supplier: Sigma Chemical Co., Poole, UK.
1Kb Ladder
Ethidium Bromide tablets
2.1.6.3 DNA Analysis Kits
Supplier: Qiagen Limited, Boundary Court, West Sussex, RH10 2AX.
Qiagen Midiprep 
Qiagen Maxiprep 
Qiaquick Gel Extraction 
Qiaquick PCR Purification Kit
2.1.6.4 DNA Analysis Solutions 
Solution I
50mM Glucose 
25mM TrisHCL (pH 8.0) 
lOmM EDTA
Solution II 
0.2N NaOH 
1% SDS
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Solution III
To 300ml Potassium Acetate add 57.5ml Glacial Acetic Acid and 142.5ml distilled H2O. 
The resulting solution is 3M with respect to potassium and 5M acetate.
Dialysis Solution (lOOmM Tris/lmM  Edta)
20ml Tris/ 4ml Edta in 2L Distilled Water.
Luria Broth (1L)
25gm of Luria Broth Base is added to 1L of Ultra Pure Milli-Q water. This solution is 
autoclaved.
Luria Agar Plates
37gm of Luria Agar is added to 1L of Ultra Pure Milli-Q water. The agar is autoclaved 
and allowed to cool to 50°C. The appropriate antibiotic is added, generally ampicillin at 
5Qag/ml, and the agar plates are poured into 90mm Sterilin dishes.
Terrific Broth (1L)
To 900ml of Ultra Pure Milli-Q water we added 12g Bactotryptone, 24g Bacto-yeast 
Extract and 4ml Glyerol. This solution is autoclaved , cooled to 50°C then 100ml of a 
sterile solution of 0.17M KI12PO4 0.72 M K2HPO4 is added.
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SOC medium (1L)
To 950ml of Ultra Pure Milli Q water add 20g Bactotryptone, 5g Bacto-Yeast Extract and 
0.5g NaCl. Dissolve. Add 10ml of a 250mM solution of KC1. pH to 7.0. Adjust the 
volume to 1L with Ultra Pure Milli Q water. Sterilise by autoclaving. Allow solution to 
cool to 50°C then all 20ml of a sterile 1M solution of glucose. Before use add 5ml of a 
sterile 2M MgCl2 solution.
TAE 5OX (1L)- Stock
Add 242g Tris Base to 57.1 Glacial Acetic Acid and 100ml 0.5M EDTA make up to 
1000ml with distilled water.
2.1.6.5 DNA Analysis Machinery
Supplier: Kontron Instruments, Blackmore, Croxley Business Park, Hertfordshire
WD1 8XQ.
Centrikon Ultra-Centrifuge T-2050
Supplier: Kendro Laboratory Products Ltd., Hertfordshire CM23 5G2.
Sorvall Centrifuge including SS-34 Rotor 
Beckman Spectrophotometer
Beckman Centrifuge J2-21 including rotors JLA-10.5 and JA-12
83
Supplier: Bibby Sterilin, Tilling Drive, Stone, Staffordshire ST15 OSA.
37°C Orbital Shaker
Supplier: Perkin Elmer Analytical Instruments, Chalfont Road, Seer Green HP9
2FX.
Perkin Elmer 9600 (BIGD) Thermal Cycler
Supplier: MJ Research INC, Watertown, MA 02172, USA.
PTC-100 Programmable Thermal Controller
Supplier: Bio-rad Laboratories Ltd., Bio-rad House, Hemel Hampstead,
Hertfordshire HP2 7TD.
Gel Electrophoresis Apparatus including Power packs
2.1.7 Cytospin Materials
Supplier: BDH Laboratory Supplies, Poole, Dorset, BH15 1TD.
Glass slides
Giemsa
Filters
Sample holders
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2.1.7.1 Cytospin Solutions
10% Giemsa in PBS 
10ml Giemsa /90ml PBS
2.1.7.2 Cytospin Machinery
Supplier: IEC Harwell Road, Poole BH1 70BD, UK.
Cytocentrifuge
2.1.8 Flow Cytometry Reagents and Associated Materials
Supplier: Boehringer Mannheim Lewes, UK.
RNaseA
Supplier: A/S Nunc TCS Limited, Botolph Claydon, UK.
FACS tubes 
Supplier: Sigma Chemical Co., Poole, UK.
Propidium iodide
2.1.8.1 Flow Cytometry Solutions
Propidium Iodide (PI) Stain
Prepare a lmg/ml PI stock solution in PBS and a lOmg/ml pre-boiled solution of 
RNaseA. To give a final concentration of 10^g/ml PI and 25/zg/ml RNaseA in PBS: add 
100/d of PI stock and 250^1 RNaseA stock to 10ml PBS.
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2.1.8.2 Flow Cytometry Machinery
Supplier: Beckton Dickinson, Plymouth, UK.
Beckton Dickinson FACScan Flow Cytometer 
Modfit Software
2.1.9 Radioactivity
Supplier: Amersham International Pic., Amersham, Bucks, UK.
14C-Chloramphenicol
2.1.10 General Chemicals
Supplier: Sigma Chemical Co., Poole, UK.
Calcium Chloride
Hepes Buffered Saline
Beta-mercaptoethanol
Hydrochloric acid
Sodium Hydroxide
Ethanol
Butanol
Methanol
Tris
86
EDTA
EGTA
Triton-X-100 
Orange G 
Ficoll
Supplier: Gibco Europe Life Technologies Limited, Paisley, UK.
1M Hepes pH 7.5 
50X HAT supplement 
50X HT supplement 
mycophenolic acid 
SDS Lauryl Sulfate 
Sodium Chloride 
Magnesium Chloride 
Potassium Chloride 
Glacial acetic acid
Supplier: BDH Laboratory Supplies, Poole, UK.
Ammonium peroxodisulfate (APS)
Glycine
All other chemicals not listed where from Fisher Scientific.
2.1.11 Other General-Use Laboratory Machinery
Supplier: Fisher
Whirlimixer
Supplier: Anachem House, Charles Street, Luton, Bedfordshire LU2 OBE.
Heat Block
Supplier: ORME Technologies, Whitbrook Way, Middleton, Manchester M24 2RH.
Stuart Scientific Magnetic Stirrers 
Grant Water Bath 
Heraus Microfuge
2.2 Methods
2.2.1 Bone Marrow Colony Assays
2.2.1.1 Production of Virus
Adherent human Bosc23 cells (Pear et al., 1993) are selected and maintained in DMEM 
(2mM L-Glutamine, and 10% Fetal Calf Serum) supplemented with hypoxanthine- 
aminopterin-thymidine or HAT, 250 [igjml xanthine, 25 jug/ml adenine (Sigma) and 
50/^g/ml mycophenolic acid. Retroviral producer cell lines are generated in Nunc T-25 
flasks each containing 2x l06 Bosc23 cells which are transfected with 4^g of DNA
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(p50MXneo, p50MEvi-lFlneo or Evi-1 mutant vectors) using the calcium phosphate 
method. For each 25cm2 monolayer of cells to be transfected the calcium phosphate- 
DNA coprecipitate is prepared as follows: 4jug DNA is made up to 437.5/d with ultra 
pure MilliQ distilled water then 62.5/d 2M CaCk is added. This mixture is vortexed and 
then added dropwise to 500/d 2XHBS whist bubbling the DNA mixture with air. The 
DNA is left to precipitate for 20 minutes. This 1ml mixture is added to 5ml of medium in 
the 25cm2 flask of cells. During transfections Bosc23 cells are supplemented with HT, 
/jg/ml xanthine, 25/jg/ml adenine and penicillin/ streptomycin.
2.2.1.2 Retroviral-Mediated Gene Transfer into Murine Bone Marrow
Bone Marrow cells are isolated from the femurs of CBA/Ba mice. The haematopoietic 
cells are flushed from each femur with 10ml of a-MEM using a 23-Gauge needle. Each 
universal, containing bone marrow from one femur, is spun down at lOOOrpm for 5 
minutes. The cells are then re-suspended in co-cultivation medium (a-MEM, 25% horse 
serum and 2mM L-Glutamine supplemented with HT, 25 jug/m\ adenine and 250 jug/ml 
xanthine). The bone marrow cells are now carefully added to T25 flasks (one 
femur/flask) of pre-irradiated Bosc23 producer cells. This co-cultivation is left for 72 
hours. After infection, the cells (bone marrow plus dead feeders) are harvested and 
washed in a-MEM. After determination of the total viable nucleated cell count by 
addition of zapoglobin to cells, 8000 cells and 20000 cells are plated out into growth 
factor supplemented methylcellulose (see section 2.1.1.1) for each infection. The plates 
were incubated at 37°C 10% CO2 and haematopoietic colonies were scored at 7-10 days.
2.2.1.3 Molecular Analysis of Individual Bone Marrow Colonies
Polymerase chain reaction (PCR) is used to assess proviral integration of individual colonies 
isolated from methylcellulose culture. To avoid contamination all the following procedures were 
carried out within an UV-irradiated sterile environment. Individual colonies are identified and 
isolated into microfuge tubes and placed on ice. Immediately after colony isolation, DNA was 
extracted from colonies using a DNA extraction kit. Two PCR reactions are carried out using 
external primers complementary to the neo cassette (5'-3') and to the p50Mxneo vector itself (3'- 
5) and nested primers to the neo cassette only. The PCR reaction contained lysate/template, lx  
Buffer (Promega), 3mM MgCl2, 2mM DNTP's, 0.35ng of each primer (140ng//d) and 2.5 units 
Taq (Promega), in a 50 /d reaction. Cycling conditions used an initial denaturation of 94 for 2 
minutes: 30 cycles of 94C for 1 minute; 55°C for 1 minute and 72° for 30 seconds; and a final 
extension of 72°C for 7 minutes. The PCR-amplified products were analysed by gel 
electrophoresis.
2.2.1.4 Cytospin slide preparation
For each colony type, 1-10 colonies are picked and suspended in 200/d of ice cold PBS.
Slide holders are prepared with slide and filter. All 200/d of each cell suspension is 
placed into the sample holders. The cells are spun onto the slide in a cytocentrifuge at 
500rpm for 5 minutes. The slide is air dried for 5 minutes, fixed in 100% methanol for 10 
minutes the stained in 10 % Giemsa in PBS for 10 minutes. The stain is then displaced 
with running water. Slides are air dried, then mounted with DPX and a coverslip.
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2.2.2 Cell Cryopreservation and Recovery
Cells are grown to 70% confluence in T175 flasks. The cells are harvested, counted and 
resuspended at 5x l06 cells/ml in 10% DMSO in Fetal Calf Serum. The cells are added 
lm l Nunc Cryotubes, wrapped in cotton wool (to slow freeze) and placed at -70C. The 
next day the cells are transferred into a Liquid nitrogen storage vessel.
When recovering cells from liquid nitrogen, the cells are thawed in water at 37°C within a 
large, covered plastic vessel. The cells are completely removed from the vial using a 19 
gauge needle and placed into a T25 tissue culture flask. 5mls of the appropriate medium 
is added to the cells drop by drop. The flasks are placed at the appropriate incubation.
2.2.3 NIH3T3 Focus-formation assays for retroviral titre estimation
CaPO4' transfections in Bosc23 are carried out as described in Section 2.2.1.1. Medium 
containing virus is harvested 48 hours post transfection and filtered through a pre-wetted 
0 .2/rni plastic filter.
NIH3T3 cells are plated in 24 well plates at 8000 cells per well in DMEM (10% FCS, 
2mM L-Glutamine and 8/^g/ml polybrene ) twenty-four hours prior to harvesting of virus. 
Duplicate wells are seeded for each virus tested.
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Serial dilutions of vims ranging from 1/10 through 1/31250 are carried out for each virus. 
Two days after the addition of virus to NIH3T3 cells the medium is replaced with DMEM 
containing 800/^g/ml G418. After 10 days in this selection media is removed, the cell 
foci are washed in PBS, fixed and stained in methanol and Giemsa respectively and then 
counted.
2.2.4 Rati Transformation Assay
2.2.4.1 Production of Selectable Population or Clones
Bosc23 cells are transfected as described above (Section 2.2.1.1). Forty-eight hours post 
transfection and after a sixteen-hour collection time in 2mls of medium, virus is 
harvested. The viral supernatant is filtered through a pre-wetted 0.45/un plastic filter and 
all 2mls are added to a 60mm dish with adherent Rat 1 cells at 5x l05 cells/dish plated 12- 
24 hours previously. The next day the Rat 1 cells in the 60mm dish are split into two 
90mm dishes and placed in a 5% CO2 incubator. Twenty-four hours later the appropriate 
selection is added to the 90mm dishes (lmg/ml zeocin and/or lmg/ml G418). The cells 
are selected for a further 7-10 days and emerging clones are either grown to confluence as 
a cell population or they are single cell cloned by ring cloning. The cells are grown up 
and whole extracts prepared to assess protein expression of introduced vectors.
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22.4.2 Plating Cells in Soft Agar
After determination of protein expression by Western Blotting the cell lines of interest are 
plated in agar. The assay is set up using two layers of agar medium. The underlayer 
consists of a 0.6% agar/DMEM mixture (see section 2.1.1.4). The top layer is 0.3% 
agar/DMEM (see section 2.1.1.4) and contains the cells plated at 103 cells per 60mm dish. 
The plates are left three to five weeks in a 10% CO2 humid incubator. After this time 
anchorage independent colonies over 0.1 cm are scored.
2.2.5 Protein Analysis
2.2.5.1 Preparation of Whole Cell Extracts
Plates are rinsed in ice cold PBS and drained for 20 minutes at 4°C. Residual PBS is 
removed and lysis buffer is added to each plate (add 75/d /60mm dish or 100/d/90mm 
dish). Plates are then scraped, drained for 5 minutes and the lysis buffer is transferred to 
a microfuge tube. Extracts are spun for 20 minutes at 13K, 4°C. The supernatant is 
transferred into a screw cap tube and protein concentrations are determined using 
Coomassie Blue. Extracts are stored at -70°C.
2.2.5.2 Western Blotting 
Protein Electrophoresis
The table in section 2.1.5.1 shows the recipes for 7.5% and 10% acrylamide gels. The gel 
apparatus is set up using 2mm gel plates and spacers. The resolving gel is poured and 
approximately 5mm of water saturated butanol is laid on top. After the gel has set, the
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butanol is poured off, distilled water is used to rinse away any last traces and the gel 
surface is blotted with Whatmann 3mm paper. The stacking gel is the poured and a 2mm 
comb is inserted. After the stack has set the comb is removed and the gel is removed 
from the gel former and placed into a tank. The tank is then filled with lx  Running 
Buffer (see section 2.1.5.1).
The samples are prepared by adding an equal volume of extract to 2X sample buffer. The 
samples are loaded into the wells along with pre-stained size markers. The gel is run at 
250V for 2hours. When electrophoresis is complete the gel is removed and washed in 
semi-dry blot transfer buffer in 20% methanol. Samples are then transferred to ECL 
membrane using a semi-dry blotter. The gel, ECL membrane and 12 pieces of 3mm 
Whatmann are subsequently soaked in semi-dry transfer buffer and arranged in the blotter 
as follows; 6 pieces of filter paper, gel, membrane and 6 pieces of filter paper. Transfer 
of proteins to ECL membrane occurs at 20V over a 2 hour period. After transfer the blot 
is blocked overnight in 5% Marvel in TBST(see section 2.1.5.1).
Antibody incubations and detection by ECL
The blot is washed for 15 minutes in TBST. The TBST is decanted and 20ml of 5% 
Marvel/TBST with the appropriate primary antibody is added. The blot is now shaken in 
the primary antibody for typically lhour at room temperature. The blot is then rinsed and 
washed in TBST for lhour with fresh buffer changes every 15 minutes. The blot is now 
shaken in 20mls of 5% Marvel/TBST with the appropriate secondary antibody - again 
typically for lhour at room temperature. The blot is rinsed and washed as after the
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primary antibody. The TBST is then drained off on Whatmann 3mm paper and ECL 
detection reagents are added according to the manufacturers instructions. The filter is 
wrapped in saran wrap and exposed to x-ray film.
Stripping immunoblots to remove anti-sera
To remove proteins from ECL membranes blots are washed in immunoblot stripping 
buffer (0.2M Glycine pH2.5/l% (w/v) SDS) for lhour. They are then washed for a further 
2hours with fresh stripping buffer changes every 15 minutes. Blots are blocked overnight 
in 5% Marvel/TBST. These blots are washed in TBST for 15 minutes and are now ready 
to reprobe with antibody.
2.2.7 Bacterial Cell Culture
2.2.7.1 Host Strains
E.Coli strains XL1 or DH5a were obtained from Beatson institute stocks. Bacterial 
strains were grown in Luria-Broth at 37°C with good aeration.
22.7.2 Competent Cells
Competent bacterial cells were obtained from Gibco.
2.2.73 Transformation o f Bacterial Cells
Competent cells were thawed slowly on ice and 100/d transferred to a pre-chilled 15ml 
flacon tube. 1/d of plasmid or an entire DNA ligation reaction was pipetted into the cells
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mixed gently and incubated on ice for 30 minutes. 1ml of Luria-Broth was then added 
and the cells were incubated for lhour in a shaker at 220rpm. The cells were heat 
shocked at 42°C for 2 minutes. 200/d L Broth and 5/d cells were then spread onto 1.5% 
(w/v) agar Luria-Broth plates containing the appropriate anti-biotic at 37°C overnight.
2.2.7.4 Glycerol Stocks
E.Coli strains containing plasmids were stored as glycerol stocks. Stationary cultures 
were mixed with an equal volume of sterile glycerol and stored at -20°C.
2.2.8 Nucleic Acids: DNA Analysis
2.2.8.1 Mini Plasmid Preparations
Bacterial colonies were picked using a sterile tooth pick and grown up overnight in 5ml 
of L broth medium, containing the appropriate antibiotic, in an orbital shaker. Glycerol 
stocks were prepared by adding 0.5ml of this overnight culture to 0.5ml sterile glycerol. 
These stocks are stored at -20°C. 3 ml of the remaining cells was harvested by 
centrifugation at 3000 rpm for 5 minutes/4°C in a microfuge. The cell pellet was 
resuspended in 200pl Solution I (50mM Glucose, 25mM Tris/HCL pH 8.0, lOmM 
EDTA) and incubated on ice for 10 minutes. 400//1 of Solution II (0.2N NaOH, 1% SDS) 
was then added, the solution mixed very gently and incubated for 5 minutes on ice. 300pl 
Solution III (3M Potassium Acetate, 11.5% glacial acetic acid ) was added , the tube was 
inverted for 15 seconds and incubated on ice for a further 10 minutes. After incubation 
the mixture was spun at 14000rpm for 10 minutes/4°C. 500 //I of the cleared supernatant
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supernatant was transferred to a fresh eppendorf andlml isopropanol was added. The tube 
was then placed on dry ice for 10 minutes then centrifuged on full speed for 10 minutes/4 
°C. The pellet was then resuspended in lOOfil 1 X TE and 0.3 M NaOAc. For 
extraction, 50 pi of phenol/chloroform/isoamyl alcohol (24parts/24parts/l part) was 
added, the tube was vortexed then spun in at 14000rpm for 5 minutes. The aqueous phase 
was then transferred to a fresh eppendorf. 300pl absolute ethanol was added to 
precipitate plasmid DNA and this was left at -20°C for 20 minutes then spun at 14000rpm 
for 10 minutes/4°C. The pellet was resuspended in 1XTE ands RnaseA (0.01/jg/ml). 
Restriction digests were carried out to analyse the new DNA.
22.8.2 Large Scale Plasmid Preparations
4.5ml of overnight culture was inoculated into 500ml of Terrific Broth Medium, 
containing the appropriate antibiotics, and grown overnight in an orbital shaker at 37°C 
overnight. The cells were harvested by centrifugation at 5000rpm at 15 minutes/4°C.
The supernatant is discarded, the pellet resuspended in 10ml ice cold solution I. The 
mixture was beaten until frothy and cloudy then left on ice for 5 minutes. 20ml solution 
II was added. The tubes were gently rolled then incubated on ice for 10 minutes. Then 
15ml solution III was added, the tubes inverted for 15 seconds and then left on ice for 15 
minutes. The lysate was then cleared of precipitated SDS, proteins, membrane, and 
chromosomal DNA by spinning at 5000 rpm for 15 minutes at 4°C and then pouring the 
resultant supernatant through several layers of cotton mesh into a 50ml falcon tube. 0.6 
volumes of isopropanol were then added at room temperature to precipitate the DNA.
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The tubes were mixed and incubated at room temperature for 30 minutes. After 
incubation the tubes are spun at 4000rpm for 30 minutes /room temp. The supernatant is 
discarded and the pellet was resuspended in 8ml of TE (lOOmM Tris/HCL pH 8, ImM 
EDTA). 8.8g of Caesium chloride and 800//1 of ethidium bromide (at lOmg/ml) was 
added to the tube. The solution was transferred to an ultracentrifuge tube and spun for 24 
hours at 55000rpm at room temperature. Plasmid bands were removed with a needle and 
syringe and transferred to a fresh tube. 8ml of TE were added along with 0.4mls of 
ethidium bromide and 8.4g Caesium Chloride. Again this solution is transferred to an 
ultracentrifuge tube and spun for a further 24 hours at 55000rpm/ room temperature. The 
ethidium bromide is removed from the DNA solution by butan-l-ol extraction. When the 
ethidium is completely remove and the butanol layer removed, the DNA is added to 4 
volumes of distilled water. 2.5 volumes of ethanol are then added. The preps were left 
overnight at -20°C for precipitation of plasmid DNA to occur. The tubes are spun down 
at 4000rpm for 30minutes/ room temperature. The supernatant was removed, the pellet air 
dried and the resuspended in 0.5ml Milli Q ultra-pure water. DNA is then dialysed in TE 
(lOOmM Tris/HCL pH 8, ImM EDTA) at 4°C overnight.
2.2.83 Optical Density Analytical Measurements
DNA is diluted 1:200 in dH20 with a total volume of 1ml. This is mixed then transferred 
to a quartz spectrophotometer cuvette. The spectrophotometer is blanked with 1ml of 
H2O. The optical density of the sample is then read at a wavelength of 260nm. The 
concentration of DNA, in micrograms per microlitre of sample is 10 times the OD
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reading. To assess the purity of the sample, the second reading is taken at 280nm. If the 
ratio of OD at 260nm to OD at 280nm is approximately 2 we can be quite confident the 
absorption is due to nucleic acids. If the ratio is lower than 1.7, the sample is 
reprecipitated by ethanol precipitation (see section 2.2.8.6 ).
2.2.8.4 Restriction Digests
Restriction digests of plasmid DNA were carried out with an appropriate amount of 
restriction enzyme in its respective buffer as recommended by the supplier. Typically, 
plasmid concentrations of 2jug were digested in a total of 30/d with 5-10 units of enzyme 
per jug DNA in lXbuffer for 3-4 hours at the appropriate temperature (usually 37°C). The 
total volume of reaction was increased for larger concentrations of DNA. Reactions were 
terminated by the addition of l/10th volume of agarose gel loading buffer.
2.2.8.5 Gel Electrophoresis
Typically 0.8% agarose gels were made to resolve restriction enzyme-digested DNA.
1.6g of agarose was added to 200ml 1XTAE. The solution was then heated in a 
microwave on high for 5 minutes then placed on a stirring block to cool. When hand hot, 
O ^ g /m l ethidium bromide was added and the solution is poured into an appropriate gel 
former. Gels are set at room temperature and then transferred to an electrophoresis tank 
containing 1XTAE. Samples containing l/10th volume agarose gel loading buffer were 
loaded in separate wells and run at 40-120V depending on the size of fragments and time 
restrictions. The molecular weight standard used was a 1Kb ladder. The DNA bands were 
visualised using an UV source and then photographed.
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2.2.8.6 Re-Precipitation of Nucleic Acids
Generally, 2.5-3 volumes of an 9.5% ethanol/ 0.12M sodium acetate solution was added 
to the DNA sample in a microcentrifuge tube, which was incubated at -20°C overnight. 
The sample is then centrifuged at full speed (13000 rpm) in a microcentrifuge for 15 
minutes at 4°C. The supernatant was then decanted and the tube inverted on a paper 
towel. The DNA pellet is then rinsed in 80% ethanol. After a second centrifugation, the 
supernatant again is discarded, and the DNA pellet is dried in a Speedi-Vac for 10 
minutes. The dried DNA is dissolved in TE pH 7.5.
2.2.8.7 Purification of DNA Fragments from Agarose Gels
DNA fragments were excised from agarose gels and placed into eppendorf tubes. The 
DNA from each fragment was isolated using the Qiagen DNA Gel Purification Kit 
according to the manufacturers protocol. After purification the quantity and quality of 
the purified fragment(s) were assessed by agarose gel electrophoresis.
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2.2.9 Subcloning of DNA
2.2.9.1 Preparation of Vector DNA
Plasmid vectors were digested with the appropriate restriction enzyme and at the end of 
the reaction 1/d of calf intestinal alkaline phosphatase (CIAP) was added and the reaction 
incubated for a further 30 minutes. The vector was gel purified with a Qiagen gel 
purification kit.
2.2.92 Generation of Inserts
Inserts were generated by either restriction enzyme digestion of plasmid DNA or PCR- 
generated DNA. Either way, the resultant fragments were resolved by agarose gel 
electrophoresis and purified, as above.
PCR DNA was generated using this protocol:
In each 100/d reaction:
lOng Template DNA, 5U Pfu polymerase, IX  Buffer, 200/iM dNTPs, 40pmoles of each 
oligonucleotide. Amplification was achieved in a Perkin-Elmer Cetus thermal Cycler by 
25 cycles of lminute at 94°C, lminutes at 55°C and 8 minutes at 72°C followed by a final 
10 minutes at 72°C extension time.
2.2.9.3 Ligation of DNA Fragments into Plasmids
The purified vector and insert DNA were digested and included in the following reaction:
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20ng vector, 5 molar excess of DNA insert/s, 1/d Ligation Buffer (Stock is 10X=300mM 
TrisHCL pH7.8, lOOmM MgC12, lOOmM DTT and lOmM ATP) and 1/d T4 Ligase made 
up to 10/d with distilled water.
The reactions were incubated at 16°C overnight. Reactions were stopped by a heat shock 
of 65°C for 5 minutes.
2.2.10 Sequencing Reactions
Big Dye Terminator Sequencing (on ABI373A)
DNA (typically 500ng double-stranded DNA, lOOng single-stranded DNA or 90ng PCR 
product DNA) is mixed with 3.2pmoles primer and the volume is made up to 12/d with 
Milli-Q grade water. 8/d of reaction premix is added and the PCR is carried out using a 
Perkin Elmer 9600 (BIGD) with the following conditions: preheat to 96°C, 30 cycles of 
96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes and soak at 4°C. The DNA 
was precipitated with 2/d of 3M Sodium acetate and 50/d absolute ethanol. This is mix 
and left to stand at -70°C for 15 minutes. The sample spun at 14000rpm for 10 
minutes/Room Temperature to pellet the DNA. The supernatant is carefully removed and 
the pellet washed in 70% ethanol. The DNA is re-pelleted and the supernatant removed. 
The pellet is dried off using a Speedi-Vac.
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2.2.11 Synthesis of DNA Oligonucleotides
Oligonucleotides are synthesised at the Beatson Institute on an Applied Biosystems model 
381A DNA synthesiser according to the manufacturers instructions. The machine 
removes 5 ’ trityl groups, and the DNA immobilised on a column. The DNA is eluted in 
29% (v/v) ammonia by passing the solution through a column approximately 20 times 
every 10 minutes for 1.5 hours. This solution is then sealed in a glass vial an incubated 
overnight at 55°C. The DNA was precipitated by the addition of ammonium acetate to
0.3M and 3 volumes of 100% ethanol. The DNA was pelleted at 7000rpm for 15 minutes 
in a Sorvall SS-34 rotor, resuspended in 0.2M sodium acetate, and reprecipitated in 3 
volumes of ethanol. The pellet is then washed in 70% (v/v) ethanol and dissolved in 1ml 
of distilled water. The oligonucleotides are finally quantified by spectrophotometry.
2.2.11.1 Oligonucleotides: Sequencing of p50MAZF2zeo andp50MAZFl2zeo
5 ’->3’ 239: aat ttg ate cag ggc aag aac cat ttt, TAD13e: aag cga att ccc tgt agg gga caa taa 
g, 514: aat tgg ate cca ttc tct etc tea atg aat g, 634: aag gga tcc ccc ttc ttc atg gac cc, 804: 
aag ctg gat ccg aga acg gca aca tgt c, ME1: ttc atg gac ccc att tat ag, 934: etc acc ggt gcc 
gcc tta cag etc ate tc, Notl: aat tgc ggc ege tgc tgt tea tga aga gtg aag aag, Hmel: cca gat 
gtc aca tga cag tgg aaa gca eta, Hme6: eta tga atg tga aaa ctg tgc cca g.
3’->5’ 238: aat tgg ate caa aac ctg gtg tgt t, E1AB: cag tgt cat gtg aca tct gg, EA2: aat tgc 
ggc ege tea tgg gtg ttt aga tag tg, 520: aag ctg gat ccg tac att gat tga gag a, EA7: aat tgc 
ggc ege tea agt ggg tct ggc atg get g, 724: aag ctg gat ccg tag ege tct ttc ccc t, EA9: aat tgc
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ggc ccgcc tea atg ttt ctt cag gtg tc, EA10 aat tgc ggc ege tea tga att ttg ggc tgg ttg, EcoRl: 
age tga att cat aca tgg ctt atg gac tgg at, D l: gaa tgc ggc ege taa gca gga tgc eta ttg gtg c, 
EA4: aat tgc ggc ege tea etc ttt ate act ttc aag, EA5: aat tgc ggc ege tea ctg gaa aaa acg gga 
gg-
2.2.12 Reporter Assays
2.2.12.1 Transfections
Kidney 293 cells were seeded with lxlO 6 cells in DMEM containing 10% FCS and 2mM 
glutamine, twenty-four hours prior to transfection. Calcium phosphate precipitates (as 
described in Section 2.2.1.1) of plasmid DNA expression vectors and reporter constructs 
were added to 5mls of medium in each 60mm dishes of lxlO 6 adherent 293’s.
2.5/jg of L8G5-CAT and l/*g of pHSV Pgal were transiently transfected in the absence 
and presence of 25ng of lexAVP16 and with 1 /ug of repressor construct or PSG424. In 
addition, to keep the volume and concentration of DNA equal in all transfections, 
appropriate amounts of the bluescript vector PCH110 were added accordingly. CAT 
activity (quantified when less than 30% of conversion of the substrate occurs) was 
normalised in all samples for transfection efficiency by using the |3-galactosidase activity 
as a control and expressed as a percentage of the reporter construct alone, which was 
taken as 100%.
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2.2.12.2 Extract Preparation
Cells from each flask are harvested and resuspended in 1ml PBS. The samples are then 
spun for 10 seconds on a bench-top microfuge. The supernatant is removed and the cells 
re-suspended in 0.25M Tris pH7.5. The samples are then subjected to two freeze-thaw 
cycles (freezing at -70°C and thawing at 37°C). The extracts are then pelleted at full 
speed in a 4°C microfuge for 20 minutes. The supernatant is then removed and placed 
into a fresh eppendorf.
2.2.12.3 Cat Assays
1 /d 14C-Chloramphenicol, 2/d 40mM Acetyl CoA, 40/d Cell Extract and 137/d 0.25M 
Tris pH7.5.
The samples are then incubated at 37°C for 30 minutes. Samples are placed on ice and 
500/d of ethyl acetate added to the samples to stop the reaction. The tubes are then 
vortexed then centrifuged for 5minutes, 13K at room temperature. The organic upper 
phase is then removed and transferred into fresh tubes. These samples are dried in a 
Speedi-Vac for 25 minutes. When the samples are dry 5/d of ethyl acetate is added to 
each sample. The samples are then spotted onto a silica gel TLC plate. The TLC plate is 
submerged in 95:5 chloroform:methanol and left for 90 minutes to run out the samples. 
The TLC plate is then air-dried. The plate is then exposed photographic film for 2 hours 
or longer. The spots are cut out and counted in a scintillation counter. Percentage 
conversion is calculated for each sample.
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Calculation Example:
Step
1. Product/substrate x product = conversion
2. Conversion/p-galactosidase (p-gal) = X
3. X/average counts of 3X plates for 1 sample X 100 = Percentage of 100% 
maximum induction
2.2.12.4 P-galactosidase Assays
20/d of extract is incubated with 500/d of Solution I (60mM Na2HPC>4, 40mM Naf^PCU, 
lOmM KC1, ImM MgCh, 50mM p-mercaptoethanol) and 100/d of Solution II (60mM 
Na2HP04 , 40mM NaH2P04 , 2mg/ml ONPG). The reactions were incubated in a 37°C 
water bath for 10 to 90 minutes, or until the yellow colour appears. After this incubation 
the reactions were stopped by the addition of 250/d of 1M Na2C03 . The samples are read 
at an absorbance of 420nm in plastic 2ml cuvettes.
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RESULTS AND DISCUSSION
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Chapter 3: Cloning of Evi-1 Deletion Mutants into Retroviral Vectors
One principle aim of this project was to examine the biological significance of evi-1 
functional domains in the transformation of mammalian cells. Since previous studies 
have demonstrated the requirement of DNA binding domains (ZF1 and ZF2) and 
repressor domain (Rp) for transcriptional repression and transformation by the evi-1 
oncoprotein (Kurokawa et al., 1995 and Kilbey and Bartholomew, 1998), it was 
hypothesised that mutants lacking these functional domains could act as dominant 
negatives over full length evi-1 (FLevi-1). The recombinant p50MXneo vector 
(originally obtained from Dr.’s C. Stocking and W. Ostertag) containing either the entire 
evi-1 coding sequence, AZF1 mutants or ARp mutants were already available (obtained 
from C. Bartholomew). However, to fully examine these proposals several more evi-1 
deletion mutant constructs had to be created.
The 8Kb p50MXneo retroviral vector is shown in Figure 5. As a retroviral vector, 
p50MXneo can be used as a genetic tool to integrate and express exogenous genes into a 
variety of animal cells, including fibroblasts and haematopoietic cells. Moreover, after 
transfection it allows constitutive expression of a transferred gene by strong transcription 
from a Myeloproliferative Sarcoma Virus Long Terminal Repeat (MPSV LTR). 
Furthermore, this retrovirus also contains a polylinker site for inserting donor fragments, 
is Neor and encodes both genomic and subgenomic transcripts (Figure 5). The 
p50MXneo construct was modified to confer resistance to the antibiotic Zeocin®to create
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p50MXzeo (Figure 6). This vector was used to create new Zeor evi-1 deletion mutant 
constructs. Creating mutants in this vector not only had the advantages of the original 
p50MXneo vector, as described above, but also enabled the co-infection and selection of 
evi-lZeor retroviruses in already FLevi-lNeor cells— a prerequisite for examining the 
potential dominant negative activities of evi-1 mutant proteins.
3.1 Plasmid Construction
The construction of Zeor vectors are discussed below. The vectors are divided into 
different sections according to the method of construction.
3.1.1 Plasmid Construction of p50MXzeo and p50MARpzeo
The p50MXneo vector was modified to p50MXzeo. Concurrently, the p50MARpzeo 
vector was created. For both constructs a 420bp zeocin fragment was derived from PCR 
amplification of pTracer (Invitrogen) using specific Bam Hl/Sall primer pairs (Figure 7). 
Bam Hl/Sall digests of the zeo fragment were inserted into pMk20 (containing the splice 
acceptor and poly linker sequences of p50MXneo) to create pMk20zeo. The neo cassette 
was then excised from both the original p50MXneo and p50MARpneo vectors by an 
EcoRl/Sall digest and replaced with the EcoRl/Sall zeo fragment from pMk20. Mini- 
preps of transformed colonies were examined by EcoRl/Sall digestion confirming that 
several DNAs had the correctly sized fragments (Figure 8).
3.1.2 Plasmid Construction of p50MAZFlzeo
Evi-1 mutants lacking the first DNA binding domain or AZF1 mutants were inserted into 
the Zeor retroviral vectors. To create p50MAZFlzeo a 2.5Kb AZF1 Notl/EcoRl 
fragment from p50MAZFlneo was inserted into the corresponding sites of the p50MXzeo 
construct. DNA mini-preps of transformed colonies were subjected to N otl/EcoRl 
digests revealing a number of DNAs with correct fragment sizes (Figure 9).
3.1.3 Plasmid Construction of p50MAZF2zeo and p50MAZF12zeo
In order to examine whether evi-1 mutants lacking the second DNA domain (AZF2 
mutants) or complete DNA binding-defective mutants (AZF12 mutants) could act in a 
dominant negative fashion over FLevi-1, two new mutant vectors were created. These 
mutants, p50MAZF2zeo and p50MAZF12zeo, were derived from PCR-amplified 
fragments derived from the evi-1 cDNA pBS21 (Morishita et. al., 1988) using specific 
primer pairs (See Figure 10 for details). Three different fragments were created (See 
Figure 11). Notl/Bam Hl Fragment 1 (2.35Kb) and BamHl/EcoRl fragment 2 (462bp) 
were used to produce AZF2 mutants and N otlzfl2/Bam H l fragment 3 (1Kb) and 
fragment 2 produced the AZF12 mutants. The fragments were gel purified and digested 
with appropriate enzymes (Figure 11B). To create p50MAZF2zeo, digested fragments 1 
and 2 (Figure 11 A) were simultaneously ligated into the N otl/EcoRl site of p50MXzeo. 
Similarly, in order to create the AZF12 constructs (p50MAZF12zeo), digested fragments 3
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and 2 (Figure 11 A) were simultaneously ligated into the Notl/EcoRl site of p50MXzeo. 
Bam Hl/EcoRl/Notl digests of DNA mini-preps indicated two AZF2 DNAs and four 
AZF12 DNAs with the expected fragment sizes (Figure 11C). The correct nucleotide 
sequences of the PCR products and cloning junctions were verified by DNA sequencing.
3.2 Expression o f Evi-1 Zeor Deletion Mutants in Bosc23 Cells
The newly constructed vectors were tested to confirm they produced the expected 
proteins. Bosc23 cells were transiently transfected with p50MAZFlzeo, 
p50MAZF2zeo, p50MAZF12zeo (Figurel2A) and p50MARpzeo (Figure 12B) vectors 
and cell extracts were examined by immunoblotting using an evi-1 specific polyclonal 
antibody (1806). It was confirmed that the proteins encoded by these new vectors were 
produced at high levels in Bosc23 cells and pre-stained molecular markers indicated that 
all proteins migrated to their expected sizes: p50MAZFlzeo ran at 94KDa, 
p50MAZF2zeo at 137KDa, p50MAZF12zeo at 82KDa and p50MARpzeo at llOKda.
Together with previously made evi-1 retroviral vectors we now had a comprehensive 
collection of evi-1 deletion mutant constructs allowing thorough examination of evi-1 and 
the biological significance of evi-1 functional domains in the transformation of 
mammalian cells.
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Chapter 3 Figures
Figure 5: Schematic Diagram of the p50MXneo Retroviral Vector
The diagram opposite shows a schematic of the p50MXneo vector where: MoMLV LTR 
is Moloney Murine Leukaemia Virus Long Terminal Repeat, MPSV LTR is 
Myeloproliferative Sarcoma Virus Long Terminal Repeat, Neo is the neomycin resistance 
gene, SA is Splice Acceptor and SD is Splice Donor.
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Figure 6: Schematic Diagram of the p50MXzeo Retroviral Vector
The p50MXzeo vector was utilised to construct Evi-1 Zeo resistant (Zeor) deletion 
mutants— as described later in this chapter. The diagram opposite shows a schematic of 
this vector where: MoMLV LTR is Moloney Murine Leukaemia Virus Long Terminal 
Repeat, MPSV LTR is Myeloproliferative Sarcoma Virus Long Terminal Repeat, Zeo is 
the zeocin resistance gene, SA is Splice Acceptor and SD is Splice Donor.
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Figure 7: Oligonucleotides Used for Creation of the 420bp Zeocin
Fragment
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Sail zeo 
Bam HI zeo
BamHl Sail
420 bp
PRIMER PAIRS 
5’ aat tgt cga etc agt cct get cct egg 3’
5’ aat tgg ate cac cat ggc caa gtt gac cag tgc 3’
Figure 8: Plasmid Construction of p50Mxzeo and p50MARpzeo
Arrows indicate digested vector and zeo fragments resolved on a 0.8% agarose gel with 
the correct fragment sizes.
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1 2 3 4 5 6 7 8 9
5.5Kb
1 .4 K b -
zeo
+ poly linker 
sequence
*» - 4 * ^
8Kb
p50M X zeo p50ARpzeo
Figure 9: Plasmid Construction of p50MAZFlzeo
Arrows indicate digests of the new p50MAZFlzeo DNAs were resolved by agarose gel 
electrophoresis revealing DNAs with the correct fragment sizes (Lanes 3,5,6,8 and 9).
117
M IN IPREP DIGESTS 
1 2 3 4 5 6 7 8 9
6 Kb p50MXzeo
2.5 K b Z F l
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Figure 10: Oligonucleotides Used in the Cloning of p50MAZF2zeo and
p50MAZF12zeo
A) Schematic diagram of FLEvi-1 with arrows showing the amplified fragments used 
to construct new deletion mutant vectors. The Evi-1 protein is shown where dark grey 
boxes represent zinc finger DNA binding domains (ZF1 and ZF2), the black box is the 
Intervening region (IR), the blue box is the repressor domain and the black/white striped 
box is the acidic region of the protein.
B) Oligonucleotide sequences of primer pairs used in PCR reactions.
(A+B: Pale Blue double-headed arrows represent the Not-724 amplified fragment, black 
double-headed arrows represent the EcoRl-804 amplified fragment and dark blue double­
headed arrows represent the AZF12 Notl-724 amplified fragment— see text for details)
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PRIMER PAIRS
AZF2
Not 1 5' aat tgc ggc cgc tgc tgt tea tga aga gtg aag agg 3 ’
7 2 4 (B a m H l)  5’ aag ctg gat ccg tag ege tct ttc ccc t 3 '
EcoRl 5 ’ age tga att cat aca tgg ctt atg gac tgg at 3 ’
804 (BamH 1) 5 ’ aag ctg gat ccg aga acg gca aca tgt c 3 ’
AZF12
Not 1 ZF12 5 ’ aat teg ggc ege tgc tgt tea tgg agg gca aga acc att 3 ’
724 (BamFl 1) 5 ’ aag ctg gat ccg tag ege tct ttc ccc t 3 ’
EcoRl 5’ age tga att cat aca tgg ctt atg gac tgg at 3 ’
804 (BamFl 1) 5 ’ aag ctg gat ccg aga acg gca aca tgt c 3 ’
Figure 11: Plasmid Construction of p50MAZF2zeo and p50MA
ZF12zeo
A) Schematic showing fragments amplified for the construction of p50MAZF2zeo 
and p50MAZF12zeo mutants. (See Figure 10 for key to Evi-1 functional domains and 
fragment colour coded arrows).
B) Arrows indicate the p50MAZF2zeo and p50MAZF12zeo Evi-1 fragments 
PCR-amplified from pBS21 (original plasmid vector containing full length murine evi-1 
cDNA). The fragments are gel purified and digested and resolved on a 0.8% agarose gel. 
(Fragment “1” = Lane 2, Fragment “2” = Lanes 3 and 5 and Fragment “3” = Lane 4).
C) Arrows indicate new p50MAZF2zeo and P50MAZF12zeo DNAs, which have 
been digested and checked on a 0.8% agarose gel. The integrity of the new DNA was 
checked by sequencing.
(A,B + C: Fragment “1” = Notl-724 fragment, Fragment “2” = Bam Hl-EcoRl fragment 
and Fragment “3” = AZF12Notl-724 fragment—see figure 10 for arrow colour-coding)
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Figure 12: Western Blot Analysis of Bosc23 Cells Transfected with 
New Mutant Zeor Constructs
A) Whole cell extracts of Bosc23 cells transfected with: Lane 1, p50MXzeo - 
Negative Control. Lane 2, p50MFLneo -Positive Control. Lane 3, p50MAZFlzeo. 
Lane 4, p50MAZF2zeo. Lane 5, p50MAZF12zeo. Proteins were fractioned on a 10% 
SDS-polyacrylamide gel and analysed by Western Blot with the anti-Evi-1 monoclonal 
antibody (1806). Arrows indicate the location of FLEvi-1, AZF1, AZF2 and AZF12 
mutant proteins.
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B) Whole cell extracts of Bosc23 cells transfected with: Lanel, p50MXzeo -Negative 
Control. Lane 2 p50MFLneo -Positive Control. Lane 3, p50MARpzeo. Proteins were 
fractioned on a 7.5% SDS-polyacrylamide gel and analysed by Western Blot with the 
anti-Evi-1 monoclonal antibody (1806). Arrows indicate the location of FLEvi-1 and 
ARp mutant proteins.
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Chapter 4: Investigating Evi-1 Deletion Mutants as Potential Dominant 
Negative Inhibitors of Evi-l-mediated Transformation of Rati cells
Previous studies have demonstrated that the transformation of R ati cells by constitutive 
expression of Full Length evi-1 (FLevi-1) depends on certain functional domains of the 
protein (Kurokawa et al., 1995, Bartholomew et al., 1997 and Kilbey and Bartholomew, 
1998). A R ati model system was adapted to examine whether the non-transforming 
mutants of evi-1, characterised as a result of this earlier work, would act in a dominant 
negative fashion over FLevi-1 proteins in R ati cells constitutively expressing Full Length 
evi-1 or RatlFL cells (Kilbey et al., 1999). As a consequence a reversion of the 
transformation in these cells was expected. Ultimately, it was envisaged that such mutant 
inhibitors would be used as reagents to probe the function of EVI-1 in leukaemia.
The model system used in these studies was based on the Rati Transformation Assay. 
Figure 13 gives a brief overview of the original assay:
4.1 Evi-1 Transformation is Dependent on Functional Domains o f the 
Protein
To examine which domains of evi-1 are essential for the transformation of Rati cells the
transforming activities of several constructs either expressing naturally occurring evi-1
isoforms or evi-1 deletion mutants were examined. Rati cells expressing either FLevi-1
(p50MFLevi-lneo), the A324 isoform (p50MA324neo) or mutants lacking the repressor
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repressor domain Rp (p50MARpneo), the first DNA binding domain ZF1 (p50MA 
ZFlneo) or the intervening region IR (p50MAIRneo) were obtained from Dr. A. Kilbey. 
These cell lines have been described previously (Kilbey and Bartholomew, 1998). In this 
study, populations of Rati cells infected with mutants lacking the second DNA binding 
domain ZF2 (p50MAZF2zeo) or both DNA binding domains (p50MAZF12zeo) were 
isolated as described in Chapter 2 Section 2.2.4. R ati populations expressing either 
p50MXneo or p50MXzeo vectors were used as controls. Figure 14A shows Western blot 
analysis with an anti-evi-1 specific antibody of the respective evi-1 mutant proteins 
expressed in these populations. This analysis revealed the expected size proteins.
Results from soft agar studies show that mutants lacking major features of the evi-1 
protein (namely ZF1,ZF2 and the Rp domain) are unable to exhibit the transforming 
activity displayed by FL proteins in Rati fibroblasts (Figure 14B). Mutants where the 
intervening region (IR) was deleted remained as transforming as FLevi-1 controls 
demonstrating that this region is not necessary for evi-l-mediated transformation.
4.2 Dominant Negative Studies
4.2.1 Revising the Original Rati Transformation Assay
The original transformation assay was modified so that potential dominant negative
effects of mutant evi-1 proteins could be investigated (Figure 15). Bosc23 cells are
transfected with mutant evi-1 retroviral DNA constructs carrying the zeocin resistance
gene. (For construction of Zeor plasmids see Chapter 3). Viral supernatant is harvested
and then used to infect RatlFL cells. Cells are selected in both zeocin® and G418, then
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populations and single cell clones are isolated. Western blot analysis confirms the 
translation of both FL and the expected sized mutant proteins in each isolated population 
or clone. These cell lines expressing high levels of both FLevi-1 and a deletion mutant of 
evi-1 are re-introduced into soft agar assays to assess their phenotype.
4.2.2 Isolation of Cell Lines co-expressing FLevi-1 and Non Transforming Evi-1 
Deletion Mutants
Initially, four new cell types were established by the method described in 4.2.1. Four 
zeocin resistant vectors (also described in Chapter 3), Zeor vector only (p50MXzeo), evi- 
1 mutants lacking the first DNA binding domain (p50MAZFlzeo), evi-1 mutants lacking 
the second DNA binding domain (p50MAZF2zeo), evi-1 mutants lacking the repressor 
domain (p50MARpzeo) and evi-1 mutants lacking both DNA binding domains (p50MA 
ZF12zeo) were separately introduced into RatlFL cells. Populations of Rati cells 
expressing these mutants had no effect on evi-l-mediated transformation of Rati cells. 
Therefore, three or more independent clones were isolated for each new cell line. After 
two weeks selection in both zeocin® and G418 individual resistant clones were grown up 
and the expression of both evi-1 and evi-1 deletion mutants were analysed by Western 
blot analysis with an anti-evi-1 specific anti-body.
In Figure 16, Lanes 3 and 4 show the Western Blot analysis of two clones expressing 
FLevi-1 and p50MXzeo vector (RatlFL/Xzeo cells). These clones provided positive 
control cell lines for the dominant negative studies. It was hypothesised that these cell
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lines would have identical transforming properties to RatlFL cells. Western Blot analysis 
of three clones expressing both FLevi-1 and ARp mutants (RatlFL/ARp cells) (Figure 17, 
Lanes 3-4) revealed that the levels of Rp tend to slightly exceed that of FLevi-1. The 
expression of FL evi-1 and AZF1 mutants in Rati cells (RatlFL/AZF1 cells) co­
expressing these two proteins appears to be similar in all three clones examined (Figure 
18, Lanes 3-5). Only one clone co-expressing FLevi-1 and AZF2 mutants (RatlFL/AZF2 
cells) with detectable amounts of AZF2 protein was isolated out of ten G418/zeo resistant 
clones. Interestingly, Western Blot analysis of this clone reveals that expression of 
FLevi-1 is dramatically decreased in this clone with a clear favouring for very high levels 
of the AZF2 mutant (Figure 19). Finally, three clones with detectable levels of both 
FLevi-1 and AZF12 mutants are shown in Figure 20 (Lanes 3-5). It was noted that 
expression levels of AZF12 proteins were favoured over FLevi-1 in these cell lines co­
expressing both of these proteins.
4.2.3 AZF1 Mutants, ARp Mutants and AZF12 Mutants of Evi-1 act as Dominant 
Negatives over FLevi-1
The phenotype of cell lines co-expressing FLevi-1 and either AZF1 mutants, AZF2 
mutants or ARp mutants of evi-1 were examined by assessing their growth in soft agar.
The histogram in Figure 21 shows the results of triplicate plates examined for each cell 
line from a typical experiment. These results demonstrate that the expression of mutants 
lacking either the ZF1 domain or the Rp region of evi-1 can revert the transformed
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phenotype of RatlFL cells. A  significant reduction in colony number was observed 
compared to RatlFL/XZeo controls. Interestingly, AZF12 mutants which completely lack 
DNA binding domains dramatically reduce evi-l-mediated transformation in R ati cells in 
an identical manner.
4.2.4 Co-operative transformation of Rati cells by FLevi-1 and AZF2 Mutants
The constitutive activity of AZF2 mutants in RatlFL cells appears to stimulate their 
transforming activity. The significant synergistic effect observed in these cells expressing 
FLevi-1 and AZF2 mutants was coupled with an altered morphology of resulting clones. 
The photograph C in Figure 22 shows the promotion of the transformed morphology of 
these clones. The colonies were enormous with irregular edges and most clones were 
>0.8cm in diameter. Only one independent clone was used in this analysis due to the lack 
of detectable expression of AZF2 protein in other G418r/Zeor RatlFL/AZF2 clones 
(Figure 19B). Therefore isolation of other such clones are required to confirm this result.
4.3 Discussion
4.3.1 AZF1 mutants, ARp mutants and AZF12 mutants act in a Dominant Negative 
Fashion over FLevi-1
Previous studies have recognised that the biological properties attributed to evi-1 are 
dependent on the ZF1, ZF2 and Rp functional domains of the protein (Bartholomew et al., 
1997, Kurokawa et al., 1995 and Kilbey and Bartholomew, 1998). This work was
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reproduced and verified in these studies. It was postulated that mutants lacking these 
important biological domains of evi-1 could be potential candidates for dominant 
negative inhibition of FLevi-1 oncogenic activity in R ati cells. Here, three evi-1 deletion 
mutants have been created and characterised that exhibit dominant negative action over 
FLevi-1 resulting in a significant reduction in evi-l-mediated transformation of Rati 
fibroblasts: namely ARp mutants, AZF1 mutants and AZF12 mutants all completely 
abrogated evi-l-mediated macroscopic colony growth in soft agar.
4.3.2 Possible Mechanisms of Dominant Negative Action
If the molecular mechanism/s of these inhibitors can be defined, the identification of the 
pathways and intermediaries involved in EVI-1 transforming activity will be forthcoming. 
The results suggest that distinct pathways may be used by dominant negative mutants to 
render RatlFLevi-1 cells with the same reverted phenotype.
4.3.2.1 “Blocking” Mechanism
With partially and fully intact DNA binding domains respectively, the AZF1 and ARp 
mutants could inhibit transformation through a “blocking” mechanism where mutants 
compete with FLevi-1 for evi-1 DNA binding sites (Figure 23B). To address this 
possibility ZF1 and ZF2 domains only should be expressed in RatFL cells. As before, the 
ability of these domains to block evi-1 transforming activity can be assessed in the R ati 
transformation assay.
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4.3.2.2 “Squelching” Mechanism
The AZF12 mutants, completely defective in DNA binding, also impair evi-l-mediated 
transformation. Therefore, these studies suggest that evi-1 protein-protein interactions 
mediate the dominant negative activity of these mutants. The DNA binding-defective 
mutant ZF12 could utilise so-called “squelching” or sequestration mechanisms to achieve 
this biological action (Figure 23C). “Squelching” mechanisms have been described as the 
mechanisms whereby an inhibitor interacts with endogenous factors that are involved in 
the regulation of transcription but not bound to DNA. In past studies when “squelching” 
of transcription factor function has been demonstrated, very high levels of expression are 
required. Moreover, this mechanism appears to be much more difficult to achieve when 
compared to “quenching” or “blocking” mechanisms (Gill and Ptashne, 1988, Berger et. 
al., 1990 and Ptashne and Gann, 1990). Interestingly, if we recall Western blot analysis 
(Figure 20) of individual Rati FLevi-l/AZF12 clones, the relative expression of these 
proteins is such that the AZF12 expression levels are higher than FLevi-1 protein levels. 
This favouring of the dominant negative protein was not such an obvious feature in Rati 
FL/AZF1 or RatlFL/ARp clones. Indeed there are several examples of an apparent 
“threshold” level of the FL protein being crucial for certain biological activities of evi-1. 
The choice of repressor pathway appears to be determined by levels of the FL protein.
The literature states that optimal evi-1 repressor activity requires binding to DNA through 
ZF1 (Bartholomew et al., 1997). In the same studies DNA binding independent 
repression was observed at higher intracellular protein concentrations of evi-1. Others 
have shown that high levels of evi-1 are critical for blocking the responsiveness of 
haematopoietic cells to granulocyte-colony stimulating factor (G-CSF) (Khanna-Gupta et
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al., 1996). Perhaps then it is the levels of dominant negative protein that determines their 
mode of inhibitory action.
So which domain of the AZF12 mutant could “squelch” proteins involved in the evi-1 
pathway? The most biologically important domain remaining in the AZF12 mutants and 
relevant to transformation is the repressor region. Therefore, it is reasonable to assume 
that the high levels of AZF12 protein observed in FLevi-l/AZF12 Rati cells could inhibit 
evi-1 transformation through a “squelching” mechanism involving the sequestration of 
endogenous FLevi-1 regulatory proteins through the repressor domain.
Interestingly, there are a considerable number of reports emerging that highlight the
importance of transcriptional repressor activity of oncoproteins in the molecular
pathogenesis of myeloid leukaemias. Specifically, the aberrant formation of stable
corepressor complexes is paramount to the leukaemogenic potential of certain fusion
oncoproteins. Examples of this include the acute myeloid leukaemia 1/eight-twenty one
(AML1/ETO) and promyelocytic leukaemia/retinoic acid receptor (PML/RAR)
transforming fusion proteins of Acute Myeloid Leukaemia (AML) and Acute
Promyelocytic Leukaemia (APL)—both of which function as repressors by the aberrant
recruitment of a nuclear receptor corepressor (Co-R)/Sin3-histone deactetylase (HDAC)
complex (Lutterbach et al., 1998 and Grignani et al., 1998 respectively). It has been
suggested that consequent alterations in chromatin structure and other effects on
transcriptional regulation could be responsible for the differentiation block associated
with the expression of these oncogenes in myeloid leukaemogenesis. Moreover,
involvement of these aberrant corepressor complexes in two genetically distinct forms of
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myeloid leukaemia strengthens the importance of this repression pathway in myeloid cell 
differentiation.
Are corepressor complexes also critical for the biological activities of EVI-1? This is 
tempting to speculate because the AML1 and PML oncogenic proteins exhibit many 
parallels with EVI-1, with the major examples being: (1) EVI-1 encodes an oncoprotein 
(Kurokawa et al., 1995) ; (2) EVI-1 is also a repressor of transcription (Bartholomew, 
1997); (3) Evi-1 also forms a oncogenic fusion protein— the AML1/EVI-1 fusion is 
found in cases of t(3;21) chronic myeloid leukaemia (CML) (Mitani et al„ 1994) and (4) 
Constitutive evi-1 expression also blocks the production of several lineage-specific 
haematopoietic progenitors (Morishita et al., 1992, Kreider et al., 1993).
4.3.2.3 “Quenching” by Heterodimerisation
Finally, the possibility that EVI-1 can bind to itself—perhaps through the acidic domain 
— cannot be ruled out. Acidic regions are typical dimerisation domains of proteins (Chen 
and Bieker, 1996 and Geiman et al., 2000) and the acidic region of evi-1 is still intact in 
all the dominant mutants tested. One possible scenario would be that all of the evi-1 
deletion mutants could heterodimerise with evi-1 interfering with FLevi-1 function.
These heterodimers could either stoichiometrically inhibit evi-1 sequence-specific 
binding or “quench” the activity of FLevi-1 by binding to evi-1 binding sites and 
subsequently inhibiting FLevi-1 transformation (Figure 23D). Performing gel-shift or co- 
immunopreciptation experiments with FLevi-1 and mutant evi-1 proteins could identify 
the formation of dimeric complexes of evi-1 and thus determine its self-association.
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4.3.3 Co-operative transformation of Rati cells by FLevi-1 and Mutants Lacking 
the Second DNA Binding Domain (AZF2 Mutants)
Surprisingly, evi-1 proteins lacking the second DNA binding domain (AZF2 mutants) do 
not act as dominant negative mutants. Interestingly, unlike the RatlFL/AZFl,
RatlFL/ARp and RatlFL/AZF12 cells, the majority of RatlFL/AZF2 clones isolated post­
selection did not survive in tissue culture. Furthermore, Rati cells seemed adverse to 
allowing co-expression of FLevi-1 and the AZF2 mutant— as illustrated in Figure 19B. 
Therefore, finding a clone co-expressing FLevi-1 and AZF2 mutants with detectable A 
ZF2 protein expression levels proved difficult, and consequently only one clone of 
eight examined, was isolated. Western blot analysis revealed very high protein levels of 
AZF2 and almost undetectable FLevi-1 levels in this clone. Furthermore, introduction of 
this clone into soft agar assays revealed a synergistic transforming effect enhancing 
transformation compared to RatlFL/RatlFLXzeo controls. Interestingly, these clones 
displayed a more severe transformed phenotype than FLevi-1 controls (Figure 22C). The 
colonies were generally double the size of controls, very dense and with invasive irregular 
edges of growing cells. These studies are in conflict with previous findings that 
populations of R ati cells expressing AZF2 mutants are not transforming (as the AZF1, 
AZF12 and ARp mutants)— suggesting the effect seen here may simply be clonal. 
Furthermore, on the basis of one solitary clone it is impossible to consider the 
significance of this result.
131
4.4 Summary
Three potent dominant negative inhibitors of evi-1 oncogenic activity have been 
identified in these studies. From the evidence described in this chapter, it is proposed that 
this inhibitory activity of dominant negative mutants can be mediated through either 
direct DNA binding or by interference with regulatory proteins necessary for evi-l- 
mediated transformation. It appears that these mutants will provide the useful genetic 
tools necessary for unravelling the complex cellular processes involved in the functioning 
of the EVI-1 oncogene in mammalian cells.
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Chapter 4 Figures
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Figure 13: The Rati Transformation Assay—Methodology
Bosc23 cells are transiently with evi-1 retroviral DNA constructs that carry neomycin 
resistance. Viral supernatant is harvested and then used to infect Rati cells. These cells, 
infected with retrovirus, are selected in G418 and populations or single cell clones are 
isolated. Expression of the evi-1 proteins is examined by Western blot analysis and the 
transformed phenotype of cells determined by growth in soft agar. The colonies scored 
are s=0.1cm in diameter following a 3-5 week incubation.
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Figure 14: Transformation of Rati Fibroblasts by Evi-1
Requires ZF1, ZF2 and Rp Domains
A) Western blot analysis of whole cell extracts derived from Rati cells constitutively 
expressing FLevi-1 and evi-1 deletion mutants. Proteins from Rati cells transfected with 
p50FLevi-lneo and evi-1 deletion mutants - as illustrated opposite - were fractioned on a 
7.5% SDS-polyacrylamide gel and subjected to Western blot analysis with a specific anti- 
evi-1 antibody (1806). Lane 1 (+) is a positive control of R ati cells expressing 
p50MFLevi-lneo, Lane 2 (-) is a negative control of Rati cells only, Lane 3 (-) is a 
negative control Rati MX cells, Lane 4 (-) is a negative control RatlMXZeo cells, Lane 5 
is RatlFL cells, Lane 6 is Rati cells expressing p50MA324neo, Lane 7 is Rati cells 
expressing p50MARpneo, Lane 8 Rati cells expressing p50MAZFlneo, Lane 9 is Rati 
cells expressing p50MIRneo, Lane 10 is R ati cells expressing p50MAZF12zeo and Lane 
11 is Rati cells expressing p50MAZF2zeo.
B) The histogram opposite shows the results from transformation assays using these 
clones. These experiments were carried out at least twice and those shown are in 
triplicate for each cell type. The DNA binding domains (grey boxes), Intervening Region 
(IR-blue boxes), Acidic Domain (Ac-black/white striped box), Repressor Domain (Rp- 
dark blue box) of evi-1 and the Long Terminal Repeats (LTR-blue/white striped box) and 
neomycin/zeocin resistance gene (neo/zeo-dark grey boxes) of the retroviral vectors are 
indicated. Standard deviations ± of the mean are shown.
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Figure 15: The Revised Transformation Assay
See text for details.
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Figure 16: Western Blot Analysis of RatlFL/Xzeo Cells
Proteins from whole cell extracts from Rati cells were fractioned on a 7.5% SDS- 
polyacrylamide gel and subjected to Western Blot analysis with a specific anti-evi-1 
polyclonal antibody (1806). Lane 1 is a Positive control of RatlFL cells. Lane 2 is a 
Negative control of Rat 1 cells containing the p50MXneo vector alone. Lanes 3 and 4 are 
two independent RatlFL clones containing p50MXzeo. These clones provide essential 
control cell lines for the dominant negative studies. The arrow indicates the location of 
FLevi-lproteins.
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Figure 17: Western Blot Analysis of RatlFL/ARp Clones
Proteins from whole cell extracts were fractioned on a 7.5% SDS-polyacrylamide gel and 
subjected to Western blot analysis using a specific anti-evi-1 polyclonal antibody (1806). 
Lane 1 (+) is a Positive control of RatlFL cells. Lane 2 (-) is a Negative control RatlM X 
cells. Lanes 3 and 4 are independent Rat lFL/ARp clones. Arrows indicate the location 
of FLevi-1 and ARp proteins.
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Figure 18: Western Blot Analysis of RatlFL/AZFl Clones
Proteins from whole cell extracts were fractioned on a 10% SDS-polyacrylamide gel and 
subjected to Western blot analysis using a specific anti-evi-1 polyclonal antibody (1806). 
Lane 1 (-) is a Negative control of Rati cells transfected with p50MXneo vector only. 
Lane 2 is a Positive control of RatlFL cells. Lanes 3 to 5 are three independent clones 
expressing p50MFLevi-lneo and p50MAZFlzeo. Arrows indicate the location of FLevi- 
land AZF1 proteins.
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Figure 19: Western Blot Analysis of RatlFL/AZF2 Clones
A) Proteins from whole cell extracts were fractioned on a 7.5% SDS-polyacrylamide 
gel subjected to Western blot analysis using a specific anti-evi-1 polyclonal antibody 
(1806). Lane 1 (-) is a Negative control of RatlM X cells. Lane 2 is a Positive control of 
RatlFL cells. Lane 3 is one clone of RatlFL/AZF2 cells. Arrows indicate the location of 
FLevi-land AZF2 proteins.
B) Western Blot analysis of several AZF2 clones. Lane 1 (-) is a Negative control of 
RatlM X cells. Lane 2 is a Positive control of RatlFL cells. Lane 3-8 are clones of 
RatlFL/AZF2 cells. Arrows indicate the location of FLevi-land AZF2 proteins.
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Figure 20: Western Blot Analysis of Ratl/AZF12 Clones
Proteins were fractioned on a 7.5% SDS-polyacrylamide gel subjected to Western blot 
analysis using a specific anti-evi-1 polyclonal antibody (1806). Lane 1 (-) is a Negative 
control of Rati cells transfected p50MXneo vector only. Lane 2 is a Positive control of 
R ati cells transfected with p50FLevi-lneo. Lanes 3 to 5 are three independent clones 
expressing p50MFLevi-lneo and p50MAZF12zeo. Arrows indicate the location of the 
FLevi-1 and AZF12 proteins.
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Figure 21: Evi-1 ARp, AZF1 and AZF12 Deletion Mutants
Revert the Transformed Phenotype of Evi-l-Transformed Rati 
Fibroblasts
The histogram opposite illustrates the results from one representative clone from each of 
these cell lines. Results shown are the mean ± Standard Error of the triplicate plates 
examined for each clone. Two or more clones were examined in triplicate for each 
deletion mutant tested . For colour coding see Figure 14B.
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Figure 22: Morphological Analysis of Evi-1 Transformed Rati
Fibroblasts Compared to Evi-1 Dominant Negative Revertants in Soft 
Agar Assays.
A) Typical control plates show transformed colonies formed from R ati cells 
expressing both p50FLEVI-lneo and p50MXzeo.
B) The dominant negative example shown here is transformed colonies emerging 
from R ati cells infected with p50MXFLevi-lneo and p50MARpzeo (the repressor 
mutant).
C) Aggressively transformed colonies formed from Rati cells expressing 
p50MFLevi-lneo and p50MAZF2zeo (mutants lacking the second DNA binding domain). 
(N.B. The RatlAZF2 mutant clones look no different to RatlFL clones at confluence).
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Figure 23: Potential Models of Dominant Negative Action
A) Normal evi-1 pathway involved in transformation utilises both additional 
accessory factors and DNA binding.
B) “Quenching” of evi-1 DNA binding Sites by deletion mutant proteins block the
transformation pathway.
C) “Sequestration” of cofactors necessary for evi-1 regulation by evi-1 deletion 
mutants.
D) Heterodimerisation of evi-1 deletion mutants with FLevi-1 proteins altering the
stiochiometry of the FL Protein and therefore inhibiting FLevi-1 regulation.
Where blue triangular shapes represent FLevi-1, grey circular shapes represent Dominant 
Negative Proteins and pink circles are accessory proteins/cofactors.
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Chapter 5: Protein-Protein Interactions Mediate Biological Activity of 
Evi-1
Recently, several sequence-specific repressor proteins have been found to reside in cells as 
components of large protein complexes, associating with co-repressors to regulate their 
biological activity. Furthermore, the pathogenesis of several haematopoietic disorders has 
been attributed to abnormal interactions between oncogenic proteins and nuclear co­
repressors (Lin et. al., 1998, Grignani et. al., 1998 and Lutterbach et. al., 1998). Several co- 
repressors involved in this mode of so-called “transrepression” have been identified 
including Groucho (Fisher and Caudy , 1998), SMRT/NCoR (Chen et al., 1995 and Horlein 
et al., 1995) and CtBP (Turner and Crossley, 1998). Recent studies have demonstrated that 
Evi-1 associates with the short-range transcriptional co-repressor murine C-terminal Binding 
Protein 2 or mCtBP2 (Turner and Crossley 1998). Interestingly, both mammalian and 
Drosophila CtBP proteins are instrumental in modulating diverse biological processes. 
Human CtBPl (hCtBPl) diminishes the tumourigenicity of adenovirus E1A (Schaeper et. al., 
1998) and the Drosophila homologue, dCtBPl has been identified as a key mediator of 
transcriptional repression by Hairy, Snail, Knirps and Enhancer o f split during development 
(Nibu et. al., 1998). The recognition motif, P-DLS-K found in mammalian, viral and 
Drosophila proteins, mediates interactions with CtBP co-repressors (Turner and Crossley et. 
al., 1998). Evi-1 has two similar motifs, PFDLTTK and PLDLSNG located between amino 
acids 553-559 (CtBPl) and 584-590 (CtBP2) within the repressor domain (Rp).
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Preliminary studies in our lab implicated a role for CtBP co-repressors in the biological 
activity of evi-1. First, mCtBP2 interactions with the Rp of evi-1 were confirmed using 
the yeast-2-hybrid assay (Dr. C. Bartholomew, unpublished data). Second, northern blot 
analysis revealed the expression of endogenous mCtBP2, in both kidney 293 cells and 
Rati fibroblasts (Dr. C. Bartholomew unpublished data - Figure 24), where evi-1 
biological activities have been demonstrated. Third, evi-1 ACtBP mutants were created 
by PCR mediated site directed mutagenesis which substituted D, L amino acids for A, S 
within the P-DLS-K CtBP motifs of evi-1. These studies showed that evi-1 mutant 
proteins with ACtBPl, ACtBP2 or ACtBPl/2 mutations relieved the evi-1 Rp/mCtBP2 
interaction in yeast-2-hybrid assays (Bartholomew, unpublished data - Figure 25).
The unexpected function of DNA-binding defective derivatives of evi-1 as dominant 
negative mutants of FLevi-1 transforming activity (described in Chapter 4 of this thesis) 
substantiated the proposal that these evi-1 mutants were able to recruit additional 
regulatory factors to mediate this inhibitory activity. Therefore from the cumulative 
evidence we hypothesised that the evi-1 oncogene could recruit CtBP2 co-repressors to 
mediate its repressor and oncogenic activities. It was hoped that these investigations 
would not only provide clues to evi-1 dominant negative function, but as a consequence 
would further disclose the intricacies of EVI-1 function in general.
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5.1 Evi-1 mutants with a Partial Deletion o f Rp, encompassing both 
CtBP sites, are Non-Transforming
Since two CtBP recognition motifs were recently discovered within in the repressor 
domain of evi-1 (Turner and Crossley et al., 1998), the transforming activity of evi-1 
mutants with a 119 amino acid deletion encompassing both CtBP sites was examined. 
This mutant retrovirus, p50MARp514-633, was obtained from C. Bartholomew. Rati 
populations expressing p50MARp514-633 were isolated (See Western Blot 
analysis— Figure 26A) and introduced into the Rati transformation assay (for method 
overview see Figure 13). Deletion of this portion of evi-1 resulted in a dramatic reduction 
in macroscopic colony production in soft agar assays (Figure 26B).
5.2 Evi-11 CtBP Interactions Modulate Transcriptional Repression 
by Evi-1
Deletion mutagenesis studies have shown that the repressor domain of evi-1, localised 
between amino acids 514 to 724, could inhibit lexAVP16 mediated transcriptional 
activation of the adenovirus E lb  minimal promoter in kidney 293 cells. In addition, 
optimal repressor activity required specific interactions of either the evi-1 ZF1 DNA 
binding domain or heterologous GAIA DNA binding domains (GAL4DBD) 
(Bartholomew et. al., 1997). This repressor assay was also used to investigate the 
repressor activity of evi-1 ACtBP deletion mutants. The pSG424 vector consists of the 
GAIA (1-147) DNA binding domain (GAJL4DBD) alone. The entire evi-1 Rp domain
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was fused to pSG424 and this would provide our positive control. Likewise, pSG424 was 
also fused to the Rp domain with a mutated first CtBP site, the Rp domain with a mutated 
second CtBP site and Rp domain with both CtBP sites mutated. These vectors were 
designated pGWTRp, pGACtBPl, pGACtBP2 and pGACtBPl/2 respectively. The assays 
examined repression of the VP 16 transactivator, which is fused to the DNA binding 
domain of lexA. The promoter activity was determined by relative CAT 
(Chloroamphenicol transferase) activity of the pL8G5CAT reporter (Hollenburg et. al., 
1995) which has the E lb  TATA box with eight copies of the lexA recognition sequence 
and five copies of the GALA UAS upstream of the CAT gene.
Figure 27 shows the results from these studies, where three separate transfections were 
carried out for each repressor construct. Transient transfections in 293 cells conferred 
low CAT activity, which is dramatically induced in the presence of lexAVP16. However, 
when the pGWTRp is also transfected, a marked 80% reduction in CAT activity is 
observed. Mutating the first CtBP site within the repressor domain had minor effects on 
repressor activity with pGACtBPl mutants reducing CAT activity by 70%. Mutating the 
second site or both sites severely disrupts repressor activity with 
pGACtBP2 and pGACtBPl/2 mutants inhibiting CAT activity by only 30% and 35% 
respectively. This demonstrated that CtBP binding was necessary for transcriptional 
repression by evi-1— with the second CtBP site being more critical than the first for this 
activity.
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5.2 Evi-l/CtBP Interactions Modulate Evi-1-mediated 
Transformation
The recombinant retroviral vectors used in these experiments were made by Dr. C. 
Bartholomew and included evi-1 mutants lacking the first CtBP binding site (p50MA 
CtBPl), evi-1 mutants lacking the second CtBP binding site (p50MACtBP2) and evi-1 
mutants which have both CtBP sites removed (p50MACtBPl/2). The Rati 
transformation assay (described in Chapter 4) was used to determine the importance of 
evi-l/CtBP interactions for evi-1 oncogenic activity in R ati fibroblasts. Rati populations 
were established which contained p50MXneo, p50MFLevi-lneo, p50MACtBPlneo, 
p50MACtBP2neo or p50MACtBPl/2neo. Figure 28A shows Western blot analysis, with 
an anti-evi-1 specific antibody, of the respective wild type and mutant evi-1 proteins 
expressed in these cell populations. This analysis revealed the populations produced 
similar levels of the expected sized proteins. These cell lines were plated out into soft 
agar assays (in triplicate for each cell line) and their abilities to form macroscopic 
colonies were assessed after 3 weeks in culture. Figure 28B shows that evi-1 proteins 
with a mutated first CtBP site partially retain the ability to transform Rati fibroblasts, 
with ACtBPl mutants producing 50% of the transforming activity of FLevi-1 controls. 
These studies also show that transformation is absolutely dependent on the second CtBP 
site of evi-1, with ACtBP2 mutants reducing colony production by 97% compared to 
FLevi-1 controls. Moreover, mutating both CtBP-binding sites (ACtBPl/2 mutants) of 
evi-1 also abolished the transforming activity of the FLevi-1 protein, with a 96%
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reduction in transforming activity compared to FLevi-1 controls. As expected, Rati cell 
populations infected with the control virus p50Mxneo did not grow in soft agar. These 
results were reproduced in two separate experiments and both illustrated that the first 
CtBP site in Rp is partially required, and the second CtBP site in Rp is absolutely 
essential, for evi-1-mediated Rati transformation.
5.3 Discussion
5.3.1 The Integrity of CtBP sites is Required for Evi-l-Mediated Transcriptional 
Repression
The repressor domain of evi-1 encompasses two putative binding sites for the CtBP 
family of co-repressors. Therefore, it was hypothesised that evi-1 may directly interact 
with CtBP proteins to function as a transcriptional repressor. Mutating the first CtBP site 
within the Rp of evi-1 retained most of the evi-1 repressor activity (Figure 27). However, 
when the second CtBP site or both CtBP sites were altered, a significant fraction—  
although not all— of the repressor activity was lost (Figure 27). This shows that the 
second CtBP site was essential for recruiting CtBP co-repressor proteins, which enhance 
the repressor activity of evi-1. The retention of a small portion of this activity suggests 
that alternative mechanisms of repression might operate. Perhaps the mode of repression 
by evi-1 depends on the context of the targeted promoter.
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5.3.2 Evi-l/CtBP interactions Modulate Evi-l-Mediated Cell Transformation
Partial deletion of the evi-1 Rp region required for CtBP binding (amino acids 514-633) 
has been found to significantly deplete the transforming activity of evi-1 in Rati 
fibroblasts (Figure 26). Subsequently, studies showed that the 514-633 region of evi-1 is 
required for binding the mCtBP2 co-repressor protein (Bartholomew, unpublished). 
Taken together, these observations suggest a model where co-repressor function mediates 
the transforming activity of evi-1. Mutating the first, second or both CtBP sites had 
profound effects on binding activity in yeast (Figure 25 - Bartholomew, unpublished). 
However, it was noted that mutating the second or both CtBP sites produced the greatest 
effects. In these studies, retroviral vectors expressing evi-1 CtBP binding-defective 
mutants were constitutively expressed in Rati cells and selected populations examined in 
soft agar assays. Evi-lACtBPl mutants produced only half of the macroscopic colony 
growth seen with FLevi-1 controls (Figure 28). Constitutively expressing evi-lACtBP2 
and evi-1 ACtBP 1/2 mutants in R ati fibroblasts completely abolished transforming 
activity of evi-1 to levels comparable to vector only controls (Figure 28). Therefore, the 
magnitude of the effects seen for the specific CtBP mutants in Rati transformation 
correlated with that of DNA binding activity in yeast. Furthermore, these results suggest 
that the integrity of the second CtBP site in evi-1 was not only essential for repressor 
activity, but also crucial for evi-1-mediated transformation.
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5.3.3 Possible Mechanisms of CtBP Action
The CtBP proteins are short-range co-repressors, which do not bind DNA but are likely to 
bridge the interaction of the evi-1 repressor with its ultimate target. CtBP may augment 
repression by 1) direct interactions with the basal machinery to assist in the recruitment of 
this machinery to the promoter, or 2) through interactions with the chromatin template, 
which may serve to modulate the accessibility of the template.
5,4 Summary
Interactions of evi-1 with the CtBP co-repressors facilitate evi-1 repressor function. 
However our results suggest that evi-1 can utilise other mechanisms for repressor activity. 
Furthermore mutating the second CtBP binding site or both CtBP sites, residing in the 
evi-1 Rp domain, can completely abolish evi-1 mediated transformation. Therefore, these 
data provide evidence for the molecular basis for both transcriptional repression and 
transformation by evi-1.
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Chapter 5 Figures
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Figure 24: Northern Blot Analysis of Rati and 293 cells with mCtBP2
(Dr. C. Bartholomew, unpublished)
To examine whether mCtBP2 proteins are expressed in 293 and Rati cell lines where evi- 
1 repressor and oncogenic activities have been demonstrated, Northern blot analysis of 
20jug of total RNA from 293 (Lane 1) and R ati (Lane 2) cells was carried out with an 
mCtBP2 probe. A control GAPDH blot is also shown.
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Figure 25: Interaction of mCtBP2 with WT and Mutant Evi-1
Repressor Domains (Dr. C. Bartholomew, unpublished)
Using the yeast-2-hybrid assay the importance of evi-1 CtBP binding sites in the evi- 
l/mCtBP2 interaction (in Saccharomyces cerevisiae SFY526) has been demonstrated. 
The graph opposite shows the interaction of the Rp domain of evi-lwith mCtBP2. GAD 
(white box) and DBD (black box) refer to the activation and DNA binding domains of 
GAL4 respectively. The evi-1 wild type Rp domain (blue box), CtBP mutated regions 
(X) and mCtBP2 (grey box) are also shown.
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Figure 26: Transformation of Rati Fibroblasts by Evi-1 Rp Domain 
Deletion Mutants
Previous deletion mutagenesis studies have shown that deletion of the region within Evi-1 
containing putative CtBP sites reduces Evi-ls ability to transform Rati fibroblasts.
A) Western Blot analysis. Proteins were fractioned on a 7.5% SDS-polyacrylamide gel 
subjected to Western blot analysis using a specific anti-Evi-1 polyclonal antibody (1806). 
Lane 1 (-) is a Negative control of Rati cells transfected P50MXneo vector only. Lane 2 (+) 
is a Positive control of R ati cells transfected with p50FLEvi-lneo. Lane 3 is Rati 
populations constitutively expressing p50MARpWTneo deletion mutants lacking the entire 
repressor domain (ARp514-724). Lane 4 is Rati populations constitutively expressing p50M 
ARp514-633neo mutants lacking the section of repressor domain containing both putative 
CtBP binding sites (ARp514-633).
B) Macroscopic colony growth (>0.3mm) in soft agar assays by constructs expressing either 
P50MXneo vector alone, FLEvi-1, ARpWT mutants or ARp514-633 mutants are shown. 
Results are the mean ± standard deviation of triplicate plates examined for each population. 
Functional domains of the Evi-1 protein are shown: grey box, DNA binding domains; black 
box, intervening region; blue box, repressor domain; stripped box, acidic domain. The long 
terminal repeats (LTR-blue/white striped box) and neomycin resistance gene (dark grey 
boxes) of the retroviral vector are also indicated and potential CtBP binding sites are also 
shown (red oval shape) .
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Figure 27: Repressor Activity of Evi-1 CtBP Binding Mutants
To determine the importance of Evi-l/CtBP interactions for Evi-1 repressor activity 2.5/ig of 
either L8G5CAT and l^g  pHSVpgal were transiently transfected in the absence (-) or 
presence (+) of 25ng of LexAVP16 with 1/^g of the wild type repressor, repressor CtBP 
mutants, or pSG424 alone as indicated. CAT activity is corrected for p-galactosidase activity 
in each sample. These experiments were performed on two occasions. Typical results are 
shown opposite: the results are the mean ± standard deviation of three independent 
transfections. For colour coding description refer to Figure 25.
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Figure 28: Rati Cell Transformation by Evi-l/CtBP Mutant Proteins
The transforming activity of Evi-1 ACtBP mutants is shown overleaf.
A) Western Blot analysis. Proteins were fractioned on a 7.5% SDS-polyacrylamide gel 
subjected to Western blot analysis using a specific anti-Evi-1 polyclonal antibody (1806). 
Lane 1 (-) is a Negative control of Rati cells transfected P50MXneo vector only. Lane 2 (+) 
is a Positive control of Rati cells transfected with p50FLEvi-lneo. Lane 3 is Rati 
populations constitutively expressing p50MACtBPlneo mutants which have an alteration in 
the first Evi-1 CtBP binding site. Lane 4 is Rati populations constitutively expressing p50M 
ACtBP2neo mutants which have an alteration in the second Evi-1 CtBP binding site. Lane 5 
is Rati populations constitutively expressing p50MACtBPl/2neo mutants which have 
alterations in both Evi-1 CtBP binding sites.
B) These constructs were introduced into the Rati Transformation Assay to assess their 
transforming abilities in soft agar. The graph opposite illustrates the results from one 
representative population expressing each vector tested. Results shown are the mean ± 
standard deviation of the triplicate plates examined for each clone. Two independent R ati 
populations were examined for each vector and the same trends were observed. For colour 
coding description refer to Figure 26B.
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Chapter 6: Investigating the Biological Activity of Evi-1 in 
Haematopoietic Cells
Aberrant overexpression of EVI-1 is frequently observed in patients with acute myeloid 
leukaemia, chronic myeloid leukaemia in blastic crisis and myelodysplastic syndromes. 
The transformed phenotype of acute myeloid leukaemia is characterised by a loss of 
normal controlled proliferation and a differentiation block leading to the production of 
immature blasts cells instead of the development of fully mature haematopoietic 
progenitors. It is postulated that ectopic EVI-1 expression disrupts the normally “highly 
orchestrated” process of haematopoiesis and through unknown mechanisms helps to 
maintain the transformed leukaemic state. Consistent with this, constitutive evi-1 
expression in primary erythroid progenitor cells (Kreider et al., 1993) and 32Dcl3 cells 
(Morishita et al., 1992) blocks erythropoietin (EPO) and granulocyte colony stimulating 
factor (G-CSF) responsiveness respectively, resulting in the cessation of the proliferation, 
differentiation or survival of these haematopoietic progenitors.
Others have shown that full length evi-1 (FLevi-1) can transform Rati fibroblasts by 
permitting growth of macroscopic colonies in soft agar (Kurokawa et al., 1995). Deletion 
mutagenesis studies show that the second DNA binding domain (ZF2) (Kurokawa et al., 
1995), the repressor domain (Rp) (Bartholomew et al., 1997) and the first DNA binding 
domain (ZF1) (Kilbey and Bartholomew, 1998) are all required for optimal Rati 
transformation. These findings are reproduced in Chapter 4 of this thesis.
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Until now no studies have addressed which of these regions, critical for optimal R ati 
transformation, are essential to the oncogenic function of EVI-1 in myeloid cell 
transformation. As a means to help dissect the complex pathway of transformation by 
evi-1 in haematopoietic cells, an experimental system was established whereby 
retrovirally-transduced haematopoietic progenitors could be examined in methyl cellulose 
colony assays.
6.1 Development o f a Cell Culture System fo r  the Clonal 
Differentiation o f Retrovirally-TransducedMurine Primary Bone 
Marrow Cells
To study the role of evi-1-mediated transformation in the pathogenesis of myeloid 
leukaemias an assay was established where retrovirally-transduced haematopoietic 
progenitors of several lineages could be examined in colony assays (see Methods section 
2.2.1). This provided a useful system to study the biological activity of both normal and 
mutant evi-1 proteins in haematopoietic cells. Figure 29 shows a schematic diagram of 
the assay. In brief, the kidney epithelial packaging cell line, Bosc23 are transfected with 
the retroviral vector of interest. The following day these cells are irradiated to halt their 
growth. Immediately after irradiation, each flask of virus-producing cells is co-cultivated 
with bone marrow cells flushed from one CBA/Ca mouse femur. These cells are 
incubated together for 48 hours, for gene transfer to take place, then plated out in methyl
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cellulose. These colony assays provided evidence for the presence of progenitor cells that 
are able to produce single and multi-lineage colonies of differentiated cells. In these 
studies, colonies are defined as greater than 50 cells and are morphologically distinct.
The three colony types scored in these assays were colony forming unit-granulocyte 
macrophage (CFU-GM), burst forming unit-erythroid (BFU-E) and colony forming unit- 
macrophage (CFU-M). Examples of these colonies are seen in Figure 30. The CFU-GMs 
(Figure 30A) are characterised by their typically dense core of cells surrounded by a 
peppering of individual cells around the periphery. A BFU-E colony can be seen in 
Figure 30B. These colonies appear as erythroid clusters or “bursts” ranging from 
transparent to brick red, depending on the haemoglobinisation status. Figure 30C shows a 
typical macrophage colony which arise as a loose scattering of individual bone marrow 
cells.
Giemsa-stained cytospin preparations of these colonies verified colony assignment. 
Photographs of cytospins are shown in Figure 31 A, 3IB  and 31C. Figure 31A shows 
er)throblastic islands of maturing erythroid cells. Cytospin 31AJ reveals an abundance of 
mature normoblast cells. The arrow in Figure 31 A ll shows fully mature red blood cells 
where nuclei are being expelled and haemoglobin synthesis is complete. Figure 3 IB 
shows typical CFU-M colonies. The cytoplasm of these large cells is often highly 
vacuolated and they can contain degenerated cell debris. Figure 31C shows CFU-GM 
cytospins, which reveal a wide range of maturing granulocyte and macrophage cells: the 
black arrows indicate mature “banded” or “segmented” neutrophils.
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6.1.1 Retroviruses Used in Bone Marrow Assays
All of the retroviruses to be utilised in these studies are illustrated in Figure 32. In 
addition to FLevi-1 (p50MFLevi-lneo) and A324 (p50MA324neo) natural evi-1 isoforms, 
deletion mutants lacking the Rp domain (p50MARpneo), the ZF1 domain (p50MA 
ZFlneo), theZF2 domain (p50MAZF2zeo) and both ZF1 and ZF2 domains of evi-1 
(p50MAZF12zeo) were examined. Retroviral titres (also seen in Figure 32) were 
determined by infecting semi-confluent NIH-3T3 cells with serial dilutions of viral 
supernatant followed by a selection in G418 or zeocin® depending on the vector.
6.2 Production o f Haematopoietic Colonies in Primary Bone Marrow 
Cells Infected with FLevi-1
Initially, the effect of enforced FLevi-1 expression on haematopoietic colony formation 
was investigated. Bone marrow harvested from 4-week-old CBA/Ca mice was 
cocultivated with Bosc23 cells producing either p50MXneo (negative control) or 
p50MFLevi-lneo viruses. Bone marrow cells cultured without virus were also used as an 
additional control. Following the two-day co-cultivation infected cells were assayed in 
the colony forming assays. Haematopoietic cells derived from 3 femurs were infected 
with each virus. Cells infected with p50FLevi-lneo vector showed an 80% reduction in 
CFU-GM production and a 90% reduction in BFU-E production, compared with the 
p50MXneo controls (Figure 33). CFU-M colonies were unaffected in both FL-infected
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cells. These experiments were repeated in more than six separate occasions and the same 
trend was observed each time.
6.3 Production o f Hameatopoietic Colonies in Primary Bone Marrow  
Cells Infected with Evi-1 Deletion Mutants
Over-expressing FLevi-1 results in a block in CFU-GM and BFU-E colony production in 
murine bone marrow cells (section 6.2). To elucidate whether certain functional domains 
of evi-1 were required for this biological activity, various evi-1 deletion mutants were 
introduced into the experimental system described in section 6.1. The effects of 
constitutively expressing deletion mutant constructs lacking the Rp domain, the ZF1 
domain, theZF2 domain and both ZF1 and ZF2 domains of evi-1 were examined. The 
alternative splice form of evi-1, A324 was also tested. As before, bone marrow was 
harvested from 4-week-old CBA mice. Bosc23 cells producing either FLevi-1 (positive 
control), p50MXneo (negative control), p50MXzeo (negative control) or the 
aforementioned evi-1 deletion mutants were cocultivated with bone marrow cells flushed 
from independent murine femurs. Bone marrow cells cultured without virus were also 
used as an additional control. After a 48-hour co-cultivation, infected cells were then 
assayed in the colony formation assays. Each retrovirus was infected into 3 femurs taken 
from different mice. The haematopoietic cells infected with FLevi-1 vector showed a 
dramatic 80% reduction in CFU-GM and 90% reduction in BFU-E compared to vector 
controls. Cells infected with A324, ARp, AIR or AZF1 mutants disrupted CFU-GM and
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BFU-E colony production by similar quantities to the FL protein (Figure 34). Expressing 
evi-1 mutants lacking the ZF2 domain also results in a drop in CFU-GM and BFU-E 
colony production but the effects were not as remarkable. CFU-GM colonies are reduced 
by 60% and BFU-E colony production by 50% in this case. These effects were also 
abated in assays with mutants lacking both DNA binding domains (AZF12 mutants). The 
results indicated that constitutive expression of AZF12 mutants reduced CFU-GM colony 
formation by 40% and the appearance of BFU-E colonies was only reduced by 25%. 
These experiments were repeated in three or more separate experiments and the same 
trends were observed each time. The transforming activities of all evi-1 retroviruses 
examined in Rati cells are compared to the relative reductions in BFU-E and CFU-GM 
colony production in Table 2.
6.4 Evaluation o f Gene Transfer Efficiency ofN eor Retroviral Vectors
Examination of proviral integration into bone marrow colonies by PCR analysis allowed: 
(1) verification that all retroviruses used were inserted into the genome of each progenitor 
cell type examined and (2) estimation of viral infection efficiency. A PCR-based 
approach was utilised for this purpose and DNA extracts from colonies were prepared 
from a Stratech bone marrow-specific DNA extraction kit. Two rounds of PCR were 
performed on DNA extracts prepared from pooled (5 colonies) and individual bone 
marrow colonies. The first round of PCR used external primers which amplified a 
1250bp region, which included most of the neo gene and a section of a poly linker site
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within the p50MXneo vector (See Figure 35). A second round of PCR with nested 
primers was used to increase the sensitivity of this procedure. It was reasoned that the 
major analysis of proviral integration should be on CFU-M colonies since CFU-M colony 
production appeared unperturbed upon expression of all retroviruses. Infection 
efficiencies of the zeocin resistant vectors were not examined here.
Figure 36 shows the agarose gel electrophoresis photographs of the second round PCR 
products. The varying intensities of PCR amplified DNA products may reflect 
differences in colony size, and therefore infected cell number, originally plucked from 
methyl cellulose assays. These results are also tabulated in Table 3. Analysis of fifty 
individual p50MXneo-transduced CFU-M colonies revealed 50% of colonies were 
positive for p50MXneo. Five individual CFU-M colonies infected with either FLevi-1 or 
evi-1 mutant viruses ranged from 20-80% positive for p50MXneo, respectively. Concerns 
raised over the PCR-sensitivity, with respect to the detection of retrovirus from such 
small cell numbers, resulted in a portion of the colonies being pooled. Indeed, pooling 
five colonies/sample generally resulted in higher values. Moreover, PCR analysis of 
p50MXneo-infected cells revealed that this vector inserts into progenitors of all cell types 
examined. No uninfected (control) colonies were positive for the p50MXneo virus. The 
Low sample numbers, analysed for colonies transduced with FL and mutant vectors 
compared to p50MXneo, may explain why in some cases the percentage of unpooled 
colonies exceeds that of pooled colonies for a particular vector type.
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6.5 Discussion
6.5.1 Enforced Expression of Evi-1 Blocks the Production of Erythroid and 
Granulocyte-Macrophage Colonies in Primary Bone Marrow Cells
These studies have shown that constitutively active FLevi-1 provokes a block in both 
erythroid and granulocyte-macrophage production. A compensatory increase of other 
lineages was not observed here, suggesting lineage switching was not involved.
FLevi-1 expression reduced both CFU-GM and BFU-E production by approximately 
80%. However, macrophage colony formation was not affected. Interestingly, the 
haematopoietic cell line MID+ , which expresses the evi-1 gene at high levels, maintains 
the capacity to differentiate to macrophages in the presence of IL-6 (Morishita and Ihle, 
unpublished data cited in Kreider et. al., 1993). This is consistent with our finding that 
evi-1 expression has no effect on macrophage production.
Results from these studies are consistent with previous findings that inappropriate evi-1 
expression in primary erythroid progenitor cells (Kreider et al., 1993) and the myeloid 
leukaemia cell line, 32Dcl3 (Morishita et al., 1992) disrupts the responsiveness of the 
cells to erythropoietin resulting in a cessation of erythroid development. However, the 
studies described here are the first to demonstrate a block in granulocyte-macrophage 
colony production in primary bone marrow cells by constitutive evi-1 expression, 
although it has been previously reported that enforced expression can block Granulocyte
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Colony Stimulating Factor (G-CSF) induced survival of 32Dcl3 cells (Khanna-Gupta et. 
al., 1996).
The observations, reported in this chapter, do suggest that one role for EVI-1 in a 
leukaemic programme is to induce a block in erythroid and myeloid development or to 
impede the survival of these cells at a stage prior to BFU-E and granulocyte-macrophage 
stages, respectively. Two potential models for leukaemia progression involving 
constitutive EVI-1 activation are (1) EVI-1 overexpression is one of the first mutations 
within these neoplasms mediating a differentiation block. However, additional genetic 
alterations are required to contribute to the proliferation and/or survival of haematopoietic 
cells in leukaemias. (2) The block of colony production observed here may reflect EVI-1 
expressing cells’ need for the support of the haematopoietic microenvironment to survive.
6.5.2 Enforced Expression of Evi-1 Deletion Mutants Impairs Haematopoietic 
Progenitor Production
Surprisingly, retroviral vectors lacking the Rati-transforming AIR mutants and the R atl- 
nontransforming A324, ARp and AZF1 mutants all seemed to act in an identical fashion to 
FL evi-1 proteins (Figure 34/Table 2): over-expression in primary bone marrow also 
resulted in reduction in CFU-GM and BFU-E colony formation. Similar to FLevi-1 
infected cells, CFU-GM and BFU-E reductions ranged from 80-90% compared to vector 
only controls. It is intriguing that domains, proven to be essential for transformation of
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R ati fibroblasts, appeared to have no influence on the biological function of evi-1 in bone 
marrow cells.
Retroviral vectors expressing mutants lacking the ZF2 domain were not as effective at 
blocking CFU-GM and BFU-E production (Figure 34). CFU-GM reductions were near 
60% and BFU-E reductions of 50% were seen, which suggested that the second DNA 
binding domain could be important for this biological activity. Indeed, mutants lacking 
both ZF1 and ZF2 domains also block CFU-GM and BFU-E growth with reduced 
efficiencies (Figure 34). However, viral titres of the p50MAZF2zeo and p50MAZF12zeo 
constructs were notably lower than those evaluated for the other viruses, which may 
explain the somewhat mediocre abilities of these mutants in blocking colony production. 
However, the AZF2 and AZF12 vectors encode zeocin® resistance and all other vectors 
encode G418 resistance. Therefore, it is impossible to compare the zeo vector and neo 
vector titres from NIH3T3 focus formation assays since the zeocin selection is a much 
harder selection than G418.
Introducing a collection of evi-1 deletion mutants into haematopoietic cells results in an 
identical phenotype to FLevi-1 proteins. The results suggest that optimal activity requires 
the ZF2 domain as AZF2 and AZF12 mutants but not AZF1 mutants have a reduced effect 
on colony formation.
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6.5.3 Testing the Experimental System
6.5.3.1 Viral Titre Analysis
Evaluation of viral titres (Figure 32) by focus formation of virus-infected NIH3T3 cells 
showed p50MXneo titres generally exceeded p50MFLevi-lneo titres 10 fold and mutant 
titres 20 fold.
6.5.3.2 PCR Analysis
From the data it was observed that the production of erythroid and granulocyte- 
macrophage colonies was not completely abolished by FLevi-1, suggesting that the 
remaining colonies arose from cells not infected with retrovirus. Therefore, the bulk of 
the PCR analysis was carried out on CFU-M, CFU-GM and BFU-E bone marrow 
colonies transduced with p50MXneo vector alone. We were able to conclude that all 
three colony types can be infected with the p50MXneo retrovirus (Figure 36). Proviral 
integration studies on the FLevi-1 and mutant retroviruses were limited by their small 
sample size and the inability to analyse CFU-GM and BFU-E colonies (owing to the 
effect these vectors have on production of these colonies). However, the analysis did 
prove that these retroviral vectors could also infect macrophage progenitors.
Indeed, from the viral titre data, overall infection efficiencies were much higher than 
expected. However, these data cannot be compared because they involve completely 
different methods: focus formation from supernatant infection and infection of bone 
marrow cells in a co-cultivation with virus producer cells, respectively. Finally, preparing
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DNA extracts from (and therefore PCR) minute numbers of cells may have limited 
detection of retrovirus by this PCR technique.
To obtain a clearer view of retroviral expression in haematopoietic cells of all constructs 
future studies must examine RNA expression levels of all of the vectors by RT-PCR 
analysis.
6.5.4 Possible Mechanisms of Evi-1 Action in Haematopoietic Cells
6.5.4.1 Distinct Domains are Required for the Biological Activity o f Evi-1 in R a ti Cells 
and Haematopoietic Cells
These studies have demonstrated that the biological activity of FLevi-1 in haematopoietic 
cells is not altered by the removal of Rp and ZF1 domains, which are both essential for 
evi-ls oncogenic activity in Rati fibroblasts. Mutants lacking both DNA binding 
domains ZF1 and ZF2 or the ZF2 domain only, suggest that evi-1 may be partially 
dependent on the ZF2 domain. These mutants have reduced biological activities 
compared to FLevi-1, but do not restore erythroid and myeloid differentiation levels to 
control levels. Therefore, there may be an unexamined region residing in the remainder 
of the protein (the C-terminus) that is absolutely essential for the disruptive effects of 
evi-1 overexpression in haematopoietic cellular development.
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6.5.4.2 High Level Expression o f FLevi-1 and Evi-1 Deletion Mutants Could Induce Cell 
Death in CFU-GM and BFU-E Progenitors
The possibility that introducing these proteins into bone marrow cells simply kills these 
cells should not be ruled out. It is conceivable that each of these constructs could 
overstimulate an evi-1 regulatory pathway leading to cell cycle arrest, senescence or 
necrosis of the cells. Studies showing that Rati fibroblasts modified to constitutively 
express evi-1 induce cell cycle progression and confer a growth advantage on these cells 
(Kilbey et al., 1999) would tend to discount this theory. However, there are several 
examples where the level of a particular oncogene appears to regulate the fate of cells.
For example, low levels of Raf activity will actuate the progression of the cell cycle, 
whereas stronger activation results in cell cycle arrest (Woods et al., 1997). Similarly c- 
Myc induces proliferation or apoptosis, depending on the concentration of serum (Evan 
et. al., 1992).
6.5.4.3 FLevi-1 and Evi-1 Deletion Mutants Dominantly Disrupt the Regulation o f  
Factors Essential for Normal Haematopoiesis
Constitutive expression of FLevi-1 and evi-1 deletion mutants could block differentiation 
pathways by physically interacting with key haematopoietic cell regulators of the 
erythroid and myeloid lineages. There is now a widely accepted view of the 
combinatorial action of transcription factors. This notion has grown to accommodate the 
idea that factors themselves form large multiprotein complexes or possibly even “lineage- 
specific machines” within the scheme of haematopoiesis (Cross and Enver, 1997). For 
example, studies have shown that LM 02 may form a transactivating complex in erythroid
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cells that includes SCL, GATA-1, E2A and LDB1/NL1 (Visvader et. al., 1997). 
Constitutively expressed EVI-1 is likely to corrupt key regulatory factors required for the 
proper development of the erythroid and myeloid lineages.
It appears that GATA-1 facilitates erythropoiesis by recruiting factors into multiprotein 
complexes and therefore GATA-1 is a potential target for EVI-1 protein-protein 
interactions. Furthermore, EVI-1 has a GATA consensus sequence in the ZF1 domain 
and reporter assays have shown that (1) EVI-1 can bind to a GATA-like binding sequence 
through ZF1 and (2) EVI-1 blocks GATA-1-mediated trans-activation (Kreider et. al., 
1993 and Kreider et. al., 1994 respectively). That fact that no known physiological 
GATA-1 sites can be bound by EVI-1 has questioned the physiological importance of 
these findings. Furthermore, we have shown here that a block in erythroid differentiation 
does not require the ZF1 domain.
An additional possibility is that EVI-1 can homodimerise. Studies examining the possible 
self-association of EVI-1 are of great importance because such interactions could 
facilitate the regulation of EVI-1 function. Acidic extensions are typical dimerisation 
domains of proteins (Chen and Bieker, 1996 and Geiman et al., 2000) and the acidic 
domain of evi-1 is still intact in all the constructs used in these studies. Therefore FLevi- 
1 and evi-1 deletion mutants infected into these cells could dimerise with endogenous evi- 
1 proteins. Consequently, this may interfere with myeloid and erythroid differentiation 
pathways that may be regulated by endogenous FLevi-1 proteins.
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6.6 Summary
In closing, the experimental system described provides an in vitro approach using primary 
bone marrow cells to assay the biological function of the evi-1 oncogene. Inappropriate 
expression of FLevi-1 and the evi-1 the deletion mutants examined either blocked the 
production of erythroid and myeloid lineages or somehow impede the survival of these 
cells at a stage prior to BFU-E and CFU-GM stages, respectively. An intermediate 
phenotype was achieved when overexpressing AZF2 and AZF12 mutants but not AZF1 
mutants of evi-1 in this biological system. This suggests that the ZF2 domain may have 
been partially required for this biological activity in haematopoietic cells.
The exact mechanism of evi-1 biological action in bone marrow cells was unclear from 
these studies. This issue is likely to be unravelled when the normal role for EVI-1 in the 
commitment and lineage determination of haematopoietic cells is fully investiagted. It 
would be useful to investigate the role of evi-1 in haematopoiesis within the context of an 
intact animal. Since evi-1 knockouts have proved lethal to mice (Hoyt et al., 1997), 
mouse chimaeras could be created by generating evi-1 +/" and evi-1_/' embryonic stem cell 
clones. Single cell suspensions could be prepared from haematopoietic organs at 
different stages, which could be examined in methyl cellulose colony assays to determine 
the morphology and frequency of erythroid and myeloid progenitors in the organs of 
mutant foetuses compared to phenotypically normal littermates. Therefore, evi-1 mutant 
mouse chimaeras could provide us with a clearer picture of EVI-1 function in 
haematopoiesis, which would undoubtedly have implications for the consequences of
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constitutive EVI-1 activation observed in myeloid leukaemias.
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Chapter 6 Figures
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Figure 29: Methodology of Bone Marrow Colony Assays
See text for details.
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Figure 30: Morphological Analysis of Haematopoietic Colonies
Examples of haematopoietic colonies scored in these assays are shown. Colony forming 
Unit -Granulocyte Macrophages (or CFU-GMs) are shown in A (40x Magnification). A 
typical Burst forming unit-Erythroid colony (or BFU-E) can be seen in B (lOOx 
Magnification). C shows a typical macrophage colony (40x Magnification).
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A) CFU-GM B) BFU-E
C) CFU-M
Figure 31: Morphological Verification of Colony Assignment by 
Examination of Cytospin Preparations
A) Cytospin preparations of Burst Forming Unit-Erythroid colonies. See text for 
details.
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B) Cytospin preparations of Colony Forming Unit-Macrophage colonies. See text for
details.
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C) Cytospin preparations of Colony Forming Unit-Granulocyte Macrophage colonies.
See text for details.
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Figure 32: Schematic Representation of Retroviral Vectors used in 
Primary Bone Marrow Studies
Evi-1 functional domains are shown with the DNA binding domains (light grey boxes), the 
intervening region (black boxes), the repressor domain (dark blue boxes) and the acidic 
domain (black/white striped boxes). The p50MXneo vector is also shown indicating the 
long terminal repeat (LTR) (blue/white striped box) and the neomycin/zeocin resistance 
gene (dark grey boxes).
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Figure 33: Production of Erythroid, Granulocyte-Macrophage and 
Macrophage Colonies in Primary Bone Marrow Cells Infected with 
FLevi-1
The graph shows haematopoietic colony formation in methyl cellulose of virus-infected 
primary murine bone marrow cells. Formation of BFU-E, CFU-GM and CFU-M are 
shown for mock-infected cells and cells infected with retrovirus p50MXneo (control) or 
p50MFLevi-lneo. Three individual femurs taken from individual mice were infected for 
each vector used. Infected cells from each femur were plated out in triplicate into methyl 
cellulose cultures. These experiments were repeated more than 4 times. The histogram 
opposite illustrates results from a typical experiment: the mean ± standard error of the 
mean is shown in each case. For colour coding key see Figure 32 legend.
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Figure 34: Colony Assays of Murine Bone Marrow Cells Infected
with FLevi-1 and Evi-1 Mutant Retroviruses
The histogram shows haematopoietic colony formation in methyl cellulose after gene 
transfer by co-cultivation of marrow with packaging cell lines independently producing 
one of the following retroviruses: p50MXneo (neo vector controls), p50MXzeo(zeo 
vector controls), p50MFLevi-lneo, p50MA324neo, p50MARpneo, p50MAIRneo, 
p50MAZFlneo, p50MAZF2zeo or p50MAZF12zeo. Bone marrow cells cultured without 
virus were used as an additional control. Three femurs taken from individual mice were 
infected for each vector used. Again, infected cells from each femur were plated out in 
triplicate into methyl cellulose cultures. These experiments were repeated more than 4 
times. The histogram opposite illustrates results from a typical experiment: the mean ± 
standard error of the mean is shown in each case. On the right of the graph the relative 
transforming activities of these constructs in Rati cells are denoted by + and -. For 
colour coding key see Figure 32 legend.
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Table 2: Table of percentage reduction in erythroid and
granulocyte-macrophage colony growth by FLevi-1 and Evi-1 deletion 
mutants
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VECTOR Percentage
CFU-GM
Reduction
Percentage
BFU-E
Reduction
Transformation 
In Rati Cells
p50MFLneo 79% 86% +++
p50MA324neo 76% 80%
p50MARpneo 82% 80%
p50MAIRneo 87% 87% +++
p50MAZFlneo 77% 90%
p50MAZF2zeo 58% 48%
p50MAZF12zeo 41% 25%
p50MXneo 0% 0%
p50MXzeo 0% 0%
Figure 35: Oligonucleotides used for Analysis of Proviral Integration 
into Bone Marrow Cells
Neor vectors were assessed for proviral integration of individual bone marrow 
colonies. Both the p50MXneo vector alone and the same vector expressing either 
FLEVI-1 or EVI-1 deletion mutant proteins were amplified using two rounds of PCR 
(See Methods Section 2.2.1). The double-headed arrows indicate approximate sites of 
primers used and the resultant product sizes for both rounds of PCR amplification. The 
5 ’->3’ primers were Neo-specific and the 3 ’->5’ primer was specific to a region within a 
polylinker site of the p50MXneo vector. For colour coding key see Figure 32 legend.
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Figure 36: PCR amplification of genomic DNA isolated from bone 
marrow colonies infected with p50MXneo and Evi-1 derivative vectors
PCR products visualised on a 0.8% agarose gel after the second round of PCR. Pink plus 
signs indicate samples that were positive in first round reactions. The ethidium bromide- 
stained product of an 833bp DNA fragment on each gel indicates specific amplification 
by p50MXneo-specific nested primers (for sequences see Figure 35 Oligos B and C). In 
the first half of each sample range colonies were pooled with 5colonies/pool. The 
remaining samples were individual bone marrow colonies.
SAMPLE RANGE VECTOR COLONY TYPE
1-100 p50MXneo MAC (macrophages)
101-110 p50MXneo BFU-E(erythroid cells)
111-120 p50MXneo GRAN-MAC (granulocyte- 
macrophage)
121-130 p50MFLevi-lneo MAC
131-140 p50MAIRneo MAC
141-150 p50MA324neo MAC
151-160 P50MARPneo MAC
161-170 NO VIRUS 4 MAC, 4 GRAN-MAC 
3 BFU-E
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833bp-^
8 3 3 b p - >
8 3 3 b p - ^
8 3 3 b p - ^
8 3 3 b p - >
8 3 3 b p - ^
8 3 3 b p - ^
8 3 3 b p - ^
8 3 3 b p - * -
8 3 3 b p - ^
8 3 3 b p - ^
8 3 3 b p - ^
Table 3: Table of Transduction Efficiencies
The table shown opposite indicates the percentage transduction efficiencies for all the 
retroviruses examined in each colony type.
187
Vector UNPOOLED COLONIES POOLED COLONIES
CFU-M CFU-GM Bfu-E CFU-M CFU-GM Bfu-E
p50MXneo 52% 80% 60% 74% 80% 40%
p50MFLneo 20% 100%
p50MA324neo 80% 60%
P50MARpneo 20% 60%
p50MAIRneo 60% 60%
No Vector 
Controls
0% 0%
Chapter 7: Summary Discussion
Evi-l deletion mutants have been created (Chapter 3), which act in a dominant negative 
fashion over full length evi-l (FLevi-1) proteins in Rati fibroblasts constitutively 
expressing full length evi-l (RatlFLevi-1 cells) (Chapter 4). From the evidence 
presented it is suggested that these mutants utilise distinct mechanisms to mediate this 
inhibitory activity. That is, AZF1 and ARp mutants with partially and fully intact DNA 
binding domains respectively could inhibit transformation through a “blocking” 
mechanism where mutants compete with FLevi-1 for evi-l DNA binding sites. On the 
other hand, AZF12 mutants may directly interact with and sequester proteins necessary for 
FLevi-1 regulation and thus inhibit the biological activity of FLevi-1. Since the initial 
studies described in Chapter 4 confirmed that the repressor domain is essential for the 
transformation of Rati fibroblasts, it was postulated that AZF12 mutants could “squelch” 
essential evi-l-regulatory proteins that directly interact with evi-l through this region. 
Interestingly, the studies described in Chapter 5 demonstrated that two conserved motifs 
— to which the murine C-terminal Binding Protein 2 (mCtBP2) co-repressor protein binds 
— are crucial for evi-l-mediated repression and transformation in kidney 293 epithelial 
cells and R ati fibroblasts, respectively. Taken together, the results from Chapters 4 and 5 
suggest that high levels of the AZF12 mutants could sequester endogenous mCtBP2 and 
in doing so, dominantly inhibit FLevi-ltransforming activity in RatlFLevi-1 cells. 
However, the possibility that other factors are involved cannot be discounted. An 
additional CtBP family member, mCtBPl has similar binding specificities to mCtBP2
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(Furusawa ct al., 1999) and is therefore likely to interact with EVI-1 and mediate EVI-1 
biological activity. However, potential evi-1/mCtBPl interactions have not been 
examined here.
The precise mechanism by which CtBP might effect the repression of transcription is not 
clear. However, some studies have shown an interaction of CtBPl with histone 
deacetylase (HDAC) (Sundqvist et al., 1998). Indeed, there is a common theme emerging 
whereby the recruitment of HDACs by oncogenic transcriptional repressors is essential to 
the progression of haematopoietic disorders. The biological role for co-repressor 
complexes in acute promyelocytic leukaemia is demonstrated in studies of the retinoic 
acid receptor alpha (RARa) fusion proteins. Recruitment of HDACs is indispensable for 
the capacity of acute promyelocytic leukaemia (APL) fusion proteins (PML-RARa and 
PLZF-RARa) to block myeloid differentiation and is responsible for the retinoic acid- 
resistant phenotype of PLZF-RARa APLs (Lin et al., 1998, Grignani et al., 1998). 
Similarly, the transcriptional repressor AML1-ETO fusion protein of AML recruits a 
HDAC complex through the ETO portion, which correlates with AML1-ETO inhibition 
of haematopoietic precursor differentiation (Lutterbach et al., 1998). The repressor 
function of these fusion proteins, like evi-l appears to be central to their transforming 
potential. Therefore, it will be extremely interesting to determine if histone deacetylation 
also plays a role in evi-l regulation perhaps via the CtBP interaction. An alternative 
mechanism of CtBP-mediated repression stems from recent observations that CtBP2 
interacts with the human polycomb proteins (Sewalt et al.,1999). Polycomb proteins are 
important in repression of certain homeotic genes in Drosophila (reviewed in Jones et al.,
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2000). Although the mechanisms of this repression are unclear, current models speculate 
that the {Polycomb-Group) PcG  proteins can package regions of DNA into 
heterochromatin-like complexes. This suggests that CtBP2 co-repressor can act as a 
bridging protein between sequence-specific DNA binding proteins and the PcG complex.
The biological consequences of enforced evi-l expression on haematopoietic cell 
production and the functional significance of evi-l functional domains for evi-l activity 
in primary bone marrow cells were also investigated (Chapter 6). It was shown that 
FLevi-1 and a selection of evi-l deletion mutants all abrogated the production of 
erythroid and myeloid progenitors in methyl cellulose colony assays. Most intriguing was 
the observation that AZF12 mutants— defective in DNA binding— could also impede 
eyrthroid and myeloid production (although an intermediate phenotype was observed 
compared to FLevi-1 controls).
Potential mechanisms for this biological activity of evi-l and evi-l deletion mutants in 
haematopoietic cells are discussed in Chapter 6 section 6.5.4. However, there is also 
some evidence to suggest that EVI-1 has a normal role to play in haematopoiesis. 
Therefore, in addition the proposals in section 6.5.4, it is also possible that introducing 
FLevi-1 or evi-l deletion mutants into haematopoietic cells deregulates endogenous 
FLevi-1 activity within these cells. Indeed, developmental studies have reported a 
hypocellularity phenotype of evi-l knockout mice, which is consistent with a role for 
EVI-1 in general proliferation (Hoyt et. al., 1997). In more recent studies an embryonic 
stem cell model for haematopoietic differentiation also suggested a normal role for EVI-1
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in differentiating haematopoietic cells (Wimmer et. al., 1998). The myelodysplastic 
syndrome 1 gene (MDS-1) has also been implicated in the progression of myeloid 
leukaemias. Interestingly, both EVI-1 and an MDS1/EVI-1 isoform have been detected in 
both normal bone marrow and leukaemic cell lines (Sigurdsson et. al., 1997) and 
MDS1/EVI-1 is also expressed in all tissues in which EVI-1 is expressed (Wimmer et. al., 
1998). MDS1/EVI-1 mRNA gives rise to a protein that contains an additional 188 amino 
acids at its N-terminus. This converts EVI-1 from a repressor of transcription into a 
transactivator (Solderholm et. al., 1997). Furthermore, EVI-1 can repress MDS1/EVI-1 
transactivation. EVI-1 and MDS1/EVI-1 are expressed at low levels in normal bone 
marrow and it is postulated that any disturbance in a finely regulated equilibrium of these 
potentially antagonistic isoforms of EVI-1 may contribute to neoplastic growth.
Therefore in the studies described in Chapter 6, overexpressing FLevi-1 in primary bone 
marrow cells could cause an imbalance in this equilibrium, resulting in mdsl/evi-1 
repression and consequently an impairment of erythroid and myeloid lineages. Indeed, 
studies have shown that the relative levels of EVI-1 and MDS1/EVI-1 favour EVI-1 in the 
bone marrow of leukaemia patients with 3q26 rearrangements (Solderholm et al., 1997). 
Alternatively, evi-1 deletion mutants expressed at high levels could act as dominant 
negatives over low level endogenous EVI-1 or MDS1/EVI-1 proteins and produce the 
same disruptive effects. Moreover, having uncovered the critical nature of CtBP binding 
for the transformation of Rati cells by evi-1 it is possible that this dominant negative 
action is elicited through evi-1 deletion mutants “mopping up” endogenous CtBP proteins 
(or other factors) necessary for the endogenous functions of evi-1 in the bone marrow.
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7.1 Future Applications
As discussed at the end of Chapter 6, future investigations examining a broad role for evi- 
1 in adult haematopoiesis are of paramount importance. However, the data from this 
thesis has collectively introduced some intriguing new twists concerning the specific 
mechanisms of EVI-1 regulation.
The discovery of the critical nature of evi-l/CtBP interactions for the biological activity 
of evi-1 (Chapter 5) may also provide mechanisms for artificially regulating gene 
expression. To examine the importance of the evi-l/CtBP interaction in haematopoiesis, 
chimaeric mice generated from FLevi-1 null mutant (-/-) ES cells and evi-lACtBP null 
mutant (-/-) ES cells could be generated and the phenotypes of haematopoietic tissues 
compared at different stages of development. Also, since EVI-1 and the CtBP co-factor 
interact through a short peptide motif, it is tempting to speculate that small molecules 
could be developed which interfere with this interaction leading to the reactivation of 
certain EVI-1 target genes. Moreover, it would also be of interest to determine whether 
these molecules could revert the transformed phenotype of myeloid leukemia cell lines 
expressing EVI-1.
The evi-1 dominant negative mutants created (Chapter 3/Chapter4) could be conditionally 
expressed in myeloid leukemia cell lines constitutively expressing evi-1 to assess whether 
these mutants can revert the transformed phenotype of these cells. For example, a
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tetracycline-regulated gene expression system in the 32Dcl3 evi-1-expressing myeloid 
leukaemia cell line could be created whereby the expression of a dominant negative 
mutant of evi-1 is under tetracycline-mediated regulation. The effects of continuous 
expression of this mutant on growth and spontaneous or growth-factor mediated 
differentiation could be examined. In 32Dcl3 cells differentiation induction is achieved 
by adding G-CSF growth factor. To assess the differentiation, proliferation and survival 
status of these repressor-mutant expressing cells genetic markers (lysozyme), cell cycle 
analysis (flow cytometry) and morphological markers (cytospins) could be examined.
Evi-1 expression was also found to block the production of erythroid and myeloid 
progenitors in primary bone marrow colony assays (Chapter 6). Moreover, deletion 
mutants, which were non-transforming in Rati colony assays produced indistinguishable 
effects from FLevi-1 in primary bone marrow assays. Whether proliferation, 
differentiation or apoptosis is blocked by these retroviruses could not be determined in 
these studies. If evi-1 was conditionally expressed in multipotential cell line such as 
FDCP-Mix, which can be induced to differentiation into various haematopoietic lineages, 
evi-1 could be switched on and the proliferation, differentiation and apoptotic status of 
the cells could be assessed using survival assays, differentiation markers and flow 
cytometry.
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Normal haematopoietic regulation consist of many molecular protein links whose specific 
patterns of combinatorial action act to guide gene transcription and regulate commitment 
and lineage determination of haematopoietic cells. Furthermore, it is becoming clear that 
another level of regulation is superimposed on this pattern of combinatorial activation, 
which involves the repression of genes specific for one lineage by transcription factors 
promoting other lineages. Indeed, it is thought that this antagonism between transcription 
factors could provide the developmental switch in the choice between two lineages, 
thereby rendering lineage commitment irreversible and preventing ectopic expression of 
lineage-specific genes. Moreover, it is postulated that such mechanisms may be 
important in understanding the differentiation blocks that can contribute to 
leukemogenesis. Therefore, EVI-1 overexpression could block erythropoiesis or 
myleopoiesis by interactions with erythroid-specific transcription factors, such as GATA- 
1, SCL or LM 02 or myeloid-specific factors such as PU.l or c-myb— all key regulators in 
the development of these lineages (See Chapter 1 section 2.2.1). EVI-1 would sequester 
these factors and consequently deregulate haematopoietic development. Co- 
immunoprecipiation experiments could examine these interactions in vivo. The future 
identification of such EVI-1 protein-protein interactions and indeed the findings 
demonstrated here that CtBP binding is crucial for evi-1-mediated transformation may 
have profound implications for the treatment of human neoplasias where EVI-1 is 
overexpressed. Indeed, the more such protein-protein interactions are revealed and their 
biological roles characterised, the greater the likelihood of interceding and altering the 
expression of genes— such as EVI-1— involved in the pathogenesis of human disease.
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